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Introduction

1.1
General Introduction
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Sounds
Hearing is the ability to perceive sound. Sounds can be simple, like beeps or pure 
tones, but sounds can also be more complex like, for example, speech. Hearing, 
therefore, is an important aspect of communication. Besides sound detection and 
speech recognition, sound localization is another important feature of hearing. 
These three components are important in another function of hearing: detection 
of danger. 
Sounds are, basically, waves in a medium. These waves can be described by means 
of three characteristics: frequency, amplitude and propagation velocity. Humans 
are capable of hearing frequencies between 20 and 20,000 Hz. The most important 
sound source for humans is the human voice. Sounds are usually consisting of 
a combination of frequencies, a frequency spectrum. For speech reception, this 
frequency spectrum is around 2000 Hz 1. 
Figure 1   Frequency and intensity of sounds. Decibel Hearing Level (dB HL) Hertz 
(Hz). This image has been copied by courtesy of Phonak.
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Sound pressure, or the amplitude of the wave, is perceived as loudness of sound. 
This loudness is defined in decibels (dB) or pascal (Pa). The hearing threshold of a 
normal hearing individual is 0 dB HL (decibel hearing level (20 µPa)) and the pain 
threshold is about 130 dB HL (20Pa). 
Propagation velocity depends on the medium. In the external auditory canal and 
middle ear this medium is air, in the cochlea this is fluid (endolymph and 
perilymph). However, sound can also be conducted through a solid medium, like 
bone. The different characteristics of sound waves are detected and processed by 
the ear.
Anatomy and physiology of the ear
The ear can be divided in three parts: 
1. External ear
2. Middle ear
3. Inner ear
The external ear comprises the auricle and the external auditory canal (EAC). 
The EAC directs sounds from the auricle to the tympanic membrane. The external 
ear alters sound wave amplitudes and therewith, provides a mechanism for 
amplification of different sounds within the frequencies of human speech. 
The middle ear consists of the tympanic membrane, tympanic cavity, ossicles and 
associated muscles. The middle ear cavity is connected to the mastoid air-cell system. 
The malleus, incus and stapes are consecutively located between the tympanic 
membrane and the cochlea. These three ossicles conduct sound from the tympanic 
membrane towards the cochlea. The middle ear is especially important in 
transforming sounds, also known as impedance matching. It converses vibration 
of air into vibration of fluid. When sound travels from air to fluid, it is partially 
reflected and a lot of sound energy is lost. Due to two features of the middle ear 
this loss of energy is restricted:
1. The difference of surface size between the tympanic membrane and the stapes 
foot plate. The sound, in other words, the pressure, applied to the tympanic 
membrane is transferred to a surface 17 times as small. 
2. Lever mechanism of the ossicles. The malleus - incus construction is a lever, 
which contributes a factor 1.3 to the transmission of sound 2.
Sound enters the cochlea through the mobile footplate of the stapes located in the 
oval window. The cochlea is shaped like a snail shell. This shell consists of three 
scalae: the scala vestibuli, scala media and scala tympani. These three scalae are 
separated by Reissner’s membrane and the basilar membrane.
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Organ of corti
Located on the basilar membrane is the organ of Corti. It contains the sensory hair 
cells of the cochlea, which convert the mechanical stimulus of the travelling 
sound wave through the cochlea into an electric potential. These sensory cells are 
organized in one row of inner hair cells and three rows of outer hair cells and are 
surrounded by supporting cells. The tectorial membrane is a gelatinous membrane 
covering the apical side of the hair cells. At the basal end of the hair cells the 
synapses of the afferent and efferent neurons are located. In the modiolus of the 
cochlea, the spiral ganglion that contains the cell bodies of the auditory neurons 
is found. These auditory neurons are part of the auditory nerve. 
At the apical side of the hair cells the hair bundle is located. The bundle is formed 
by stereocilia that are arrayed in rows of increasing height. The stereocilia are 
connected by means of links. 
Both the inner and outer hair cells are so-called mechanoelectric transductor 
(MET) cells. A minimal deflection (1-100 nm) of the stereocilia is transmitted via 
stereociliary tip links to open the MET channels 3. By opening these MET channels, 
a positive current of potassium ions flows into the hair cells that subsequently 
depolarize. Depolarization opens the voltage gated calcium channels, which 
induces calcium influx. This influx of calcium ions is necessary for the release of 
glutamate, a neurotransmitter that stimulates the ends of the auditory nerve 
fibers 4. 
Figure 2   Organ of corti. This image has been copied by courtesy of J. Brigande and 
S. Heller 5.
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The deflection of stereocilia of the outer hair cells occurs via direct contact of the 
hair bundle by the tectorial membrane. The hair bundles of the inner hair cells are 
thought to be deflected by the fluid movement in the subtectorial space 6. Inner 
hair cells are responsible for the transduction of sound into a neural signal with 
high spatial and temporal resolution. Outer hair cells are the cochlear amplifiers 
and by electromotility enhance the sensitivity, tuning and dynamic range 7.
Tonotopy 
The relation between detection of sounds of specific frequencies and position in the 
cochlea is called tonotopic organization of the cochlea 8, 9. This tonotopic organization 
is retained up to the auditory cortex, which enables frequency identification. 
Due to decreasing stiffness in the basilar membrane, the velocity of the wave 
decreases, while the amplitude increases, as the sound wave travels through the 
cochlea. At the point where the amplitude reaches its maximum, the sliding 
motion between the basilar and tectorial membrane will be the largest. At this 
position in the cochlea, hair cells will be stimulated. The stiffness of the basilar 
membrane is the largest at the base (the oval window) and decreases exponentially 
towards the apex. The hair cells and the associated stereocilia also differ in length 
from the base to the apex. This difference in height enhances the efficiency of 
flexoelectricity. 
The vestibule
The vestibular organ is, besides the cochlea, also part of the labyrinth. The vestibular 
organ consists of three semicircular canals, and two satellite organs: the utricle 
and saccule. The horizontal, superior and inferior semicircular canals detect angular 
accelerations and the utricle and saccule detect linear accelerations in the vertical 
and horizontal plane, respectively 10. 
Each part of the vestibular organ has its own neuroepithelial area. In the sacculus 
and utriculus this neuroepithelial areas are called the macula sacculi and macula 
utriculi, respectively. The neuroepithelial area in each semicircular canal is called 
crista ampullaris and is located in the ampulla, the dilated end of the semicircular 
canal. Similar to the cochlea, the neuroepithelium consists of hair cells and 
supporting cells. At the apex of each hair cell are several stereocilia and one 
kinocilium located. The stereocilia are arranged evenly in rows of increasing 
height. Next to the tallest row of stereocilia, the kinocilium is located. The 
stereocilia are connected by tip-links. When the stereocilia bend, these tip-links 
open (or close) transduction channels, which results in a change of receptor potential. 
The stereocilia and kinocilia of the maculae protrude in a gelatinous membrane, 
which is covered by statoconia (calcium carbonate crystals). Movement of these 
statoconia causes the stereocilia and kinocilia to bend. The stereocilia and kinocilia in 
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the crista ampullaris are also covered by a gelatinous mass which is called the cupula. 
Angular accelerations of the head cause the cupula to bend, which causes depolarization 
or hyperpolarization of the hair cells, depending on whether the direction of the 
deflection is away from or towards the kinocilium. 11. The vestibular organ only 
detects motion of the head, therefore it is also important to have appropriate 
information about the orientation of the head in respect to the body. This 
information comes from proprioceptors in the neck and body. Besides this, visual 
information is also important in the maintenance of balance 10-12. 
Hearing impairment
Causes of hearing impairment can be divided into conductive and/or sensorineural. 
A conductive hearing impairment indicates that sound cannot be conducted properly 
towards the cochlea. In sensorineural hearing impairment the defect is located in 
the cochlea, the auditory nerve or the further auditory system. Conductive as well 
as sensorineural hearing impairment can be hereditary or acquired. Of all early 
onset sensorineural cases of hearing impairment, about half is due to environmental 
factors and the other half is due to inherited factors 14. 
The most common cause of acquired early onset hearing impairment is a congenital 
cytomegalovirus (CMV) infection, which is the causative agent in 10-20% of hearing 
impaired children. Of all children with a congenital CMV infection, 12.6% will 
develop hearing impairment 15. Hearing loss may present with a delayed onset, and 
can be unstable, with fluctuations and progression. Other causes of acquired hearing 
impairment are trauma, prematurity and ototoxic medication. 
Figure 3   Human vestibular organ; psc, posterior semicircular canal; hsc, horizontal 
semicircular canal; asc, ascending semicircular canal; um, utrical macula; 
pa, posterior ampula. This image has been copied and adjusted by courtesy 
of Büki et al 13. 
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When sensorineural hearing impairment is not acquired, it is inherited. Currently, 
over 75 genes are known to be expressed in the cochlea and to cause hearing 
impairment, when mutated 16. Since different genes are known to function in 
different structures in the cochlea, mutations can cause different types of loss of 
function of the cochlea. 
Hereditary hearing impairment
When hearing impairment is associated with other distinct features it is called 
syndromic hearing impairment. These features can change physical appearance, 
as is for example the case in Treacher Collins, Stickler, Waardenburg or Branchio- 
oto- renal syndrome. These features can also be less obvious or occur at later age 
and therefore be missed in first respect. Examples of the latter are a prolonged 
QT-syndrome in Jervell- Lange Nielsen syndrome, retinitis pigmentosa in Usher 
syndrome or renal failure in Alport syndrome. These syndromes can exhibit all 
known mendelian, as well as mitochondrial inheritance patterns 17. In the cases of 
early onset hereditary hearing impairment about 30% is estimated to be syndromic. 
In these cases, the mutated gene has a significant impact on the function of the ear 
and another organ or organs 18. 
Nonsyndromic hearing impairment can present with different inheritance patterns: 
autosomal recessive (70-80%), autosomal dominant (20-30%), X-linked (<1%), 
mitochondrial (<1%) or Y-linked (rare) 19, 20. The different genetic loci associated 
with nonsyndromic sensorineural hearing impairment are defined by DFN 
(DeaFNess). The inheritance pattern determines the next character; an A for 
autosomal dominant - DFNA, B for autosomal recessive – DFNB, X for X-linked – 
DFNX and Y for Y-linked – DFNY. Every locus for hearing impairment is numbered 
chronologically in order of discovery. 
Several mutated genes can be causative for syndromic as well as non-syndromic 
hearing impairment. Good examples are the genes mutated in Usher syndrome 
type I. MYO7A, CDH23, USH1C, PCDH15, USH1G and CIB2 are all also associated with 
non-syndromic hearing impairment. 
Mutations in several specific deafness- associated genes may lead to autosomal 
dominantly as well as autosomal recessively inherited hearing impairment. This 
is, amongst others, seen in DFNB7/11 and DFNA36, which are both caused by 
mutations in TMC1 16. The differences in syndromic/ non-syndromic or autosomal 
dominant/ recessive inheritance depend on the affected protein domain and the 
type of mutation 21, 22. In general, mutations can cause:
- loss of function.
- gain of function.
- a dominant negative effect: the product of the mutant gene interferes with the 
product of the wild type copy of the gene 23.
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Clinical characteristics
All but one (MIR9624) of the known deafness- associated genes encode a protein. 
These proteins may have different functions in the cochlea. The phenotypes associated 
with different mutated genes may, therefore, also differ. To display these differences 
correctly, phenotypes are described by means of several characteristics. These 
features are summarized in table 1. 
Genetic testing 
In order to find the genetic defect that underlies hearing impairment one can 
follow several strategies. 
Homozygosity mapping
In order to identify the region in which the genetic defect is located, one can apply 
homozygosity mapping. This method is based on the fact that an affected 
individual, from a consanguineous family, inherits two copies of a disease allele 
from a common ancestor of father and mother. These copies are therefore 
homozygous. Since small chromosomal regions intend to inherit as a whole, the 
nearby marker loci will also inherit in the same way. A marker is a specific DNA 
sequence with a known location on a chromosome. These homozygous regions 
will be mapped by means of a single nucleotide polymorphism (SNP) array 26. One 
can compare the genotypes of two or more family members, and herewith identify 
regions shared by affected family members.
 
Linkage analysis
Linkage analysis is measuring the cosegregation of any DNA sequence variant 
with a disease. This is also based on the tendency of two or more genetic loci to be 
transmitted together during meiosis because they are physically close on the 
chromosome 27. Whether loci are linked or not can be identified by means of 
polymorphisms, such as single nucleotide polymorphisms (SNPs) 28. It can be used to 
reject or to prove whether a specific (gene) locus segregates with the disease in a 
family.
 
Mutation analysis
When a gene is suspected to be mutated, one can examine this gene by mutation 
analysis, e.g. by Sanger sequencing 29. The obtained sequence is compared to the DNA 
sequence of an unaffected individual 30. Whether a variant is a known common 
or rare variant can be evaluated in public databases, e.g. the Exome Variant Server 31. 
The impact of a nucleotide change on gene function can be predicted by different 
prediction programs, e.g. Mutation Taster 32.
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Table 1  Characteristics to describe hearing impairment
Characteristics25
Type of hearing impairment Conductive
Sensorineural
Mixed
Severity
(based on the best hearing ear, averaged  
over 0.5, 1, 2 and 4 kHz)
Mild
Moderate
Severe
Profound
Audiometric configuration Low ascending
Mid frequency (U-shaped)
High descending (gently downsloping)
High descending (steeply downsloping)
Flat
Frequency ranges Low
Mid
High
Extended high
Symmetry Unilateral - asymmetric
Bilateral - symmetric
Age of onset Congenital
Prelingual
Postlingual
Progression
Variability Interfamilial
Intrafamilial
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Associated to disease or deformity of outer/middle ear. 
Characterized by normal bone-conduction thresholds (<20 dB HL) and an air-bone gap  
>15 dB HL averaged over 0.5, 1 and 2 kHz.
Associated to disease or deformity of the inner ear/auditory nerve
Characterized with an air/bone gap < 15 dB HL averaged over 0.5, 1 and 2 kHz. 
Associated to combined involvement of the outer/middle ear and the inner ear/auditory 
nerve. Audiometrically >20 dB HL in the bone conduction threshold together with  
>15 dB HL air-bone gap averaged over 0.5, 1 and 2 kHz.
20-40 dB HL
41-70 dB HL
71-95 dB HL
>95 dB HL
>15 dB HL difference between the poorer 0.25 and 0.5 kHz thresholds and those at 1, 2,  
4 and 8 kHz.
>15 dB HL difference between the poorest thresholds of 1 and 2 kHz, and those at 4 and  
8 kHz and 0.25 and 0.5 kHz.
15-29 dB HL difference between the mean of 0.5 and 1 kHz and the mean of 4 and 8 kHz.
>30 dB HL difference between the mean of 0.5 and 1 kHz and the mean of 4 and 8 kHz.
<15 dB HL difference between the mean of 0.25, 0.5 kHz thresholds, the mean of 1 and  
2 kHz and the mean of 4 and 8 kHz.
≤ 0.5 kHz
>0.5 kHz ≤ 2 kHz
>2 kHz ≤ 8 kHz
> 8 kHz
> 10 dB HL difference between the ears in at least two frequencies. 
< 10 dB HL difference between the ears in all frequencies.
Present at birth
Before language development
After language development
Deterioration of >15 dB HL in the average over the frequencies of 0.5, 1, and 2 kHz within  
a 10-year period. 
Differences in above mentioned characteristics between families with hearing impairment 
based on the same genetic defect.
Differences in above mentioned characteristics between family members with hearing 
impairment based on the same genetic defect.
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Whole exome sequencing
Successively sequencing single genes is laborious and time-consuming. Since the 
beginning of this century novel techniques were introduced that can determine 
the sequence of all exons (expressed region) by one test: whole exome sequencing 
(WES) 23. The efficacy of these techniques has been improving gradually. WES has 
become more cost-effective and result interpretation has been enhanced (i.e. 
discrimination between a benign variants and causative mutations) over time 33. 
Novel deafness- associated genes have already been discovered by WES, however, 
single gene tests are still of practical significance to confirm the causative mutation 34. 
The aforementioned method of Sanger sequencing seems to become outdated with 
WES as replacement. However, Sanger sequencing is useful to determine which 
variant is likely to be causative, and segregates with the disease in the family, or 
whether a variant is inherited or de novo 27. One can also focus on a specific set of 
genes via next generation sequencing; this is called targeted next generation 
sequencing. 
In 31-60% of the cases of hereditary hearing impairment, the causative mutation is 
found by targeted next generation sequencing 35.
Main goals of otogenetic research
There are two main reasons to conduct otogenetic research. The first goal is to be 
able to counsel a patient and its family on prognosis e.g. progression of the hearing 
impairment and possible involvement of other organs. The second goal of 
otogenetic research is to gain insight into the pathophysiological effects of a 
mutated gene in the cochlea, which might eventually lead to a therapy for specific 
types of hereditary hearing impairment. Gaining insight in pathophysiological 
effects is mainly achieved by studying the protein function in the cochlea of 
mouse and mouse mutants 36. Gaining insight into the function of a protein in the 
human cochlea is supported by describing a genotype- phenotype correlation, 
according to the characteristics of table 1. For example, age of onset and progression 
can provide clues whether a protein is involved in developing a structure or in 
maintenance of this structure. And by means of vestibular function tests the 
involvement in the vestibular organ can be determined 37. 
In order to better categorize hearing impairment and to evaluate cochlear function 
in detail, de Leenheer et al. introduced the extensive psychophysical test battery 
from Nijmegen38.
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Psychophysical tests
Psychophysical tests evaluate loudness perception, and spectral and temporal 
processing. 
Loudness perception is examined by means of loudness scaling. A stimulus is 
presented with different intensities and the individual is asked to classify these 
intensities from inaudible to unbearable loud. This test is based on the Würzburger 
Hörfeld Skalierung developed by Moser 39. 
Temporal processing is evaluated by means of gap detection. Stimuli are presented 
randomly with a pause of variable lengths. The test individuals have to report 
whether a pause is present within the stimulus 40, 41. Spectral processing is estimated 
by means of a difference limen for frequency test. A stimulus is presented with 
fluctuation of frequencies. The test person has to indicate whether the fluctuation 
is present or not 40. These tests are combined with standard pure tone, speech and 
speech in noise audiometry.
Schuknecht and Gacek introduced a categorization of hearing impairment 42. They 
stated that there are four types of hearing impairment, each correlated to specific 
structures of the inner ear. These four types are sensory, strial, neural and cochlear 
conductive. Loss of hair cells would cause a sensory hearing impairment. A strial 
hearing impairment would be caused by strial atrophy, while loss of cochlear 
neurons would be the base of a neural hearing impairment. Cochlear conductive 
hearing impairment is speculated to be caused by alteration in the physical aspects 
of the cochlear duct 42.
Two of these four types have been identified by psychophysical testing. Patients with 
Usher syndrome type 2a have been subjected to these psychophysical tests. When 
compared to individuals with sensory hearing loss, comparable results were observed. 
A sensory type of hearing impairment would be expected since USH2A is part of the 
Usher interactome, which is essential for the morphogenesis of the hair bundle 43.
In patients with mutations in TECTA (DFNA8/12), a cochlear conductive hearing 
impairment has been demonstrated. A parallel shift of the curves during loudness 
scaling was seen, combined with normal ranged results of gap detection, difference 
limen for frequency and speech reception in noise. DFNA8/12 patients perform 
comparable to patients with DFNA13 (caused by mutations in COL11A2) 38, 44. Both 
TECTA and COL11A2 are expressed in the tectorial membrane. Impaired protein 
function can cause tectorial membrane dysfunction 45. These results are also seen 
in patients with a conductive hearing loss where processing is not affected but 
transduction of sound is. 
These examples demonstrate the pathological effect of a mutated gene on the specific 
structures in the cochlea. This knowledge can be important in the application of 
different types of rehabilitation.
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Counseling 
When the genetic defect has been identified, the patient needs adequate counseling. 
Genetic counseling is needed in order to communicate information about the 
nature of the disease, inheritance mode and implications for possible mutation 
carriers in the family 46. The nature of the disease includes the degree of hearing 
impairment, prognosis and expectations on rehabilitation options 47, but also 
possible additional symptoms. In this process, one should take cultural aspects, 
socials needs and educational level into account 46. The nature of the disease is 
important because it not only influences rehabilitation but also occupational 
choices. In patients with syndromic hearing impairment counseling on early 
detection and possible treatment of additional symptoms is necessary. In addition, 
prevention or slowing down the progression of hearing loss might be possible, for 
example in patients with an enlarged vestibular aqueduct or with an elevated 
susceptibility for aminoglycoside induced hearing impairment 48. 
Not much research has been done on the, mainly psychosocial, consequences of 
genetic testing for hereditary hearing impairment 49. A recent evaluation, however, 
suggests an increase in psychosocial well being after counseling on a positive 
genetic test 50.
When hearing loss has been diagnosed and examined, rehabilitation options have to 
be considered. Rehabilitation options for hereditary hearing impairment in general 
vary from FM (frequency modulation) equipment for mild types of impairment, 
hearing aids for mild to severe hearing losses and cochlear implantation for severe 
to profound types of hearing impairment. 
Different studies have focused on the results of rehabilitation in hereditary 
hearing impairment. These studies are mainly evaluating cochlear implantation. 
The results are difficult to interpret because the postoperative performance in 
patients after cochlear implantation is influenced by many factors. DFNB1 is, 
because of its high prevalence, the most commonly studied type of hereditary 
hearing impairment with regard to results of cochlear implantation. Compared to 
non-DFNB1 patients, patients with DFNB1 present with similar or better 
performance results after cochlear implantation 51. 
Eppsteiner et al. state that genetic defects that affect the spiral ganglion may result 
in worse performance after cochlear implantation. This is supported by results of 
two patients with mutations in TMPRSS3 52. However, Weegerink et al. reported seven 
patients with fairly good speech recognition scores one year after implantation 53. 
When such good results are achieved, Eppsteiner et al. hypothesize that the initial 
good performance will diminish over time 52. The conclusion of this spiral ganglion 
hypothesis can only be confirmed when larger numbers of patients are available, 
including an extensive follow up. 
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In general, the first results of cochlear implantation appear to be good in patients 
with hereditary hearing impairment. However, more research needs to be done to 
second this 54. The results of these studies are, amongst others, important for 
counseling a patient on its expectations on performance after cochlear implantation. 
Additionally, the right type and early start of rehabilitation is important for an 
adequate speech and language development, but in general also for cognitive and 
psycho-affective development 55. Research on the different rehabilitation options 
in hereditary hearing impairment therefore deserves more attention. 
Aim of this thesis 
This thesis is aimed to contribute to the expanding knowledge on effects of 
mutated deafness genes on hearing. As a result, this expansion of knowledge will 
improve counseling on hereditary hearing impairment. The research described in 
this thesis is focused on providing an overview of several types of currently known 
autosomal recessive hereditary nonsyndromic types of hearing impairment. In 
addition, novel genotype-phenotype correlations of autosomal recessive hearing 
impairment types are described. This thesis also contributes to expanding an 
already known genotype-phenotype correlation, that of DFNB1. Since the 
knowledge on hereditary hearing impairment is expanding, the psychosocial 
impact of an otogenetic diagnosis was evaluated as well.
Thesis outline
1.2   An overview of all, currently known autosomal recessive types of hereditary 
hearing impairment.
2.1 OTOG and OTOGL are two deafness- associated genes that show large similarities 
in expression and structures of the encoded protein. The audiometric charac-
teristics of several families with mutations in either of these two genes are 
evaluated and compared. In addition, psychophysical tests were performed to 
evaluate the effect of mutations in these genes on the function of the cochlea.
2.2  A novel deafness- associated gene, CLIC5, which is expressed in several organs, 
is found to be associated with autosomal recessive hearing impairment. In 
this chapter, phenotypic and genotypic features of mutations in CLIC5 are 
delineated.
2.3  USH1G is one of the genes known to cause Usher syndrome type I, when 
mutated. All other genes involved in Usher syndrome type 1 are also known to 
be involved in nonsyndromic hearing impairment. The audiometric, vestibular 
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and ophthalmologic characteristics of an autosomal recessive nonsyndromic 
form of hearing impairment caused by mutations in USH1G are described. 
3. DFNB1 is the most common type of autosomal recessively inherited hearing 
impairment. This type of hearing impairment is, therefore, extensively 
studied. Inconsistent results on vestibular function and imaging characteris-
tics in DFNB1 are described in literature. In this chapter, vestibular function 
in combination with temporal bone imaging in DFNB1 patients are evaluated. 
4.  Knowledge on different types of hereditary hearing impairment is expanding, 
however, knowledge on the impact of an otogenetic diagnosis lags behind. 
This chapter focuses on the psychosocial impact of an otogenetic diagnosis on 
patients with hearing impairment. 
5. General discussion
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Abstract
Nonsyndromic sensorineural hearing impairment is inherited in an autosomal 
recessive fashion in 75-85% of cases. To date, 61 genes with this type of inheritance 
have been identified as related to hearing impairment, and the genetic 
heterogeneity is accompanied by a large variety of clinical characteristics. 
Adequate counseling on a patient’s hearing prognosis and rehabilitation is part of 
the diagnosis on the genetic cause of hearing impairment and, in addition, is 
important for the psychological well-being of the patient. 
All articles describing clinical characteristics of the audiovestibular phenotypes of 
identified genes and related loci have been reviewed. 
This review aims to serve as a summary and a reference for counseling purposes 
when a causative gene has been identified in a patient with a nonsyndromic 
autosomal recessively inherited sensorineural hearing impairment.
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Prevalence and causes of hearing impairment
Hearing impairment is the most prevalent sensorineural disorder in developed 
countries and also the most common birth defect. Approximately one out of every 
1,000 newborns is born profoundly deaf and one out of every 300 newborns has a 
permanent mild-to-profound congenital hearing impairment. In addition, for every 
ten congenitally hearing impaired children, five to nine children will develop a 
similar hearing loss before adulthood1-3. Globally, 360 million people have a 
hearing impairment, which is defined as a hearing loss greater than 40 dB HL 4.
Hearing impairment can be acquired or inherited. In about half of early-onset 
cases, it is inherited. Noise exposure is the most common environmental factor 
that contributes to acquired hearing loss in adults. An individual’s susceptibility 
to hearing loss caused by noise exposure is, in addition, a good example of gene-en-
vironment interaction 1. 
Hereditary hearing impairment
More than half of prelingual hearing impairment cases occur due to genetic 
factors. In 30% of cases, the hearing impairment is syndromic and accompanied by 
other symptoms, and in 70% of cases it is nonsyndromic. The latter group of 
hearing impairments can be divided by the mode of inheritance. Nonsyndromic 
hearing impairments are autosomal recessively inherited in 75-85% of cases and 
autosomal dominantly inherited in 15-24% of cases. The remaining 1-2% 
demonstrate mitochondrial or X- or Y-linked inheritance. Currently, over 80 genes 
and over 140 loci have been identified for nonsyndromic hearing impairment 5. 
The loci are defined by the mode of inheritance and are designated by the letters 
DFN (DeaFNess). DFN is followed by an A for autosomal dominant inheritance 
(DFNA) and a B for autosomal recessive inheritance (DFNB). Both loci are affixed 
with a number based on their order of identification/publication. Hereditary 
hearing impairments with an X-linked inheritance are designated DFNX 2, 5-7. So 
far, 61 genes have been identified for autosomal recessively inherited nonsyndromic 
hearing impairment (arNSHI) 5. arNSHI is therefore highly heterogeneous, making 
it difficult to give an overview of all of the related phenotypes. 
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Obtaining a genetic diagnosis of hereditary  
hearing impairment
A genetic diagnosis of hereditary hearing impairment is currently much easier 
established in the out-patient setting than it was a decade ago. An increasing 
number of genes can now be sequenced on a regular basis, and high-throughput 
techniques, such as massive parallel sequencing (e.g. Affymetrix array), are being 
introduced in the clinic and will lead to easier identification of causative genes in 
the near future. This is especially important for the identification of autosomal 
recessive sensorineural hearing impairment in isolated cases and is therefore an 
important step forward in obtaining a genetic diagnosis on hearing impairment 
in these cases. In the Western world, most families are small and most cases, 
therefore, are isolated. In these cases, other causes appear to be more obvious and 
it is difficult to identify underlying genetic defects. Discovery of the genetic causes 
of hearing impairment and subsequent counseling of patients has been shown to 
improve scores on the scale of perceived personal control, depression and anxiety. 
In other words, these patients experience an increase in their degree of psychological 
well-being 8. It is important to know the genetic diagnosis if one wants to counsel 
patients on, for example, prognosis of hearing impairment (“will my hearing loss 
progress or not?”) on the outcomes of rehabilitation with, for example, cochlear 
implantation and on the consequences for potential progeny 9.
Purpose of this review
This review presents a summary of the clinical characteristics of all currently known 
nonsyndromic autosomal recessively inherited types of sensorineural hearing 
impairment. For this purpose, all articles describing clinical characteristics of the 
audiovestibular phenotype of identified genes and related loci have been reviewed. 
This paper can be used for counseling purposes with patients in whom the causative 
gene for autosomal recessive sensorineural hearing impairment has been identified. 
The focus of this review is only on this type of hearing impairment. Other types, 
such as dominant types, syndromic types and mixed hearing impairment are 
outside its scope. However, it should be kept in mind that syndromic hearing 
impairment can present at first with hearing impairment as its only feature. 
Each type of arNSHI will be described by its age of onset, severity, progression, 
audiogram configuration and associated vestibular function. The severity, affected 
frequencies and audiogram configurations will be described according to GENDEAF 
recommendations, which are described in Tables 1, 2 and 3, respectively 10. 
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First, the most common type of arNSHI, DFNB1, will be described. This will be 
followed by a description of the most prevalent phenotype of arNSHI: prelingual 
profound hearing impairment. The remaining phenotypes, with different, more 
specific characteristics, will then be described and, finally, two auditory neuro- 
pathy spectrum disorders with autosomal recessive inheritance will be described.
GJB2/GJB6 (DFNB1)
DFNB1 is caused by mutations in GJB2 and/or GJB6. Both genes are found at the same 
locus, and mutations in both genes can cause hearing impairment. It was suggested 
that DFNB1 may have a digenic inheritance pattern; however, the data of Wilch 
et al. indicate that it does not 11. DFNB1 is known for its high prevalence around 
the world. The percentage of hereditary hearing impairments caused by mutations 
in GJB2/GJB6 varies by geographical location. A range of 18-41% has been reported 
Table 1 Severity of hearing impairment Table 2 Frequency ranges    
Severity Pure Tone Average
Mild 20-40 dB HL
Moderate 41-70 dB HL
Severe 71-95 dB HL
Profound >95 dB HL
Severity of hearing impairment (table 1) and  frequency ranges (table 2) according to GENDEAF  
recommendations 9.
Table 3  Audiogram configurations
Configuration
Low frequency ascending >15 dB HL difference between the (poorer) lower frequencies  
to the higher frequencies
Mid frequency U-shaped 
(or cookie bite)
>15 dB HL difference between the (poorer) mid frequencies  
and the lower and higher frequencies 
Gently downsloping 15-29 db HL difference between the mean of 0.5 and 1 kHz  
and the (poorer) mean of 4 and 8 kHz
Steeply downsloping >30 dB HL difference between the mean of 0.5 and 1 kHz  
and the (poorer) mean of 4 and 8 kHz
Flat <15 dB HL difference between the mean of 0.25 and 0.5 kHz,  
the mean of 1 and 2 kHz and the mean of 4 and 8 kHz.
Definition of different audiogram configurations according to GENDEAF recommendations 9.
Frequencies
Low ≤ 0.5 kHz
Mid >0.5 ≤ 2 kHz
High >2 ≤ 8 kHz
Extended high >8 kHz
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for Europe, Northern America, Australia, the Middle East and East Asia. In Southern 
Europe, GJB2 mutations are found more frequently than in Northern or Central 
Europe (where carrier frequencies are 1:35 and 1:79, respectively). The latter 
correlates with the prevalences found in North America and Australia 12. DFNB1 is 
encountered less frequently in Iran and India (15%), and even less so in Pakistan 
(6%) 13,14. The high carrier prevalence has led different studies to recommend 
sequencing of GJB2 and screening for deletions in GJB6 as a first step in cases of 
suspected autosomal recessive inheritance or in isolated cases of congenital or 
prelingual nonsyndromic hearing impairment 15, 16. This strategy has a sensitivity 
of over 98%. Therefore, when no mutations are found with this strategy, other 
genetic causes are highly likely 17.
DFNB1 has most often a congenital and prelingual onset. In most cases, hearing 
impairment in DFNB1 is congenital and is reported to be stable or only slightly 
progressive. However, when the onset is not congenital, hearing impairment can 
be very progressive. The audiogram configuration is flat to downsloping, though 
this is not pathognomonic. There is a large variability in severity that is reported 
to range from mild to profound 14. Snoeckx et al. 18 concluded that truncating 
mutations are associated with a higher degree of hearing impairment than 
non-truncating mutations in a large multicenter study of 1,531 DFNB1 patients. In 
addition, the authors also stated that the pathogenicity of missense mutations 
depends on the position and nature of the substitution. This is one of the possible 
explanations for the substantial phenotypic variability among cases with different 
mutations in the same gene, which is not only applicable to DFNB1. Due to the 
large variability in phenotypes, it may be difficult to give prognostic information 
regarding hearing impairments 19. Such information should only be provided to 
the DFNB1 patient who carries a specific combination of GJB2/GJB6 mutations for 
which reliable evidence regarding the genotype-phenotype correlation is available. 
The most prevalent and important mutation combinations have been explored in 
this respect in the multicenter study by Snoeckx et al. 18. The predominant 
phenotype was associated with homozygous 35delG mutations: the audiometric 
configuration was fairly similar to the one shown in Fig. 2D for CDH23 mutations. 
So far, only limited research on vestibular function in DFNB1 patients has been 
published, which is remarkable considering its high prevalence. There is no 
consensus in the literature on vestibular function in DFNB1 20-22. Further evaluation 
of vestibular function in larger numbers of DFNB1 patients is clearly needed to 
reach a more definitive conclusion on vestibular function in DFNB1. 
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Severe to profound hearing impairment
Aside from GJB2/GJB6 (DFNB1), 31 other genes have been identified that can be 
associated with prelingual severe to profound sensorineural hearing impairments. 
Supplemental Table 1 describes the phenotypes of these genes when they have 
mutations. Because all of these phenotypes are described as severe to profound 
hearing impairments, it is difficult to clinically differentiate between them. In 
addition, the manner in which the severity of each hearing impairment was 
assessed is often not clearly described, and audiograms are also frequently missing 
in articles reporting on the identification of novel deafness– associated genes. 
Some of these genes will be discussed briefly here due to their relatively high 
prevalence of mutations, reported variable onset of the hearing impairment and 
associated vestibular dysfunction.
MYO15A (DFNB3)
MYO15A (DFNB3) is, after GJB2/GJB6, the gene that has been found to be mutated 
most often in patients with prelingual, severe to profound sensorineural arNSHI 
without vestibular dysfunction. So far, approximately 28 different mutations of 
this gene have been reported in more than 50 families 6. 
TMC1 (DFNB7/11)
Another frequent cause of prelingual or postlingual severe to profound sensorineural 
arNSHI are mutations in TMC1 (DFNB7/11)23. Thus far, approximately 21 different 
mutations have been reported and over 50 families with prelingual severe to profound 
hearing impairments due to DFNB7/11 have been described. This is similar to the 
phenotype seen in TMC1 knockout mice 24. DFNB7/11 can also present with postlingual 
hearing impairment, as described by de Heer et al. (Supplemental table 1). The 
hearing impairment in this specific family occurs after 4 years of age in the high 
frequencies and progresses rapidly in the first 3 decades to a profound hearing 
impairment. The authors suggest that this may be related to mutations that do not 
completely abolish normal splicing of TMC1 mRNA or to a truncated protein that 
still has some residual function 25. 
MYO7A (DFNB2)
It has been reported that severe-to-profound sensorineural hearing impairment 
due to DFNB2 can have a congenital onset but can also go unnoticed until up to 16 
years of age. Balance problems and vestibular dysfunction on caloric testing have 
been described 26. DFNB2 has only been described in seven families and not in the 
Caucasian population 27. In addition to DFNB2, mutations in MYO7A can also cause 
Usher syndrome type 1b, a congenital form of deafblindness with profound deafness, 
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vestibular areflexia and retinitis pigmentosa as characteristic features. Riazuddin 
et al. stated that DFNB2 is associated with residual protein function of myosin 
VIIA, whereas mutations in MYO7A that cause Usher syndrome type 1b lead to no 
residual function of the mutated protein 28. 
ESPN (DFNB36) and MYO6 (DFNB37)
Mutations in ESPN and MYO6 result in a phenotype with severe to profound prelingual 
sensorineural hearing loss and variable vestibular function, ranging from normal 
to complete vestibular areflexia. In addition to this, mutations in MYO6 are also 
reported to cause mild, not further specified, facial dysmorphic features. Defects 
in MYO6 have only been reported to cause arNSHI in 3 Pakistani families. DFNB36 
has only been described in three families from Pakistan and Morocco 29-31.
 
Autosomal recessive hearing impairment with 
characteristic features (Figure 1A-D). 
STRC (DFNB16) 
Patients with hearing impairment caused by mutations in STRC generally have a 
mild to moderate, gently downsloping audiogram. The hearing impairment has an 
early childhood onset and remains stable over time. It can, however, also be more 
severe (up to profound). Vestibular abnormalities are not reported 32. Francey et al. 
suggest that STRC mutations might greatly contribute to mild to moderate hearing 
impairments in the pediatric population worldwide, because the prevalence of 
STRC deletions in a GJB2 negative cohort was approximately 5.5% 33. Thus far, 20 
families with DFNB16 have been identified. 
GRXCR2 (DFNB101)
DFNB101 is another recently discovered type of arNSHI that presents with moderate 
hearing loss and a gently downsloping audiogram configuration. The hearing 
impairment is usually diagnosed at the age of two years and is reported as being 
progressive. Balance problems have not been observed 34.
OTOGL (DFNB84B)
Mutations in OTOGL cause a prelingual hearing impairment; one patient failed the 
neonatal hearing screening and his siblings were subsequently diagnosed with 
hearing loss at 2 and 3 years of age. The hearing impairment is mild to moderate 
and stable, and has a flat to gently downsloping configuration. Vestibular hypo- 
function is seen in DFNB84B patients, resulting in delayed motor milestones 35. 
DFNB84B is phenotypically similar to DFNB18B.
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OTOG (DFNB18B)
DFNB18B presents with a prelingual sensorineural hearing impairment that 
causes delayed speech development. The hearing impairment begins as mild to 
moderate but can be slightly progressive after the second decade 35. The audiogram 
configuration is flat to gently downsloping. Delayed motor milestones have been 
reported and bilateral weakness has been observed during caloric testing. The 
resemblance between DFNB18B and DFNB84B is probably a result of similarities in 
the structure and expression of otogelin and otogelin-like, the protein products of 
OTOG and OTOGL, respectively, in the inner ear.
GJB3 
GJB3 is reported to be primarily seen in non-consanguineous Chinese families. 
The related hearing impairment occurs prelingually or in early childhood and is 
moderate in severity with a flat audiogram configuration. Vestibular problems have 
not been reported 36. 
Figure 1 A-D  Examples of audiogram configurations. The Y-axis indicates hearing 
thresholds (dB HL). On the right, the genes that, when mutated, can present with 
that type of audiogram configuration are listed. The X-axis indicates thefrequencies 
(kHz). A. Flat. B. U-shape. C. Gently downsloping. D. Steeply downsloping in the 
high frequencies.
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GRXCR1 (DFNB25)
In DFNB25, patients have a moderate to severe hearing impairment with a flat to 
gently downsloping audiogram configuration. This can progress until the hearing 
impairment is profound. This hearing impairment is defined as congenital because 
the patients failed their neonatal hearing screenings or had delayed speech 
development. The hearing thresholds of patients with DFNB25 are displayed in 
figure 2A. Vestibular dysfunction is noted in some DFNB25 patients, who had 
normal motor milestones with later difficulties in motor development or abnormal 
rotatory chair test results 37.
USH1G
A downsloping audiogram configuration is also seen in patients with hearing 
impairment due to mutations in USH1G. One Dutch family with two affected siblings 
presented with a nonsyndromic, moderate hearing impairment with an onset at 
around 4 years of age. A mild progression in hearing thresholds, especially in the 
higher frequencies, was found. Electronystagmography showed normal vestibular 
responses to rotatory and caloric stimulation. An ophthalmologic examination 
found no abnormalities, and, specifically, no signs of retinitis pigmentosa 38.
LOXHD1 (DFNB77)
When LOXHD1 is the causative gene for hearing impairment, the audiogram shows 
a flat configuration in all frequencies or a downsloping configuration in the lower 
frequencies and flat configuration in the mid and high frequencies. The hearing 
impairment is reported to be congenital as well as postlingual (at 7-8 years of age), 
and its level is moderate but can progress to a profound hearing impairment. Age 
Related Typical Audiograms (ARTA) for DFNB77 are shown in figure 2B. DFNB77 
has, so far, only been reported in 6 families, including two Ashkenazi Jewish 
families 39-42. 
TECTA (DFNB21)
When TECTA is mutated, a prelingual moderate to severe hearing impairment is 
reported. DFNB21 presents with a distinct U-shaped audiogram configuration and 
is stable 43. It has been reported to present unilaterally in one DFNB21 patient 44.
CAPB2 (DFNB93)
A flat to U-shaped audiogram can also be seen in patients with DFNB93. The level 
of the hearing impairment is moderate to severe, and it is stable and reported to 
have a prelingual onset 45, 46.
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Figure 2 A. Mean thresholds and standard deviations of all known patients with 
DFNB25 (GRXCR1), age ranges from 10-25 years. B. Age Related Typical Audiograms 
(ARTA) for DFNB77 (LOXHD1). C. ARTA for DFNB84A (PTPRQ ). Significant Annual 
Threshold Deterioration (ATD, in dB per year) is shown in the graph. D. Mean thresholds 
and standard deviations for all known patients with DFNB12 (CDH23). E. ARTA for 
DFNB4 (SLC26A4). F. ARTA for DFNB30 (MYO3A), significant ATD at 0.5 and 8 kHz. G. ARTA 
for DFNB91 (SERPINB6); ATD is not significant. H. ARTA for DFNB59 (PJVK) with 
significant ATD at 2 and 4 kHz.
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GIPC3 (DFNB15/72/95)
Mutations in GIPC3 cause an early onset (3-11 months of age) hearing impairment 
that can present with several audiogram configurations, including flat, gently 
downsloping and U-shaped. The hearing impairment is reported to be stable. The 
level of the hearing impairment is generally severe to profound, but moderate 
levels have also been observed. Vestibular problems have not been reported 47.
TMPRSS3 (DFNB8/10)
Mutations in TMPRSS3 can present with a very characteristic steeply sloping or 
ski-slope audiogram configuration (figure 1D). In our clinic, approximately 25% of 
arNSHI that display a ski slope audiogram configuration can be explained by 
mutations in TMPRSS3 [unpublished data]. The hearing impairment is progressive 
and eventually leads to a flat profound hearing loss. It is designated as DFNB8 
when the onset of the hearing impairment is postlingual (5-12 years) and DFNB10 
when the onset is prelingual (0-1.5 years). The severity of mutations in TMPRSS3 
predicts how the hearing impairment will present. When mutations cause a greater 
change within the protein, patients can present with a prelingual severe to profound 
hearing impairment without the characteristic audiogram configuration. Balance 
problems have not been reported. Although Weegerink et al. observed vestibular 
hyporeflexia and hyperreflexia during electronystagmography in some cases, the 
overall prevalence was not above chance level 48. 
PTPRQ (DFNB84A)
DFNB84A is characterized by a congenital, moderate hearing impairment with a 
flat configuration that deteriorates over time to a profound hearing impairment 
(figure 2C). Normal motor milestone are reported; however, vestibular dysfunction 
(hyporeflexia or areflexia) may occur. Another feature is that variation is seen in 
the severity of hearing impairments and vestibular problems between affected 
family members within one family 49, 50. 
CLIC5 (DFNB102)
Mutations in CLIC5 present with an early onset hearing impairment; patients 
passed the neonatal hearing screening but failed otoacoustic emissions (OAEs) 
testing after 4 months. The hearing impairment is initially mild and progresses 
within the first decade to severe to profound levels. The audiogram configuration 
is gently to steeply downsloping. The vestibular phenotype is probably also progressive 
because motor milestones were not delayed, however later in life balance problems 
occurred. Electronystagmography showed complete vestibular areflexia and associated 
balance problems with increasing age. In addition, signs of a mild subclinical 
nephropathy were seen in one patient 51. 
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SYN4 (DFNB76)
DFNB76 presents with an early onset (congenital- 6 years of age), progressive hearing 
impairment. The audiogram is configuration is steeply sloping. DFNB76 has been 
reported in two Iraqi Jew families52.
CDH23 (DFNB12)
Another type of arNSHI that may present with a progressive hearing impairment, 
though without vestibular problems, is DFNB12. DFNB12 is a prelingual hearing 
impairment that mainly affects the high frequencies, but the audiogram 
configuration can range from flat to downsloping. The hearing impairment may 
progress from moderate to profound (figure 2D); however, the hearing impairment 
can also be stable and severe to profound 53. Miyagawa et al. reported that the onset 
of the hearing impairment can occur at a later age (2-60 years of age) in addition to 
a prelingual onset 54. Vestibular problems were not reported 55. Because CDH23 is 
also involved in Usher syndrome type 1D, an ophthalmologic evaluation should be 
considered. Pennings et al. reported abnormal fundoscopic findings in two DFNB12 
patients who were not typical for retinitis pigmentosa, and the patients had 
normal vision 53. Mutations in CDH23 have been described frequently in arNSHI 
patients and in the Caucasian population 6. 
SLC26A4 (DFNB4)
Worldwide, DFNB4 is, like DFNB1, a common cause of deafness 6. It is usually characterized 
by an enlarged vestibular aqueduct (EVA) or an incomplete partition type II (classic 
Mondini dysplasia). These temporal bone abnormalities may occur unilaterally or 
bilaterally 56, 57 and cause progressive, fluctuating or stable hearing impairments 
that may present at birth. Hearing impairments range from mild to profound and 
may be purely sensorineural or mixed in nature (figure 2E). The latter occurs in 
combination with a normal tympanogram 58. Head trauma, even if mild, can lead 
to a sudden loss of hearing 59. Vestibular symptoms, such as vertigo, may also occur. 
Mutations in SLC26A4 can also cause Pendred syndrome, which is marked by the 
presence of thyroid dysfunction and/or possible development of goiter. Differentiating 
between DFNB4 and Pendred syndrome can be difficult at young ages because the 
thyroid dysfunction usually appears in the second decade 58, 60, 61. 
MYO3A (DFNB30)
One consanguineous Iraqi family has been reported to have DFNB30. The hearing 
impairment often presented in the second decade, but the age of onset varied between 
family members. A moderate hearing impairment that progressed to a profound 
hearing impairment, with a downsloping audiogram configuration, was observed 
(figure 2F). No vestibular problems were reported 62.
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BDP1 (DFNB49)
A consanguineous family from Qatar was described to have a post-lingual, moderate 
to severe, mildly progressive hearing impairment. The audiogram demonstrated 
a gently downsloping configuration 63.
SERPINB6 (DFNB91)
DFNB91 is reported to have an onset at over 20 years of age. The hearing impairment 
is moderate to severe, and flat or gently to steeply downsloping audiogram 
configurations have been observed. This hearing impairment is progressive (figure 2G) 
and vestibular symptoms have not been reported. Thus far, this type has only been 
found in one consanguineous Turkish family 64.
Autosomal recessive auditory neuropathy  
spectrum disorder
An auditory neuropathy is characterized by absent auditory brainstem responses 
and intact OAEs and/ or cochlear microphonics 65. These OAEs may disappear at 
later age 66. One should be aware that children with an auditory neuropathy 
spectrum disorder (ANSD) may be missed at neonatal hearing screenings because, 
in many countries, screening is performed using OAEs 66, 67. Currently, mutations 
in two genes are known to cause ANSD with prelingual mild to profound hearing 
impairments (Supplemental Table 3).
DFNB9 (OTOF) occurs as a prelingual (<2 years) mild to profound hearing 
impairment 66, 68. Mutations in OTOF are frequently found in autosomal recessive 
hearing impairments 6. Although one would be inclined to expect unfavorable 
results with cochlear implantation in patients with ANSD, good post-implant 
results have been reported for patients with DFNB9 69, 70. Mutations in OTOF can also 
cause temperature-sensitive nonsyndromic ANSD. Patients with this type of ANSD 
have normal hearing or a mild hearing impairment when afebrile. When febrile, 
hearing levels are reduced to a severe or profound level and return to normal when 
the fever diminishes 71. 
Another gene that is involved in ANSD is PJVK (DFNB59). DFNB59 is known for 
causing a prelingual moderate to profound sensorineural hearing impairment. 
The hearing impairment can be stable or progress over time. The audiogram 
configuration is flat to gently downsloping (figure 2H). DFNB59 does not always 
present as ANSD. Delmaghani et al. have, in fact, been the only researchers to 
report that OAEs were present 72. Vestibular dysfunction is not commonly noted in 
patients with PJVK mutations, but central vestibular dysfunction was reported by 
Ebermann et al. 73. 
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Vestibular phenotypes
In addition to the various hearing characteristics, a vestibular phenotype can also 
be a characteristic of a genetic dysfunction. Mutations in ten genes are known to 
cause vestibular problems in addition to hearing impairments, all of which have 
been described above. For severe prelingual hearing impairments, vestibular 
problems have been reported for DFNB2 (MYO7A) 27, DFNB36 (ESPN) 30 and DFNB37 
(MYO6) 29. For progressive hearing impairments, hyporeflexia and areflexia were 
found in DFNB84A (PTPRQ ) 49 and DFNB102 (CLIC5) 51. Flat to downsloping audiogram 
configurations can be accompanied by vestibular dysfunction in DFNB18B (OTOG), 
DFNB84B (OTOGL) and DFNB25 (GRXCR1) 35, 37. In DFNB4 (SLC26A4), taking into account the 
anatomical abnormalities, vestibular dysfunction can be expected to occur 58, 60, and 
for auditory neuropathies, central vestibular dysfunction is reported in DFNB59 
(PJVK) 73.
Essence of genotype- phenotype correlations
Many novel deafness- associated genes have been described in the literature, but 
the articles often lack important additional information, particularly those char-
acteristics that are essential to providing proper counseling to patients regarding 
future expectations for their hearing impairment when the causative genetic defects 
are identified. Therefore, we advocate for the inclusion of a thorough phenotype 
description in all articles about the genetics of hearing loss. Such a description 
should include the age of onset, severity, progression of hearing impairment, 
audiogram configuration and vestibular function according to GENDEAF recom-
mendations. The latter, especially, can be a distinctive feature. One should keep in 
mind that vestibular problems are not always reported by patients, who often 
compensate well for vestibular dysfunction 74. Extensive vestibular examination 
including vHIT, caloric testing, and otolith function tests should, therefore, be 
routinely performed for a number of patients in genotype-phenotype correlation 
descriptions. 
44 | Chapter 1
Conclusion
Counseling of patients with hereditary hearing impairment is important because 
it informs them about the prognosis of their hearing loss, and on the implications 
for their progeny. This review of different types of autosomal recessively inherited 
nonsyndromic hearing impairment can serve as a reference for this purpose. 
Many articles on the identification of novel deafness- associated genes often lack 
exact and thorough data on clinical features. Therefore, we recommend a thorough 
genotype-phenotype description be included in such articles. 
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Supplemental table 1  Phenotype characteristics of prelingual, severe to profound 
autosomal recessive hearing impairment.
Locus Gene Onset Severity Audiogram configuration
DFNB2
[1-5]
MYO7A Variable (congenital – 16 years) Severe-profound Flat
DFNB3 
[6-17]
MYO15A Congenital Severe-profound Downsloping 
DFNB6
[18-22]
TMIE Congenital/ prelingual Severe-profound All frequencies
DFNB7/11
[23-34]
TMC1 Congenital,
1 postlingual [35]
Severe-profound Flat- U shaped - downsloping
DFNB18A 
[36-38]
USH1C Prelingual Severe-profound
DFNB22
[39-42]
OTOA Prelingual Severe-profound Flat
DFNB23
[43-45]
PCDH15 Prelingual Severe-profound
DFNB24 
[46-48]
RDX Congenital, prelingual Severe-profound Flat- shallow U shape
DFNB28 
[49-51]
TRIOBP Congenital/ prelingual Profound All frequencies
DFNB29
[52-57]
CLDN14 Congenital, prelingual Severe-profound Flat- gently downsloping
DFNB31 
[58-60]
WHRN Congenital, prelingual Profound
DFNB35
[61-65]
ESRRB Prelingual Severe-profound Flat
DFNB36
[66, 67]
ESPN Prelingual Profound Flat
DFNB37 
[68]
MYO6 Congenital Profound
DFNB39
[69, 70]
HGF Prelingual Severe-profound Downsloping
DFNB42
[71, 72]
ILDR2 Congenital, prelingual Severe-profound Flat- steeply downsloping
DFNB48
[73, 74]
CIB2 Congenital Severe-profound Flat
DFNB49 
[75-78]
MARVELD2 Congenital Severe-profound Flat-downsloping
Introduction | 51
Vestibular involvement Geographic occurrence Additional information
Variable (some do have 
vestibular dysfunction).
Pakistan, Tunisia, Iran, China Atypical Usher is also reported  
(mild retinitis pigmentosa, clinically 
no problems).
No vestibular problems. Indonesia, India, Pakistan, Turkey, 
Iran, Brazil, Tunisia, Qatar, the 
Netherlands*
Can be moderate in the low  
frequencies.
1 family delayed motor 
milestones. Further NA
India, Pakistan, Jordan, Turkey, 
Taiwan
No vestibular problems. The Netherlands, Greece, Turkey, 
Tunisia, Lebanon, Jordan, India, 
Pakistan, China, Sudan, Iran
Progressive in family with post  
lingual onset
NA India, China
NA Palestine, Pakistan
NA Pakistan, New Foundland (Canada)
NA Pakistan, Iran, India
NA Turkey, India, Palestine, Pakistan
NA Pakistan, Morocco, Greece Variability intrafamiliar. Can be  
moderate in the low frequencies
Palestine, Tunisia
NA Pakistan, Tunisia, Czech, Turkey
1/3 families shows areflexia 
during caloric testing
Pakistan, Morocco 
Abnormal (2/9), others not 
tested
Pakistan Variable other findings
NA Pakistan, India
NA Pakistan, Iran, the Netherlands* Not progressive
Can be moderate in the low 
frequencies
Pakistan, Curacao*
NA Pakistan, Czech (Roma) Progressive from severe to profound
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Supplemental table 1  Continued.
Locus Gene Onset Severity Audiogram configuration
DFNB53 
[79]
COL11A2 Prelingual Profound Flat
DFNB61
[80]
SLC26A5 Congenital Severe-profound Flat
DFNB63 
[81-86]
COMT2 Congenital Severe-profound Gently- steeply downsloping
DFNB67 
[40, 87, 
88]
LHFPL5/ 
LRTOMT
Congenital, prelingual Severe- profound
DFNB66 
[89]
DCDC2 Congenital Profound
DFNB70 
[90]
PNPT1 Prelingual Severe-profound
DFNB73 
[91]
BSND Severe-profound Flat
DFNB74 
[92, 93]
MSRB3 Prelingual Profound Flat
DFNB79
[94-97]
TPRN Prelingual Severe- profound Flat-steeply downsloping
DFNB82
[98, 99]
GPSM2 Prelingual Severe- profound Gently downsloping
DFNB86 
[100, 101]
TBC1D24 Prelingual Profound
DFNB89 
[102, 103]
KARS Prelingual Moderate- 
profound
Flat-gently downsloping
DFNB94 
[104]
NARS2 Prelingual, congenital Profound
DFNB97 
[105]
MET Prelingual Severe- profound
DFNB98 
[106]
TSPEAR Prelingual Profound Flat
DFNB99 
[107]
TMEM132E Prelingual Severe- profound
DFNB102 
[108]
EPS8 Congenital Profound
[109] FAM65B Congenital Profound
*marks the origin of a family where mutations are found, but which is not published
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Vestibular involvement Geographic occurrence Additional information
NA Iran
NA Caucasian (USA)
NA Iran, Turkey, Pakistan, Morocco, 
Tunisia
Can be moderate in the low 
frequencies
NA Turkey, Palestine, India, Pakistan
NA Tunisia 
NA Morocco
NA Pakistan Subclinical renal metabolic changes
NA Pakistan
NA The Netherlands, Morocco, 
Pakistan
Progression reported
NA Palestine, Turkey
NA Pakistan
NA Pakistan
No vestibular problems Pakistan
No vestibular problems Pakistan
Iran
No vestibular problems China
NA Algeria 
No vestibular problems Turkey
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Supplemental table 2 Autosomal recessive types of hearing impairment with 
specific phenotypes characteristics.
Locus Gene Onset Severity Audiogram  
configuration
DFNB1 GJB2/GJB6 Congenital, prelingual Mild-profound 
(variable)
Flat- downsloping  
(variable)
DFNB4
[1-5]
SLC26A4 Mostly prelingual Mild- profound
DFNB8/10
[6-18]
TMPRSS3 Prelingual (DFNB10) and 
postlingual (DFNB8)
Moderate-
profound
Steeply downsloping, 
progression until flat
DFNB12 
[19-27]
CDH23 Congenital, prelingual Moderate- 
profound
Flat- steeply downsloping
DFNB15/72/95
[28-33]
GIPC3 Prelingual Moderate-
profound
Flat- U shaped- gently 
downsloping
DFNB16 
[34-37]
STRC Early childhood Mostly mild- 
moderate, can be 
severe - profound
Downsloping
DFNB18B
[38, 39]
OTOG Prelingual Mild- moderate Flat-gently downsloping
DFNB21
[40-46]
TECTA Prelingual Moderate- severe Flat- shallow U shape
DFNB25 [47] GRXCR1 Congenital Moderate- 
profound
Flat- gently downsloping
DFNB30 [48] MYO3A Second decade Moderate- severe Downsloping
DFNB49 [49] BDP1 Post lingual Moderate- severe Gently downsloping
DFNB76 [50] SYN4 Early onset (congenital – 6 
years)
Severe by 
adulthood  
(initial level is  
not reported)
Steeply downsloping
DFNB77
[18, 51, 52]
LOXHD1 Reported prelingual and post 
lingual
Moderate- 
profound
Steeply sloping in low 
frequencies, flat in mid  
and high frequencies
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Vestibular  
involvement
Number of 
families in 
literature
Geographic occurrence Additional information
No consensus >100 Most common form of ARNSHI
Progressive and stable types are 
reported
Vestibular dysfunction, like 
complaints of vertigo, are 
reported
>100 Caucasian, Asia Temporal bone abnormalities. 
Great variability. Fluctuation 
and/ or progression.
Hyporeflexia and 
hyperreflexia were detected 
during 
electronystagmography, 
although the overall 
prevalence was not above 
change level.
>30 8: Pakistan, Turkey, UK, 
Germany, the Netherlands, 
Korea
10: Palestine, Tunisia, 
Turkey, Pakistan, Greece, 
Spain, the Netherlands, 
Italy, India
Progressive
Normal vestibular function >40 Pakistan, Japan, Germany, 
African America, European, 
the Netherlands, India, 
North America, Korea
Progression is reported.
No vestibular problems 
reported
11 The Netherlands*, Turkey, 
Pakistan, Saudi Arabia, 
India.
No vestibular problems 
reported
20 French, Pakistan, Caucasian, 
Asian, Middle East
Non progressive
Delayed motor milestones, 
vestibular hypofunction
2 The Netherlands, Spain. Might be slightly progressive 
later in life
NA 9 Lebanon, Pakistan, Iran, 
Korea
Non progressive, unilateral HI 
reported in one patient
Vestibular dysfunction has 
been reported.
4 The Netherlands, Pakistan Can be progressive
No vestibular problems 
reported
1 Jewish family (Iraq) Progressive
NA 1 Qatar Mildly progressive
NA 2 Iraqi (Jew) Progressive
No vestibular problems 
reported
6 Iran, Turkey, Askenazi Jews, 
Qatar, the Netherlands*
Progressive
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Supplemental table 3  Phenotype characteristics of auditory neuropathies.
Locus Gene Onset Severity Audiogram configuration
DFNB9
[1-17]
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PJVK Congenital, prelingual Moderate- profound Flat- gently downsloping
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Colombia, China, Japan, Taiwan.
Temperature sensitive
NA, central vestibular 
dysfunction
Pakistan, Israel, Morocco, Iran, Turkey, 
China
Can be moderate in the low 
frequencies
Stable and progressive have 
been reported.
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Abstract
Recently, OTOG and OTOGL were identified as human deafness genes. Currently, only 
five families are known to have autosomal recessive hearing loss based on mutations 
in these genes. Since the two genes code for proteins (otogelin and otogelin-like) 
that are strikingly similar in structure and localization in the inner ear, this study 
is focused on characterizing and comparing the hearing loss caused by mutations 
in these genes.
To evaluate this type of hearing, an extensive set of audiometric and vestibular 
examinations was performed in the 13 patients from four families.
All families show a flat to downsloping configuration of the audiogram with mild 
to moderate sensorineural hearing loss. Speech recognition scores remain good 
(>90%). Hearing loss is not significantly different in the four families and the 
psychophysical test results also do not differ between the families. Vestibular 
examinations show evidence for vestibular hyporeflexia. 
Since otogelin and otogelin-like are localized in the tectorial membrane, one could 
expect a cochlear conductive hearing loss, as was previously shown in DFNA13 
(COL11A2) and DFNA8/12 (TECTA) patients. Results of psychophysical examinations, 
however, do not support this. Furthermore, the authors can conclude that there 
are no phenotypic differences between hearing loss based on mutations in OTOG or 
OTOGL. This phenotype description will facilitate counseling of hearing loss caused 
by defects in either of these two genes.
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Introduction
Hearing impairment is the most common sensorineural disorder in humans and 
has many underlying causes e.g. infection, trauma or genetic defects. The latter 
are responsible for at least half of the cases with an early onset 1. For hereditary 
early onset hearing loss the inheritance pattern is recessive in about 80% of the 
cases. Different techniques are available to identify the causative gene. An example 
is linkage analysis in which parental consanguinity and large family size enable 
easier identification of causative genes 2. Since these family characteristics are not 
common in Western populations, it was difficult to identify new loci and genes for 
autosomal recessive deafness in these populations in the past. The introduction of 
novel screening techniques including exome sequencing has led to an increase in 
the number of identified genetic causes of recessively inherited hearing loss also in 
the Western population 3. So far, over 60 genes harboring more than 1,000 mutations 
were identified for non-syndromic hearing impairment 4, 5. 
OTOG (DFNB18B) is one of the novel human deafness- associated genes. It codes for 
otogelin, which is a non-collagenous protein that was found to be specific to the 
inner ear in mice by Cohen-Salmon et al. 6. Subsequently, Simmler et al. 7 indicated 
OTOG to be a mouse deafness gene. Otogelin is held responsible for binding of the 
otoconial membrane and cupula to the neuroepithelium. In the tectorial 
membrane, otogelin might be important for the interaction or stabilization of the 
type-A and B fibers 8. OTOG was therefore also considered to be a candidate gene for 
hereditary non-syndromic hearing impairment in humans 7. The gene was mapped 
to chromosome 11 of the human genome by Cohen- Salmon et al. 9 and we recently 
confirmed that mutations in OTOG cause deafness in humans 10.
Shahin et al. 11 described a gene homologous to OTOG, which is called OTOGL 
(DFNB84B). The predicted product of this gene is otogelin-like and 33.3% of the 
amino acid sequence is identical to that of otogelin 12. Furthermore, otogelin-like 
is a component of the tectorial membrane, as is otogelin. When expression of otogl 
is knocked down in zebrafish, it leads to sensorineural hearing loss. Recently, we 
also have shown that OTOGL is a human deafness gene 12. 
Because of the striking similarities between otogelin and otogelin-like in terms of 
structure and expression, we wanted to evaluate whether the phenotypes of 
mutations in OTOG and OTOGL are also similar. This study presents an extensive 
audiometric and vestibular evaluation of the patients currently known with 
recessive sensorineural hearing loss caused by mutations in either OTOG or OTOGL 
10, 12. This description facilitates the identification of causative genetic defects in 
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the outpatient clinic and improves counseling of patients on prognosis and 
rehabilitation of their hearing loss.
Patients and methods
Family data
Thirteen patients, from four different families were included in this study. 
Families A (W11-0186) and C (W00-384) are of Dutch origin, family B originates in 
Turkey and family D (S1778) is of Spanish origin. An autosomal recessive type of 
inheritance is apparent in the pedigrees, which show hearing loss in only one 
generation (figure 1). In family B a consanguineous marriage is present as the 
parents are first cousins. 
Figure 1 Pedigrees of families participating in this study. A square indicates a 
male, a circle indicates a female. A filled symbol means affected an open symbol 
means unaffected.
Novel genotype-phenotype correlations | 77
All participants voluntarily participated in this study and informed consent was 
obtained from the patients or parents when the patient was a minor. This study 
was approved by the local medical ethical committee. All hearing impaired family 
members filled in a standardized questionnaire on audiovestibular symptoms and 
underwent ENT examination, including otoscopy and external ear inspection, to 
exclude external ear deformities, previous surgery and other possible causes of 
hearing impairment. A computed tomography (CT) scan of the temporal bone was 
performed in one member of family B and family C (II:3), in order to screen for 
possible anatomical causes of congenital hearing loss.
Genetic analysis of families A and B has been described by Yariz et al. 12. Mutation 
analysis of OTOGL was initiated in family A and two compound heterozygous 
mutations were identified, a nonsense mutation (c.547C>T (p.(Arg183X))) and a 
splice site mutation (c.5238+5G>A). They found a mutation in a homozygous state 
in OTOGL in family B (c.1430delT (p.(Val477Glufs*25))). 
Genetic results for families C and D have been described by Schraders et al. 10. In 
family C a homozygous region containing OTOG was identified by homozygosity 
mapping and therefore, Sanger sequencing was applied to OTOG. A deletion 
(c.5508delC) was found in a homozygous state. This deletion is predicted to cause a 
frameshift and a premature stopcodon (p.(Ala1838ProfsX31)). In family D two 
pathogenic compound heterozygous mutations in OTOG (c.6347C>T (p.(Pro2116Leu)) 
and c.6559C>T (p.(Arg2187X))) were identified. 
Audiovestibular examination
Pure tone audiometry
Pure tone audiometry was performed according to current standards to determine 
hearing thresholds at frequencies of 0.25, 0.5, 1, 2, 4 and 8 kHz. To exclude 
conductive hearing impairment, air and bone conduction thresholds were 
determined. 
Speech recognition test
In families A and C standard Dutch phonetically balanced word lists (NVA Dutch 
CVC lists, Bosman 1992) were used to measure speech recognition scores. The 
average of the maximum percentage correct for both ears is the maximum 
phoneme score. These scores were obtained from monaural performance versus 
intensity curves. 
Otoacoustic emissions (OAEs) and acoustic ref lexes
OAEs were assessed in individual II:1 from family C. In all members of families A, 
B and C acoustic reflexes were measured contralateral and ipsilateral at 0.5, 1, 2 
and 4 kHz up to the loudness discomfort level. 
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Vestibular function tests
Unterberger stepping test, Romberg test, head thrust test, head shake test and 
smooth pursuit eye movements were used to roughly evaluate vestibular function 
in family A. The parents of family A did not give consent for more extensive 
vestibular testing. Vestibular function was evaluated in family B, C and D by elec-
tronystagmography. This involved calorics in families C and D and a velocity-step 
test in all three families. Calorisation was performed by bithermal (30 and 44˚C) 
water irrigation of the external auditory canal. The velocity step test was performed 
with patients seated in a rotary chair and their head anteflexed at 30 .˚ The chair 
was accelerated and when the rotatory nystagmus had subsided during constant 
rotation the chair was suddenly stopped. Areflexia was defined as no responses 
during vestibular function tests. Hyporeflexia was defined when responses are 
below normal ranges (i.e. velocity step test: gain < 33%, slow phase velocity < 300/s, 
time constant < 11 s; caloric tests: < 70/s and <100/s for cold and warm irrigation, 
respectively). This test was previously described by Theunissen et al. 13. 
Psychophysical examination
In order to try to distinguish further than a mere conductive or sensorineural 
hearing loss we performed the following psychophysical examinations to families 
A and C: loudness scaling, gap detection, difference limen for frequency and 
speech reception in noise. The latter was measured in the soundfield, the other 
tests were measured with a headphone at the best performing ear. Results of 
loudness scaling, gap detection and difference limen for frequency were compared 
to results of psychophysical examination of normal hearing individuals. The data 
of normal hearing individuals were previously described by de Leenheer et al. and 
Plantinga et al. 14, 15. The results of speech reception in noise were also compared to 
those of presbyacusis patients 16 and normal hearing individuals. 
Loudness scaling was measured with the Würzburger Hörfeld Skalierung developed 
by Moser 17. Pure tones that ranged from threshold level (category 1) to loudness 
discomfort level (category 7) were presented with duration of one second. Patients 
were asked to rate the perceived loudness of stimuli on a scale from one to seven. 
Loudness scaling was performed with 0.5 kHz and 2 kHz pure tones. At these two 
frequencies, each stimulus level was presented four times in a random order. 
Gap detection was performed as described by De Leenheer et al. 15. Unfiltered white 
noise, octave band filtered white noise with 0.5 kHz centre frequency and with 2 
kHz centre frequency were used to test the patient’s ability to perceive a period of 
silence between two noise bursts. These bursts are of equal duration and intensity 
and were presented at the most comfortable listening level (MCL). Gap widths of 0 
(no gap), 2, 2.8, 4, 5.6, 8, 11.2, 16 and 22.4 ms were randomly presented. The random 
gap procedure was repeated four times for each type of noise.
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Difference limen for frequency (DLF) was measured at 0.5 kHz and 2 kHz with 
randomly emitted frequency modulated pure tones generated by an Interacoustics 
AC-40 audiometer. Frequency fluctuations were 0 (no fluctuation), 0.2, 0.4, 0.6, 0.8, 
1, 2, 3 and 5%. All the stimuli were presented three times at the MCL. The lowest 
percentage of fluctuation that was detected by the patient was designated to be the 
DLF.
The speech reception thresholds in noise (SRT), i.e. the presentation level at which 
a score of 50% correct is achieved for whole sentences, were determined as described 
by de Leenheer et al. 15. To define these SRTs, sentences in noise in the soundfield, 
according to Plomp and Mimpen, were used 18. The noise level was fixed at the MCL 
and the adaptive procedure described by Plomp and Mimpen was used to set the 
level of the sentences. Both speech and noise were presented via one loudspeaker 
facing the patient who was not wearing hearing aids. Outcome measure in this 
experiment was the signal-to-noise ratio (S/N ratio), which is the difference in 
decibels between the SRT and the noise level.
The youngest member of family A did not participate in the psychophysical 
examinations since these tests were too difficult for his age. 
Statistic analyses
To evaluate progression of hearing impairment linear regression analysis was 
performed with Prism 5.0 (Graphpad, San Diego, Ca, USA). For each measured 
frequency it was tested whether the regression coefficient differed significantly 
from 0. Loudness scaling was evaluated with linear regression analysis as well. To 
compare hearing loss between all four families a mean audiogram was calculated 
and compared by means of an unpaired Students T-test. When more than two 
groups were compared a one-way ANOVA was used.
Results
Clinical data
Family A consists of three hearing impaired boys in one generation aged five to 
eight years at first visit. Follow-up comprised 1.8 years. In family B, four siblings 
were analyzed. At first visit, II:1 was 34 years old, II:4 33 years, II:6 14 years and II:7 
was 10 years old. Two audiograms were available of three of the four family 
members each (II:1, II:6 and II:7). The time between both audiograms is about eight 
years. Only one audiogram was available of individual II:4. In family C, one 
generation consisting of four affected male siblings was analyzed. They were three 
to seven years old at first visit and were followed for on average 11.5 years. Family 
D consists of two hearing impaired siblings aged 4.9 and 6.7 years at first visit. 
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Follow-up comprised on average 21 years. The onset of hearing loss is potentially 
prelingual in families A, C and D. One member (AII:3) of family A failed neonatal 
hearing screening. Subsequently, the two older brothers were diagnosed with 
hearing loss at the age of two (II:2) and three (II:1) years. Speech development was 
Figure 2 A. Audiogram with the average hearing loss of all affected family members of 
family A. Standard deviations are indicated by vertical lines. B. All affected family 
members of family B. C. Family C. D. Family D. E. All four mean audiograms 
combined. F. All audiograms (mean of both ears) of individual II.1 of family D 
combined (6.7-24 years of age). G. All audiograms (mean of both ears) individual II.2 
of family D combined (4.9-30.4 years of age).
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delayed in families C (II:1, II:2 and II:4) and D (both affected members). Physical 
examination did not demonstrate any dysmorphic features. CT scans of the 
temporal bone in subjects of family B and family C did not show any abnormalities. 
Audiometric results
Overall, affected individuals in family A-D have a mild to moderate sensorineural 
hearing loss with a configuration that is flat to gently downsloping from the low- 
to the mid-frequencies 19. This is equivalent to the results recently presented by 
Bonnet et al. 20 for a patient with mutations in OTOGL. Figure 2A-E shows the mean 
audiograms for each family separately, as well as combined. Hearing loss varies 
between 25 and 65 dB HL, depending on the frequency. Hearing thresholds do not 
significantly differ between the four families. Affected individuals of families A, B 
and C do not report progression of hearing loss. Longitudinal regression analysis 
indeed does not show progression. In family D, significant increase of thresholds at 
frequencies 0.25 kHz (0.63 dB/yr), 1 kHz (0.53 dB/yr), 2 kHz (0.85 dB/yr) and 4 kHz 
(1.17 dB/ yr) is seen in II:1 and at 1 kHz (0.35 dB/yr) and 2 kHz (0.50 dB/yr) in II:2 
(figure 2F-G). This progression predominantly occurs after the age of twenty years. 
Cross-sectional analysis of speech recognition scores shows that speech recognition 
remains stable and above the 90% score. 
OAEs could not be detected in II:1 from family C. Average reflex thresholds for 
normal hearing individuals and patients with a hearing loss up to 50 dB HL are 85 
dB HL. There is an interindividual standard deviation of 7 dB 21. Reflexes within 
the normal range were detected in all individuals, except for II:4 of family C. His 
reflex thresholds were beyond the loudness discomfort level.
Psychophysical results of both Dutch families
Individuals of family A had an average age of 9.3 years and those in family C 
16.5 years at psychophysical examination. Mean results for loudness scaling 
experiments at 0.5 and 2 kHz are depicted in figure 3. For 0.5 kHz, the curves of 
loudness growth run almost parallel to or slightly steeper than those of normal 
hearing individuals. For 2 kHz, the curves are clearly steeper in the affected 
individuals as compared to those of controls. This suggests recruitment at 2 kHz, 
which holds for both families. The slopes for both frequencies do not differ 
significantly between both families (0.5 kHz p=0.62; 2 kHz p=0.57).
The results of average gap detection for unfiltered white noise stimuli and for 
filtered white noise stimuli with 0.5 kHz and 2 kHz centre frequencies are displayed 
in figure 4. Results of the youngest family member of family C (II:4, aged 13.9) were 
qualified as unreliable since he failed to understand the explanation of the test 
and therefore the results were excluded. For unfiltered white noise stimuli, the 
average gap width was a little higher for patients than for normal hearing 
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individuals (one way ANOVA, F(2,20)=280, p<0.001). This was more prominent in 
family A compared to family C, although the two families did not differ 
significantly from one another (p=0.30). For filtered white noise stimuli with 0.5 
kHz centre frequency the average values for families A and C were both smaller 
than for the average normal hearing individual (one way ANOVA, F(2,18)=0.82, 
p=0.45). On the other hand, for the filtered white noise stimuli with 2 kHz centre 
frequency the average value for family A was higher than for the average normal 
hearing individual and the average value for family C was lower than for the 
Figure 3 A. Loudness scaling at 0.5 kHz, dotted line indicates mean results of 
normal hearing individuals, dashed lines represent the results of family A, solid 
lines indicate family C. B. Similar results of loudness scaling at 2 kHz.
Figure 4 Gap detection measured in milliseconds (ms) for unfiltered white noise 
stimuli and for filtered white noise stimuli with 0.5 kHz and 2 kHz centre frequencies. 
Mean results for families A and C compared to those of normal hearing individuals.
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average normal hearing individual (one way ANOVA. F(2,19)=0.12, p=0.89). Between 
both families the differences were not significant (0.5 kHz p=0.67; 2 kHz p=0.43). 
The average results for the difference limen for frequency experiments with 0.5 
kHz and 2 kHz stimuli are compared between the affected individuals and controls 
in figure 5. Individuals with normal hearing achieve an average DLF of 0.5% in 
response to a 0.5 kHz tone. The DLF averages of families A and C were slightly 
Figure 5 Difference Limen for Frequency (DLF) measured in percentage (%) for 
0.5 kHz and 2 kHz. Mean results for families A and C and the results for normal 
hearing individuals are presented.
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compared to those for normal hearing individuals, presbyacusis patients and 
presbyacusis corrected for audibility.
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higher at 0.5 kHz than normal hearing individuals. As for the 2 kHz stimuli, the 
average DLF values of families A and C were clearly higher than the average value 
of normal hearing individuals. Again, both families did not differ from one 
another (0.5 kHz, p=0.34; 2 kHz, p=1).
The average values of speech reception thresholds in noise are higher, i.e. worse, 
for both families than for the average normal hearing individual. This is more 
prominent in family A, but does not differ significantly from family C (p=0.07) 
(figure 6).
Vestibular examination
In family A, individual II:1 reported delayed motor development. He could only 
roll over at 12 months of age and started walking after 21 months. The head thrust 
test showed signs of hyporeflexia of the right vestibulum. In family C, delayed 
motor development was reported for two boys. Individuals II:2 and II:4 were able to 
sit at 12 months, could stand at 14 months, crawled at 12 and 11 months respectively 
and walked after 18 and over 24 months, respectively. The rotatory tests revealed 
hyporeflexia and calorisation showed bilateral weakness in all affected males of 
this family. Both members of family D underwent vestibular testing and calorisation 
showed a bilateral deficit. In family B one member (II:7) underwent calorisation 
and showed vestibular hypofunction of the left vestibulum.
Discussion
Recently, OTOG and OTOGL were identified as novel human deafness genes and their 
striking similarities in protein structure and localization in the tectorial membrane 
were emphasized 10, 12. In the present study, the phenotypic characteristics of two 
families with OTOG mutations and two families with OTOGL mutations are evaluated 
to compare both phenotypes. All affected family members show a mild to moderate 
hearing loss and a flat to gently downsloping audiogram, no differences between 
the four families were noted. Mild progression may be seen in families with 
hearing loss caused by mutations in OTOG when long term follow-up is present. 
This progression occurs mainly in the mid frequencies and mainly after 20 years 
of age. 
In one family with mutations in OTOG and one family with mutations in OTOGL 
additional psychophysical tests were performed. The results are similar in both 
families, but differ from results of normal hearing individuals. Vestibular 
examination showed evidence of hyporeflexia in all tested and affected family 
members. In addition, delayed motor development was noticed in three individuals 
(AII:1, CII:2 and CII:4). 
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Mutations in genes encoding components of the tectorial 
membrane give a similar hearing loss
Otogelin and otogelin-like are components of the tectorial membrane. TECTA 
(DFNA8/12 and DFNB21), CEACAM16 (DFNA4B) and COL11A2 (DFNA13 and DFNB53), 
are human deafness- associated genes that code for other proteins of the tectorial 
membrane 22-24. The phenotypic characteristics of these inherited types of 
sensorineural hearing loss are summarized in table 1. Non-syndromic hearing 
impairment caused by defects in one of the tectorial membrane proteins is usually 
characterized by a flat to U-shaped audiogram, has an early onset and is often not 
progressive, especially when the defects are inherited in an autosomal recessive 
way. These characteristics are comparable to those of the patients described here. 
The hearing loss is not of the cochlear conductive type despite 
suspected tectorial membrane involvement 
Psychophysical evaluation in patients with a defect in the tectorial membrane due 
to mutations in TECTA and COL11A2 revealed a clear cochlear conductive hearing 
loss. This type of hearing loss is characterized by performance in the (near-)normal 
range for the gap detection test, difference limen for frequency test and speech 
reception in noise test, elevated acoustic reflex thresholds and a parallel shift of 
the curve for loudness scaling 14, 15. 
Otogelin and otogelin-like are also components of the tectorial membrane and 
Simmler et al. 8 stated that the resistance of the tectorial membrane to mechanical 
stress produced by sound wave pressure is reduced in the absence of otogelin. 
Therefore, we also predicted a cochlear conductive hearing loss in patients with 
mutations in OTOG or OTOGL. The present psychophysical and audiological data, 
however, do not support this. On the other hand, the S/N value is obviously better 
(mean value OTOG/OTOGL patients: -1.8 dB) than that found in presbyacusis patients 
(+0.7 dB) (figure 6) which contradicts a sensorineural type of hearing loss. This 
discrepancy is possibly caused by an audibility problem: speech and noise have a 
broad frequency spectrum. When carrying out the speech in noise test in hearing 
impaired subjects, amplification should enable full audibility. This is easily 
acquired in case of a relatively flat hearing loss, as is found in phenotypes caused 
by mutations in OTOG and OTOGL. Typically, hearing loss in presbyacusis is not flat 
but downsloping, affecting predominantly the higher frequencies. In such 
patients, whenever amplification is acceptable in the low and mid-frequencies, 
speech sounds might still be poorly audible in the high frequencies. As shown by 
Killion and Christensen 25, corrections can be made to deal with this audibility 
problem. Following their method, the S/N ratio for the studied group of presbyacusis 
corrected for audibility, is approximately -1.3 dB instead of +0.7 dB. That S/N value 
is comparable with the mean S/N value of the patients with mutations in OTOG and 
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OTOGL. This strengthens the suggestion that, although the defect is located in the 
tectorial membrane, it does not cause hearing loss of the cochlear conductive type. 
A possible explanation might be that the outer hair cells, with their stereocilia in 
contact with the tectorial membrane, do not function normally because of an 
ineffective connection. 
One should keep in mind that psychophysical tests are not easy to perform and 
require good concentration. Therefore, the young age of the participants might 
have influenced the reliability of the results of psychophysical examinations. This 
might explain the minor, although not significant, differences between families A 
and C, since the affected individuals of family A are younger than those of family 
C. A more accurate description can and must be made when larger numbers of 
(older) patients with OTOG and OTOGL mutations are available. 
Consequences of impaired otogelin function for hearing and balance
In Otog knock-out mice, detachment of the otoconial membrane and cupulae from 
the neuroepithelia endorses the requirement of otogelin for anchoring the 
acellular membrane to the underlying neuroepithelia 8. This detachment of the 
otoconial membrane and cupula may explain the impaired vestibular function in 
the affected individuals and thereby the delayed motor development in AII:1, CII:2 
en CII:4. Because of compensatory mechanisms, vestibular dysfunction will probably 
not have any further clinical consequences 26.
Mice with a mutation in OTOG have progressive moderate to profound hearing loss. 
However, in histology the tectorial membrane of these mice appears to be normal. 
Otogelin does not seem to be involved in anchoring the tectorial membrane to the 
spiral limbus. However, in transmission electron microscopy some abnormal fibrillar 
or rod-like structures roughly parallel to the axis of the tectorial membrane were 
detected. Simmler et al. 7 stated that the resistance of the tectorial membrane might 
be reduced in the absence of otogelin, which might reduce sound transduction and 
leads to sound attenuation. However the results of psychophysical testing in the 
patients point towards a defect in the hair cells or the connection between the 
stereocilia and tectorial membrane. Further research is necessary to unravel a 
possible of role of otogelin and otogelin-like in these defects. 
Progression of hearing loss
Progression of hearing loss is not seen nor reported in three out of four families. In 
family D, which carries mutations in OTOG, progression is mainly seen after the 
age of twenty and is relatively mild. The individuals of family C are too young to 
make a statement on progression in this family. The slow progression might be 
explained by the fact that otogelin transcription almost vanishes in the cochlea in 
adult mice, but otogelin labeling persists. This suggests a slow turnover process of 
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otogelin in the cochlea 27. Yariz et al. 12 also describe high levels of OTOGL transcripts 
in early development and down regulation in later development, which suggests 
involvement in the development of the structure, but a low turnover. Further 
follow-up or identification of older patients with hearing loss caused by mutations 
in OTOG or OTOGL will reveal how hearing loss presents over time. 
Conclusion
In this paper, the audiovestibular phenotypes of two families with autosomal 
recessively inherited mutations in OTOG are compared with two families with 
mutations in OTOGL, because of the striking similarities in structure of the proteins 
and their localization in the tectorial membrane. So far, there are only five families 
known with hearing loss with underlying mutations in OTOG or OTOGL. The present 
results show that there are no significant phenotypic differences between all 
examined families. Overall one can conclude that mutations in either OTOG or 
OTOGL lead to a mild-to-moderate sensorineural hearing loss with a flat to gently 
downsloping audiogram. So far, mild progression is only seen in one family with 
mutations in OTOG. Clear evidence of vestibular hyporeflexia is found with 
relatively mild clinical consequences. Additional psychophysical examinations in 
two Dutch families also do not show any differences between the phenotypic 
expression of OTOG and OTOGL mutations. Since otogelin and otogelin-like are 
detected in the tectorial membrane, one could expect a cochlear conductive 
hearing loss, as was shown in DFNA13 and DFNA8/12 patients. However, present 
results of psychophysical examinations do not support this. Further research is 
needed to determine the exact role of otogelin and otogelin-like in the cochlea. 
Meanwhile, present results will improve genetic counseling of patients with 
mutations in OTOG or OTOGL. 
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Abstract
Currently, six genes are known to be associated with Usher syndrome type I and 
mutations in most of these genes can also cause nonsyndromic hearing loss. The 
one exception is USH1G, which is currently only known to be involved in Usher 
syndrome type I and atypical Usher syndrome. 
A Dutch family with autosomal recessively inherited hearing loss was examined. 
Audiometric, ophthalmic and vestibular evaluations were performed besides the 
genetic analysis.
The hearing loss had an early onset with a downsloping audiogram configuration. 
Slight progression of the hearing loss was seen in both affected individuals. 
Compound heterozygous mutations in USH1G were found to segregate with the 
hearing loss in this family, a missense (c.310A>G, p.(Met104Val)) and a frameshift 
mutation (c.780insGCAC, p.(Tyr261Alafs*96)). Extensive ophthalmic and vestibular 
examinations demonstrated no abnormalities that are usually associated with 
Usher syndrome type I.
This is the first family presented with nonsyndromic hearing loss caused by 
mutations in USH1G. Our findings expand the phenotypic spectrum of mutations 
in USH1G.
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Introduction
Usher syndrome is the most common cause of combined hereditary hearing and 
vision loss 1. It is clinically and genetically heterogeneous, but it is mainly characterized 
by bilateral sensorineural hearing loss and retinitis pigmentosa (RP). Vestibular 
dysfunction is seen in part of the cases. Based on severity of hearing loss and presence 
or absence of vestibular dysfunction, Davenport and Omenn distinguished three 
types in 1977 2. Type I is characterized by congenital, stable, severe to profound 
hearing loss, vestibular areflexia and RP that has an onset before puberty. Type II 
can be distinguished from type I based on severity of hearing loss (moderate - 
severe), absence of vestibular dysfunction and a later onset of RP. Type III is 
characterized by progressive hearing loss, variable vestibular dysfunction and 
variable onset of RP 1, 3. Up to now, twelve loci are known for Usher syndrome and 
for ten of these loci the involved genes have been identified. Eight loci are known 
for Usher syndrome type I and the six causative genes are: MYO7A, CDH23, USH1C, 
PCDH15, USH1G and CIB2 4. 
Like in Usher syndrome, clinical and genetic heterogeneity are also seen in autosomal 
recessive nonsyndromic hearing loss, for which 49 genes have been identified so 
far 4. Interestingly, five genes known to be involved in Usher syndrome type I, 
MYO7A, CDH23, USH1C, PCDH15 and CIB2, are also involved in nonsyndromic hearing 
loss: DFNB2, DFNB12, DFNB18A, DFNB23, and DFNB48, respectively. These DFNB 
phenotypes are generally characterized by prelingual, severe to profound hearing 
loss, occasionally including minor retinal abnormalities not typical for RP 5-8. 
Exceptions are DFNB2, which is reported to have a more variable onset age 9, 10, and 
DFNB12 which can also present with moderate hearing loss, but with a progressive 
nature 11, 12. 
USH1G is located at chromosome 17q25.1 and encodes the protein SANS. Mutations 
in this gene have, up to now, only been described to cause Usher syndrome type I 
or atypical Usher syndrome 13-15. The latter is characterized as atypical since the 
patients did not suffer from visual problems. Ophthalmic examination, however, 
revealed bone spicules and atrophy of the retinal pigment epithelium (RPE), which 
was characterized as late-onset RP 14, 15. To our knowledge there are no reports that 
describe hereditary non-syndromic sensorineural hearing loss caused by mutations 
in USH1G. In this study, we report a Dutch family with nonsyndromic sensorineural 
hearing loss caused by compound heterozygous missense and frameshift mutations 
in USH1G. 
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Material and methods
Clinical examinations
A non-consanguineous Dutch family (W08-2221) was studied. The pedigree 
demonstrates that hearing loss is present in only one generation, which may 
indicate an autosomal recessive inheritance pattern (Figure 1). This study was 
approved by the local medical ethics committee. All participants signed an 
informed consent, which additionally was used to retrieve relevant data from 
other medical centers. All family members of the second generation completed a 
questionnaire on hearing and balance. Hearing impaired participants underwent 
complete ear, nose and throat examination including otoscopy and external ear 
inspection to exclude external ear deformities, previous surgery and other possible 
causes of hearing impairment. A computed tomography (CT) scan of the temporal 
bone was performed in individual II.1 in order to exclude cochlear malformations.
Genetic analyses and molecular modeling 
Peripheral blood was drawn from all family members for genetic analysis. Genomic 
DNA was isolated from lymphocytes according to standard procedures. Single 
Nucleotide Polymorphism (SNP) genotypes of individuals II.1 and II.4 were 
determined by use of the Affymetrix® Genome-Wide Human SNP Array 6.0. All 
SNP array experiments were performed and data was analyzed according to the 
Figure 1 Pedigree of W08-2221. Squares indicate males, circles females. Solid 
symbols depict affected individuals, clear symbols mean unaffected. WT means 
wild type. The genotypes of individuals II.2 and II.3 are not shown because of 
privacy reasons.
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manufacturer’s protocol. Genotype calling and calculation of the regions of 
homozygosity was performed with the Affymetrix® Genotype Console Software v2.1 
with use of default settings. The segregation of the genotypes for each previously 
reported nonsyndromic, recessive deafness gene was visually evaluated.
Haplotype analysis of Variable Number Tandem Repeat (VNTR) markers was used 
to evaluate the family for involvement of OTOGL, PTPRQ , STRC, GJB3 and SYNE4. VNTR 
marker analysis was performed as described before by Schraders et al. 16 
We performed Sanger sequence analysis for genes associated with autosomal 
recessive hearing impairment in shared genotype regions, TRIOBP, SOX10, GIPC3, 
MSRB3, TECTA, BSND, WHRN, TPRN, SLC26A4, SLC26A5, GRXCR1, PJVK, TMC1 and USH1G. 
The effect of the missense mutation on the surface and structure of the SANS 
protein was predicted by using a hybrid model of the protein constructed by the 
automatic script in YASARA 17. The structure of the area surrounding amino acid 
residue 104 is based on the Protein Data Bank file 1n0r, which has a sequence 
identity of 41% with SANS.
Audiometry
Pure tone audiometry was performed, according to current standards to determine 
hearing thresholds at frequencies of 0.25, 0.5, 1, 2, 4 and 8 kHz. To exclude 
conductive hearing impairment, both air and bone conduction thresholds were 
determined. Speech recognition scores were measured by using standard Dutch 
phonetically balanced consonant-vowel-consonant word lists. The maximum 
phoneme recognition score (mean value of both ears) was obtained from monaural 
performance versus intensity curves. The mean value of both ears was plotted 
against age and mean pure tone average (PTA) at 1, 2 and 4 kHz. These curves were 
compared to the curves of presbyacusis patients 18. 
We additionally tested acoustic reflexes, as well as loudness scaling and speech 
perception thresholds in individual II.1. Acoustic reflexes were measured at the 
contralateral ear as well as at the ipsilateral ear at 0.5, 1, 2 and 4 kHz up to the 
loudness discomfort level. Loudness scaling and speech perception thresholds in 
noise were evaluated as described before 19, 20. The results of these examinations 
were compared to those of normal hearing individuals, retrieved from our own 
clinic, and to those of presbyacusis patients 19. 
Prism 5.0 (Graphpad Software Inc., San Diego, CA, USA) was used to evaluate 
progression of hearing loss, speech recognition scores and loudness scaling by 
means of regression analysis.
Vestibular examination
Vestibular function was evaluated by electronystagmography in individual II.1. 
This involved calorisation and a rotary chair testing using the velocity-step test. A 
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smooth pursuit, a gaze, an optokinetic test and saccadic tests were performed to 
confirm normal vestibule-oculomotor function and to exclude the presence of 
possible central lesions. To determine the reactivity and possible vestibular 
preponderance of both individual vestibuli bithermal (30 and 44˚C) water 
irrigation of the external auditory canal was used for calorisation. For the velocity 
step test, the patient was seated in a rotary chair with the head ante-flexed at 30˚ 
to obtain a horizontal position of the horizontal semicircular canals. The chair 
was accelerated and when the rotatory nystagmus had subsided during constant 
rotation, the chair was suddenly stopped. This was done for both directions in 
order to calculate the possible presence of directional preponderance (asymmetry). 
Analyses were performed as described previously 21.
Ophthalmic evaluation
Retinal function was evaluated in detail in individual II.1. We performed history 
taking and standard ophthalmic examination including best-corrected visual 
acuity (BCVA), slit-lamp biomicroscopy and ophthalmoscopy. Goldmann perimetry 
was performed using targets V-4e, III-4e, I-4e, I-3e, I-2e and I-1e. In addition to 
fundus photography (Topcon TRC50IX, Topcon Corporation, Tokyo, Japan), we 
obtained 30˚x30˚ and 55˚x55˚ fundus autofluorescence (FAF) images (Spectralis, 
Heidelberg Engineering, Heidelberg, Germany). Cross-sectional images of the 
central and peripheral retina were obtained with a commercially available Spec-
tral-domain optical coherence tomography (SD-OCT) instrument (Spectralis, 
Heidelberg Engineering, Heidelberg, Germany) using a 20°x15˚ 19-line volume 
scan covering the fovea as well as a 20˚ single line scan in the superior midperiphery. 
The patient underwent a full-field electroretinography (ERG) performed according 
the guidelines of the International Society for Clinical Electrophysiology of Vision 
(ISCEV) 22. Additionally, color vision was evaluated using Hardy-Rand-Rittler (HRR) 
plates.
Results
Clinical evaluation
Family W08-2221 consists of parents and four siblings of whom two are hearing 
impaired: a female (II.1) and a male (II.4). Hearing loss was noted since the age of 
four in both siblings. Physical examination did not demonstrate any dysmorphic 
features suggestive of syndromic disease. A CT scan of the temporal bones in 
individual II.1 did not show any abnormalities. 
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Genetic analyses and molecular modeling
Autozygosity mapping revealed 22 homozygous regions larger than one Mb including 
one known gene for recessive deafness, STRC. For 17 other known autosomal recessive 
deafness- associated genes the genotypes segregated with the hearing loss upon 
manual inspection of the SNP genotypes. OTOGL, PTPRQ , STRC, GJB3 and SYNE4 were 
excluded by haplotype analysis of flanking VNTR markers. Mutation analysis was 
performed for the other genes by Sanger sequencing and three rare variants were 
identified. A heterozygous synonymous variant was detected in TRIOBP (c.4809T>C; 
p.= (p.(Asp1603Asp)), NM_001039141.2) and two variants in USH1G (NM_173477.2). 
One novel variant, c.780insGCAC, which causes a frameshift and a predicted 
premature stop codon (p.(Tyr261Alafs*96)), and a missense variant (c.310A>G; p.
(Met104Val)). The USH1G variants segregated with the hearing loss in the family 
(Figure 1) and were not present in 350 Dutch control alleles. The insertion was also 
not present in the exome variant server (EVS), while the c.310G>A variant was 
identified in 4 out of 13002 European American and African American alleles 23. 
The amino acid substitution p.(Met104Val) is predicted to be benign by Polyphen2 
(score 0.066; range 0-1 with 0= benign and 1= probably damaging) 24. SIFT predicts 
that the substitution affects protein function (score 0.03; a score ≤ 0.05 predicts the 
change to be damaging and >0.05 predicts it to be tolerated) 25. Mutation taster 
predicts the substitution to be disease causing with a probability of 0.99 (0-1) 26. 
Molecular modeling predicts that substitution of methionine for valine in the 
third ankyrin domain of SANS causes a change at the surface of this domain, and 
therefore possible loss of hydrophobic contacts but no change in structure of the 
domain (Figure 2A). For comparison, modeling of a previously described missense 
mutation (p.(Leu48Pro)) in patients with Usher syndrome type Ig was performed 27. 
This missense mutation is predicted to cause a disturbance of the protein structure 
(Figure 2B). Ankyrin domains are mainly formed by helical structures, and proline 
is known to disrupt helical structures. Therefore, it is expected that this missense 
mutation changes the helical structure of the protein and hence affects protein 
function (figure 2B). 
Audiometric evaluation
Figure 3A demonstrates the deterioration of air conduction thresholds of individual 
II.1 over time. Air conduction thresholds did not differ from bone conduction 
thresholds. At onset, her hearing loss was moderate, but over time it progressed to 
severe. The audiogram configuration was initially flat to gently downsloping, but 
over time the curve became steeper downsloping, demonstrating significant 
progression especially in the high frequencies (Table 1). 
100 | Chapter 2
Figure 2 A. Molecular modeling of missense variants in SANS. Close-up of the 
third ankyrin domain with wild type amino acid (methionine) in green and the 
variant (valine) in red. The change of methionine to a valine at position 104, leads 
to a change at the surface of the ankyrin domain. B. Close-up of the first ankyrin 
domain with wild type (leucine) in green and the variant (proline) in red. Insertion 
of a proline for a leucine at position 48 causes a change in structure, due to the 
interference with the helix structure of the ankyrin domain. 
Table 1 Annual deterioration thresholds
0.25 kHz 0.5 kHz 1 kHz 2 kHz 4 kHz 8 kHz
II.1
p-value
-0.25 
(n.s.)
0.09
(n.s.)
-0.25 
(0.02)
-1.51
(<0.0001)
-1.71
(<0.0001)
-1.60
(<0.0001)
II.4
p-value
-0.82
(0.03)
-0.25 
(n.s.)
-0.09
(n.s)
-0.51 
(n.s.)
-1.17
(0.0001)
-2.02
(0.0001)
Results of longitudinal regression analysis of individual binaural mean air conduction thresholds in dB/yr. 
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When speech perception scores were plotted against age, scores began to 
deteriorate after the age of 20 years. When speech perception scores were plotted 
against PTA
1,2,4kHz
, individual II.1 clearly performed better than presbyacusis 
patients (Figure 4).
Figure 3 Longitudinal binaural mean air conduction threshold data of family 
members II.1 (A); aged 4.8-25.6 years and II.4 (B); aged 4.9-20.3 years. Age (years) is 
shown with a symbol key.
Figure 4 A. Longitudinal regression analysis of mean monaural phoneme recognition 
score (% correct) related to age (year) of both affected family members. Scores of II.1 
are indicated in grey circles, the regression line is a dashed grey curve. Scores of 
II.4 are indicated as black squares, the regression line is black and solid. The dashed 
curve indicates nonlinear regression of presbyacusis patients. B. Longitudinal 
regression analysis of mean monaural phoneme recognition score (% correct) related 
to PTA
1, 2, 4 kHz
 (dB HL). Same legend as figure 4A.
II.1
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
140
25.6
20.9
15.2
10.0
4.8
II.4
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
140
20.3
15.2
10.3
4.9
A B
0 20 40 60 80 100
0
20
40
60
80
100
90
A
Age (y)
%
 C
o
r
r
e
c
t
0 20 40 60 80 100
0
20
40
60
80
100
90
B
PTA1, 2, 4 kHz
%
 C
o
r
r
e
c
t
102 | Chapter 2
Patient II.4 also showed a moderate hearing loss and progression was less outspoken 
over time than in case II.1. Audiogram configuration remained flat to gently 
downsloping (Figure 3B) but progression was significant at 0.25, 4 and 8 kHz (Table 
1). Speech recognition scores plotted against age were comparable to those of 
individual II.1 and remained stable. However, individual II.4 had just reached the 
age at which the scores of individual II.1 began to deteriorate. When the scores 
were plotted against PTA
1,2,4kHz
, they were comparable to those of individual II.1.
Acoustic reflexes were absent in individual II.1. Loudness scaling of II.1 showed a 
steeper loudness growth than one would expect from normal hearing individuals 
for both 0.5 kHz and 2 kHz. The signal to noise ratio was worse than the average 
ratio of normal hearing individuals and presbyacusis patients. 
Vestibular evaluation
Patient II.1 complained of motion sickness. She showed a spontaneous nystagmus 
of 3 deg/s to the left, which was considered to be non-significant. Recording of the 
optokinetic nystagmus and results of all vestibule-oculomotor tests were normal. 
During the velocity step test, gain and start speed were slightly higher than 
normal; time constant and amplitude were normal. Results of calorisation were 
normal as well. There was a slight asymmetry between both labyrinths, to the 
detriment of the right vestibulum. Based on these results, vestibular function was 
considered normal. 
Ophthalmic evaluation
Both patients had no visual complaints, including absence of night blindness, 
visual field loss and decrease in central vision. Patient II.1 presented with amblyopia 
of the right eye, with a suboptimal visual acuity of 20/30 after occlusion therapy, 
whereas visual acuity reached 20/12 in the left eye. Ophthalmic examination 
revealed normal anterior segments and retinas. There were no signs of RP: no bone 
spicules, no attenuation of the retinal vasculature, no (waxy) pallor of the optic 
disc or degeneration of the RPE were observed (Figure 5A). FAF images revealed 
normal autofluorescence of the RPE (Figure 5B) and SD-OCT revealed normal 
retinal architecture, including intact photoreceptor layer reflectance in the 
macula and midperiphery (Figure 5D and 5E). Additionally, Goldmann perimetry 
showed normal visual field sizes and sensibility levels and HRR plates were named 
correctly. Rod- and cone-derived responses on full-field ERG were normal in both 
eyes.
We concluded that subject II.1 had normal retinal appearance and function in both 
eyes. The amblyopia found in this patient was not considered to be a (prodromal) 
symptom of an Usher syndrome phenotype. 
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Discussion
Here, we present, to our knowledge, the first cases of non-syndromic autosomal 
recessively inherited hearing loss caused by mutations in USH1G. The moderate 
hearing loss has an onset during early childhood. Mild progression of hearing loss, 
especially in the higher frequencies, was observed. Resulting in a downsloping 
audiogram configuration. Although it was only performed in one individual, 
results of psychophysical examination were in line with a cochlear, sensorineural 
hearing loss. No vestibular abnormalities were detected. During ophthalmic 
examination of patient II.1, no retinal pathology was observed, especially no signs 
Figure 5 Multi-modal imaging of the right eye of patient II.1 at age 25. A. Fundus 
photography of central fundus of the right eye showing no abnormalities. B. Fundus 
autofluorescence imaging of the right eye with normal autofluorescence levels in 
the posterior pole. C. Infra-red en face image of the posterior pole of the right eye. 
The green lines indicate the location of the optical coherence tomography (OCT) 
images depicted in panels D and E. D. OCT image of the central retina of the right 
eye depicting the fovea, which reveals no retinal abnormalities and especially a 
normal photoreceptor layer and retinal pigment epithelium (RPE). E. OCT image of 
the midperipheral retina of the right eye revealing normal retinal architecture.
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of RP which is a clinical hallmark for Usher syndrome. This absence of ophthalmic 
abnormalities made us characterize the phenotype in individual II.1 as 
nonsyndromic. However, while absent at the age of 25 years, RP may develop at a 
later age, which is highly atypical for type I Usher syndrome. Atypical USH1G-asso-
ciated Usher syndrome has been described by Kalay et al. and Bashir et al. in 
patients with retinal abnormalities, but without visual problems 14, 15. However, 
these retinal abnormalities were already observed in patients younger than 
individual II.1. 
Of the six known Usher syndrome type I genes, five were already known to be 
involved in nonsyndromic autosomal recessive hearing loss, except for USH1G 6, 8, 
28-30. A number of explanations have been given for the fact that mutations in these 
genes either lead to syndromic or nonsyndromic hearing loss. Ouyang et al. 
illustrated the importance of tissue-dependent alternative splicing as a cause of 
phenotypic heterogeneity in Usher syndrome type 1c, since harmonin has isoforms 
that are only expressed in the inner ear and not in the retina 5. However, to our 
knowledge, only one isoform is currently known for the USH1G encoded protein 
SANS. 
The difference between Usher syndrome type 1f and DFNB23 has been correlated 
to the mutational effect and residual function of specific protein domains. Only 
missense mutations that do not affect calcium binding and rigidification of 
protocadherin15 (PCDH15) cause DFNB23 thus far 6, 29, 31. Missense mutations are 
more likely to result in residual protein function than truncating mutations. 
Furthermore, Riazuddin et al. hypothesize that some residual function of myosin 
VIIA is retained in DFNB2 and that no residual function of the protein will be 
found in Usher syndrome type 1b 8, which was also hypothesized for CDH23 
(DFNB12 and Usher syndrome type 1d) 7, 30. 
Families have been described with Usher syndrome type Ig carrying USH1G 
missense mutations that are expected to result in residual protein function. 
Therefore, we assume that the differences of the genotypic spectrum depend on 
the extent of residual protein function. In addition, other factors are probably also 
involved in the heterogeneity of the phenotypic spectrum of USH1G-associated 
disease.
When compared to other USH1G genotypes, the genotype described here mostly 
resembles the genotype of a German family described by Weil et al. 27. In this 
family, one allele contains a missense mutation (c.143T>C) which leads to a 
substitution of proline for leucine (p.(Leu48Pro)) in the first ankyrin domain. The 
second mutation (c.186-187delCA) is predicted to lead to a truncated protein (p.
(Ile63Leufs*71)). The phenotype in the affected members of this German family 
deviates from that in family W08-2221 as the former demonstrates an Usher 
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syndrome type I phenotype. As shown by modeling, the change of methionine to 
valine at position 104 might only alter the surface of SANS, and not the overall 
structure (figure 2A). This may result in a reduction or loss of binding of one or 
more interactions partner of SANS. The p.(Leu48Pro) substitution is predicted to 
lead to a more severe structure alteration and predicted loss of hydrophobic 
contacts (Figure 2B). This may interfere more with interaction partners than the 
slight surface change caused by p.(Met104Val). Interacting with other proteins is 
essential for the function of SANS, since it is a scaffold protein and is known to 
bind with multiple proteins of the Usher interactome 32. Furthermore, the p.
(Leu48Pro) mutation might affect binding of one or more proteins that are essential 
in both inner ear and retina whereas the p.(Met104Val) might affect the interaction 
with protein(s) that are only essential in cochlear function. To our knowledge, no 
interaction partners for the ankyrin domains of SANS have been identified. 
Questions now rise on the prevalence of nonsyndromic hearing loss based on 
mutations in USH1G. One is probably less vigilant on USH1G as a causal gene for 
nonsyndromic hearing loss since it has not been described before to be associated 
with a nonsyndromic type of the disease. We assume that more patients with 
USH1G-associated isolated hearing loss will be identified in the future, especially as 
the c.310A>G mutation has been found in 0.03% of alleles in the EVS database. We 
demonstrate that several different phenotypes can trigger one to consider USH1G 
as the causative gene: when a patient presents with Usher syndrome type I or with 
atypical Usher syndrome, but most certainly also when a patient presents with a 
nonsyndromic, autosomal recessive, slightly progressive hearing loss. 
Conclusion
We describe, to our knowledge, the first family with nonsyndromic sensorineural 
hearing loss based on mutations in USH1G. The hearing loss has an onset during 
early childhood, is progressive and has a downsloping audiogram configuration. 
Ophthalmic and vestibular abnormalities are absent. More knowledge on 
interaction partners and how they bind to SANS will probably clarify the 
heterogeneous spectrum of phenotypes found with mutations in USH1G in the 
near future. 
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Abstract
In a consanguineous Turkish family diagnosed with autosomal recessive non- 
syndromic hearing impairment (arNSHI), a homozygous region of 47.4 Mb was 
shared by the two affected siblings on chromosome 6p21.1-q15. This region 
contains 247 genes including the known deafness- associated gene MYO6. No 
pathogenic variants were found in MYO6 neither with sequence analysis of the 
coding region and splice sites nor with mRNA analysis. Subsequent candidate gene 
evaluation revealed CLIC5 as an excellent candidate gene. The orthologous mouse 
gene is mutated in the jitterbug mutant that exhibits progressive hearing 
impairment and vestibular dysfunction. Mutation analysis of CLIC5 revealed a 
homozygous nonsense mutation c.96T>A (p.(Cys32X)) that segregated with the 
hearing loss. Further analysis of CLIC5 in 213 arNSHI patients from mostly Dutch 
and Spanish origin did not reveal any additional pathogenic variants. CLIC5 
mutations are thus not a common cause of arNSHI in these populations.
The hearing loss in the present family had an onset in early childhood and 
progressed from mild to severe or even profound before the second decade. 
Impaired hearing is accompanied by vestibular areflexia and in one of the patients 
with mild renal dysfunction. Although we demonstrate that CLIC5 is expressed in 
many other human tissues no additional symptoms were observed in these 
patients. 
In conclusion, our results show that CLIC5 is a novel arNSHI gene involved in 
progressive hearing impairment, vestibular and possibly mild renal dysfunction 
in a family of Turkish origin.
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Introduction
Hearing impairment is the most common sensory disorder worldwide and it is 
clinically and genetically very heterogeneous 1. Approximately 80% of early onset 
hereditary non-syndromic hearing impairment inherits in an autosomal recessive 
pattern. Currently, 80 loci and 49 genes have been identified for autosomal 
recessive non-syndromic hearing impairment (arNSHI), showing the great genetic 
heterogeneity 2. This heterogeneity might well be explained by the complexity of 
the auditory system. Defects in a large variety of biological processes such as gene 
regulation, ion homeostasis and hair bundle morphogenesis can lead to hearing 
impairment 3.
In the last decade, homozygosity mapping using genome-wide SNP genotyping has 
been a powerful tool in the identification of arNSHI loci and genes 4. Lately, next 
generation sequencing technologies have revolutionized the genetics field and 
also led to the identification of novel arNSHI genes at fast pace 5. The most powerful 
evidence to assign a candidate gene as a novel deafness gene is to discover 
pathogenic variants in several families and not in controls. However, due to the 
large genetic heterogeneity of hearing impairment this can be very difficult even 
with the current technologies. This is also evident from three recently identified 
arNSHI genes, PNPT1, SERPINB6 and TSPEAR, for which mutations have only been 
described in a single family each 6-8. Further evidence to assign a candidate gene as 
a deafness gene can come from animal models, especially mouse models with 
hearing loss. Several genes essential for hearing in humans were identified after 
they had already been demonstrated to be associated with deafness in mice 9.
Using homozygosity mapping and candidate gene analysis we identified a 
homozygous nonsense mutation in CLIC5 in a consanguineous Turkish family 
(W05-009). The orthologous mouse gene, Clic5, was described to be mutated in the 
jitterbug ( jbg) mouse exhibiting congenital progressive hearing impairment and 
vestibular dysfunction due to progressive hair cell degeneration 10. 
Materials and Methods
Subjects and clinical evaluations
This study was approved by the local medical ethics committee of the Radboud 
university medical center and Hospital Universitario Ramon y Cajal. Signed 
informed consent was obtained from the parents, since all patients are minors. In 
addition, a signed form was used to retrieve relevant data from other medical 
centers.
For the affected individuals of family W05-009 general physical examination was 
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performed by a pediatrician. Blood and urine samples were analyzed to evaluate 
renal and thyroid function. ENT examination was executed to exclude other 
possible causes of hearing impairment like previous ear surgery and external ear 
deformities. A computed tomography (CT) scan of the temporal bone was performed 
in order to exclude possible anatomical causes of hearing loss. Pure tone audiometry 
was performed according to current standards to determine hearing thresholds at 
0.25, 0.5, 1, 2, 4 and 8 kHz. To exclude conductive hearing loss both air conduction 
and bone conduction thresholds were obtained. Classification of the hearing loss is 
in accordance with the GENDEAF guidelines 2. In addition, otoacoustic emissions 
(OAEs) were measured in individual II.3. Vestibular function was evaluated by 
electronystagmography and rotatory tests 11. GraphPad Prism 5.00 (GraphPad, San 
Diego, CA, USA) was used to perform linear regression analysis to evaluate 
progression of the hearing impairment.
Three panels of arNSHI patients were analyzed for involvement of CLIC5. GJB2 
mutations or GJB6 deletions were excluded by routine analysis in most of these 
patients. The first panel consisted of 76 arNSHI index patients, mostly of Dutch 
origin, and these were selected based on the hearing loss phenotype. They 
presented either with a downsloping audiogram configuration and progression of 
hearing loss or early onset progressive hearing loss accompanied by vestibular 
areflexia or hyporeflexia. 
The second panel consisted of 69 unrelated arNSHI sibships of Spanish origin 
which were not preselected based on type or severity of their hearing impairment. 
The third panel contained 18 arNSHI index patients of Spanish origin selected 
based on the hearing loss phenotype. In most of the cases, the hearing loss was 
postlingual (16 in childhood, at school age; two in the second decade of life) and 
progressive with a downsloping audiogram configuration.
Homozygosity Mapping
Genomic DNA was isolated from peripheral-blood lymphocytes by standard 
procedures. Individuals II.2 and II.3 from family W05-009 were genotyped using 
the Affymetrix mapping 250K NspI SNP array. All SNP array experiments were 
performed and analyzed according to the manufacturer’s protocol (Affymetrix, 
Santa Clara, CA, USA). Genotype calling and calculation of the regions of 
homozygosity were performed with the Genotyping Console software (Affymetrix) 
with the default settings. The cosegregation of the genotypes for each previously 
reported arNSHI gene was visually evaluated.
Mutation Analysis
Primers for amplification of exons and exon-intron boundaries of CLIC5 
(NM_016929.4, CLIC5A and NM_001114086.1, CLIC5B), ESPN (NM_031475.2), MYO6 
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(NM_004999.3) and for mRNA analysis of MYO6 (NM_004999.3) were designed with 
ExonPrimer 12. Primer sequences and PCR conditions are provided in Supplemental 
Table S1. Amplification by PCR was performed on 40 ng of genomic DNA with Taq 
DNA polymerase (Roche, Mannheim, Germany). For MYO6 mRNA analysis, total 
RNA was isolated from Epstein-Barr-virus (EBV)-transformed lymphoblastoid cells 
of affected individual II.2 using the NucleoSpin RNA II kit (Machery Nagel, Düren, 
Germany) according to the manufacturer’s protocol. Subsequently, cDNA synthesis 
was performed with 1.5 µg RNA as starting material by using the iScript cDNA 
Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA), according to the 
manufacturer’s protocol. PCR reactions were performed on 2 µl cDNA with the Taq 
DNA polymerase (Invitrogen, Carlsbad, CA, USA). 
PCR fragments were purified with the use of NucleoFast 96 PCR plates (Clontech, 
Mountain View, CA, USA) or ExoI/FastAP (Fermentas, Vilnius, Lithuania) in 
accordance with the manufacturer’s protocol. Sequence analysis was performed 
with the ABI PRISM BigDye Terminator Cycle Sequencing V2.0 Ready Reaction kit 
and analyzed with the ABI PRISM 3730 DNA analyzer (Applied Biosystems Foster 
City, CA, USA). The presence of the CLIC5 c.96T>A transversion was investigated in 
111 ethnically matched healthy controls. Exon 2 of CLIC5 was amplified and PCR 
products were purified as described above. Digestion of the PCR products with 
HpyCH4III (New England Biolabs, Ipswich, MA, USA) was performed in accordance 
with the manufacturer’s protocol, and restriction fragments were analyzed on 
gels containing 1.5% agarose and 1% low-melting agarose. The mutation removes a 
restriction site.
Nonsense-mediated mRNA decay (NMD) evaluation
EBV-transformed lymphoblastoid cell lines were established from heparin blood of 
individuals II.2 and II.3. Cells were grown with and without cycloheximide, a 
protein synthesis inhibitor, which prevents the nonsense-mediated mRNA decay 
process as described previously 13. Total RNA was isolated as described above. cDNA 
synthesis was performed with 3 µg RNA as starting material by using the iScript 
cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA), according to the 
manufacturer’s protocol. For the quantitative PCR (qPCR), specific primers 
(Supplemental Table S1) were designed with Primer3Plus14 and reference sequence 
NM_016929.4. PCRs were performed with the Applied Biosystem Fast 7900 System 
in accordance with the manufacturer’s protocol. The human beta glucuronidase 
gene (GUSB [MIM 611499]) was employed as an internal control. PCR mixtures were 
prepared with the Power Syber Green Master Mix (Applied Biosystems) in 
accordance with the manufacturer’s protocol. Temperatures and reaction times 
for PCR were as follows: 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 30 
s at 60°C. All reactions were performed in duplicate. Relative gene expression 
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levels were determined with the delta delta Ct method as described previously 15.
CLIC5 Expression Profile
RNA derived from adult heart, retina, brain and kidney was purchased from 
Clontech (Mountain View, CA, USA). RNA derived from adult skeletal muscle, liver, 
duodenum, testis, spleen, thymus, and placenta were purchased from Stratagene 
(La Jolla, CA, USA) and bone marrow from Bio-chain (Newark, CA, USA). RNA 
derived from fetal brain, colon, kidney, stomach, spleen, heart, skeletal muscle, 
lung and thymus was purchased from Stratagene. In addition, RNA was isolated 
from adult lung, fetal cochlea and fetal liver as described previously 16. The inner 
ear was derived from a fetus at 8 weeks of gestation and the other fetal tissues 
from fetuses at 20 – 21 weeks of gestation. cDNA synthesis, primer design 
(Supplemental Table S1) and qPCR analysis were performed as described above. The 
forward primer was located on the boundary of exons 2 and 3, and the reverse 
primer in exon 3. This enabled detection of all CLIC5 isoforms affected by the 
nonsense mutation that is located in exon 2. Relative gene expression levels were 
determined with the comparative delta Ct method as described previously 17.
Results
Hearing loss and vestibular dysfunction in family W05-009
ENT examination and CT scanning did not reveal an apparent cause of hearing 
impairment in the two affected children of family W05-009. The parents have 
normal hearing and are first cousins of Turkish ancestry (Figure 1A). The patients 
presented with an early onset sensorineural hearing loss since the bone conduction 
thresholds did not differ from the air conduction thresholds. The hearing 
impairment probably was not congenital since individual II.2 passed a behavioural 
reflex audiometry test which is performed between 7 and 9 months of age (Ewing 
test) and individual II.3 had normal hearing at the age of 3 months during 
brainstem evoked response audiometry. The hearing loss started mildly, affecting 
the mid and high frequencies mostly. OAEs were not present in individual II.3 at 
the age of 4 months. It progressed to a severe-to-profound hearing loss with a 
gently to steeply downsloping audiogram configuration as is shown in Figure 1B. 
Longitudinal linear regression analysis indicated significant progression in all 
frequencies (Figure 1C). Individual II.2 received a cochlear implant at the age of 11 
years. Five years post-implantation, the speech recognition scores were 88% (using 
the standard Dutch phonetically balanced consonant-vocal-consonant word lists) 
18. Initial motor milestones were reported to be normal, but later in life balance 
problems did occur e.g. difficulties with walking in the dark and cycling. Vestibular 
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areflexia was found in both individuals during the rotatory test at the age of 16 
years (II.2) and 11 years (II.3).
General physical examination showed that both children had a normal height and 
weight. No other abnormalities besides the hearing impairment were noted in 
individual II.2. On history, there were no signs of any other abnormalities in 
individual II.3. Thyroid function was also normal in individuals II.2 and II.3. Renal 
function was normal in II.2. However, in individual II.3 a blood pressure of 127/73 
to 129/88 mmHg (90% value for this age and length: 120/76 mmHg) was measured 
and an elevated albumin/creatinine ratio was detected at the last two visits in the 
outpatient clinic (9.2 and 3.8 mg/mmol, respectively, normal value <2.5 mg/mmol) 
during urine analysis at the age of 11 years. The glomerular filtration rate, 
calculated with the Schwartz equation, was normal with a value of 114 ml/
min/1.73 m2 (normal > 90 ml/min/1.73 m2). Since the elevated blood pressure and 
albumin/creatinine ratio were seen in repeated measurements, these might be the 
first signs of a nephropathy. However, no other more invasive studies were 
performed, since the renal function was overall only mildly affected. Subsequent 
renal function follow-up of patient II.3 in the future will be needed to determine 
whether it is indeed a nephropathy.
Homozygosity mapping confines a critical region on chromosome 
6p21.1-q15
To identify genes for arNSHI, homozygosity mapping was performed in some large 
series of familial and isolated arNSHI patients living in the Netherlands. In family 
W05-009 homozygosity mapping revealed a homozygous region of 47.4 Mb on 
chromosome 6p21.1-q15 (Figure 2A). This was the largest homozygous region 
shared by the two affected individuals. This region contains the known deafness- 
associated gene MYO6. There were 15 other shared homozygous regions larger than 
1 Mb (Supplemental Table S2), and in one of them ESPN is located, which is another 
gene known for arNSHI. Mutation analysis was performed for all exons and 
exon-intron boundaries of ESPN and MYO6, which revealed no putative causative 
variants. Since MYO6 was located in the largest shared homozygous region, MYO6 
mRNA was analyzed by RT-PCR. No PCR-products of an aberrant size were 
indentified and also sequence analysis of the PCR products did not reveal 
indications for aberrant splicing. To exclude compound heterozygous or allozygous 
mutations in the other known arNSHI genes, cosegregation of the genotypes was 
visually evaluated for each gene. PNPT1, ILDR1, RDX, TECTA, OTOGL, PTPRQ and OTOA 
were present within the genotype shared regions. OTOA could be excluded by short 
tandem repeat (STR) marker analysis in the family. No putative pathogenic variants 
were identified in the other genes by sequence analysis of the exons and exon-intron 
boundaries.
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A nonsense mutation in CLIC5 causes arNSHI
Since no pathogenic variants could be identified in MYO6 or ESPN we hypothesized 
that another gene would be underlying the hearing loss in this family. Therefore, 
we continued with the evaluation of the 247 annotated genes in the largest 
homozygous region, 6p21.1-q15 19. For three of the genes, mutations in the 
orthologous mouse gene cause deafness. Slc17a5 (MGI:1924105)20 and Bmp5 
(MGI:88181) are associated with mixed and conductive hearing loss in the mouse, 
respectively. The third gene, Clic5, was described to underlie progressive 
Figure 1 A. Pedigree of family W05-009 and segregation of the CLIC5 c.96T>A 
variant. B. Longitudinal binaural mean air-conduction pure tone thresholds are 
shown of affected members of family W05-009. Age (years) is shown with a symbol 
key. The p95 line, matched for age and sex, indicates that 95% of the population 
has thresholds lower than these. C. Regression analysis of longitudinal binaural 
mean air conduction threshold data for each frequency separately. Circles indicate 
individual II.2, squares indicate individual II.3. Annual threshold deterioration is 
shown behind the symbol key for each frequency.
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Figure 1  Continued.
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sensorineural hearing loss and vestibular dysfunction in the jbg mouse mutant 10. 
Therefore, CLIC5 represented an excellent candidate gene.
Mutation analysis of CLIC5 revealed a homozygous nonsense variant c.96T>A 
(p.(Cys32X)) (Figure 2B), which segregated with the hearing impairment in family 
W05-009 (Figure 1A). This variant was not present in 222 Turkish control alleles, 
the Exome Variant Server21 and the Nijmegen in-house exome database (1302 
exomes). This variant was submitted to the Leiden Open Variant Database 22.
The homozygous CLIC5 c.96C>T mutation is predicted to result in NMD, since it 
creates a premature stop codon (p.(Cys32X)) more than 54 bp upstream of the 
3’-most intron 23. However, we could not confirm NMD. The relative CLIC5 mRNA 
expression is comparable in cycloheximide treated and untreated patient EBV-cell 
lines (157.24% vs. 157.89%, respectively) and higher - albeit not significantly - than 
in controls (set at 100%) as shown in Supplemental figure 1. 
Figure 2 A. Schematic overview of the chromosomal region 6q21.1-q15 showing 
the homozygous regions (black bars) identified in the affected individuals of 
family W05-009. The homozygous region of individual II.2 delimits the region to 
47.4 Mb. Mb positions and chromosome bands are according to the UCSC genome 
browser (GRCh37). B. Partial sequences are shown of CLIC5 exon 2 from an affected 
member, a parent and an unaffected sib of family W05-009. The predicted amino 
acid changes and the surrounding amino acids are indicated above the sequence. 
Mutated nucleotides are marked by an arrowhead. As reference sequence NM_016929.4 
was employed.
A
B
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For identification of other families with CLIC5 mutations, sequence analysis of the 
coding region and splice sites of CLIC5 was performed in 76 arNSHI index patients, 
mostly of Dutch origin, and 18 Spanish arNSHI index patients. These patients were 
preselected based on the hearing loss and vestibular phenotype as described in the 
materials and methods section. No putatively causative variants were identified in 
these patients. In a parallel approach, compatibility with linkage to DFNB102 was 
investigated in a panel of 69 unrelated arNSHI sibships of Spanish origin. These 
were genotyped for STR-markers D6S459, D6S1920, D6S1632 and D6S1638, which 
flank CLIC5. Haplotype analysis revealed compatibility with linkage of the disease 
locus to these markers in 18 sibships. Sequence analysis of CLIC5 in the index cases 
of these sibships did not reveal any putative pathogenic variants. Finally, data of 50 
whole exome sequence analysis of arNSHI patients, mainly of Dutch origin were 
evaluated for the presence of variants in CLIC5. These patients were not preselected 
based on the type or severity of the hearing loss. No putatively pathogenic variants 
were identified in this cohort.
CLIC5 is expressed in the human inner ear
The expression of CLIC5 was studied via qPCR in human fetal inner ear and 
compared to that in additional 13 adult and 10 fetal-stage human tissues (Figure 
3). Since this was performed in two separate experiments for adult and fetal 
tissues, fetal inner ear was included in both for comparison. The tissues were not 
derived from fetuses of the same gestational stage; therefore, a direct comparison 
of the transcript levels cannot be made. In fetal tissues, CLIC5 transcript levels were 
highest in skeletal muscle, kidney, spleen, heart and colon. A lower expression 
level was found in fetal brain, thymus, lung and stomach. Expression in the fetal 
inner ear was 26 fold higher than in fetal liver in which the expression level was 
the lowest. In adult tissues, the highest expression levels were found in heart, lung, 
skeletal muscle and kidney and there was a gradual decrease through retina, 
spleen, brain, placenta, duodenum and thymus. Finally, the lowest expression 
levels were found in bone marrow, testis and liver. We can conclude that CLIC5 is 
widely expressed in both fetal and adult human tissues.
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Discussion 
We present a homozygous nonsense mutation, c.96T>A (p.(Cys32X)) in CLIC5 
(DFNB102) as a cause of sensorineural hearing impairment accompanied by 
vestibular dysfunction. This nonsense variant will lead to an early truncation of 
the protein. Screening a series of arNSHI index patients did not reveal additional 
causative variants, suggesting that mutations in CLIC5 are not a common cause of 
arNSHI neither in the Netherlands nor in Spain. 
Initially, the hearing loss in the affected individuals of family W05-009 was mild, 
mainly affecting the mid and high frequencies, and then it progressed to severe to 
profound. They also showed vestibular areflexia in the second decade of life. The 
combination of progression to profound hearing loss and complete vestibular 
dysfunction in the patients of family W05-009 resembles the phenotype of the jbg 
mutants. Auditory-evoked brainstem responses (ABRs) at 1-5 months of age in jbg 
Figure 3  CLIC5 expression profile in human tissues. Relative CLIC5 mRNA levels as 
determined by qPCR in human fetal (A) and adult (B) tissues. The relative expression 
values were determined by using the comparative delta Ct method 17. The expression 
levels are relative to those in liver, which showed the lowest CLIC5 expression of all 
the tissues that were tested.
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mutant mice, which are null for Clic5, were 40-50 dB above those of wildtype mice. 
By 7 months of age their hearing loss had progressed to complete deafness due to 
progressive hair bundle degeneration and a reduced density of spiral ganglion 
cells 10. The vestibular hair cells of jbg mice also showed a progressive degeneration. 
In the crista ampullaris, the number of vestibular hair cells was reduced at 3 
months and hair cells were nearly absent at 12 months of age 10. 
Besides inner ear dysfunction, the phenotype in humans and mice with Clic5 
mutations may well overlap with respect to the renal phenotype. The jbg mice have 
abnormalities in the foot processes of the kidney podocytes leading to proteinuria 24,25. 
The elevated albumin/creatinine ratio and pre-hypertension in affected individual 
II.3 indicate mild renal dysfunction and may well be the first signs of a nephropathy. 
Therefore, follow-up of renal function is indicated for individual II.3 but also for 
his hearing impaired sister. 
In addition to the inner ear and kidney phenotypes, the jbg mutant mice also 
exhibit emphysema-like lung pathology, hyperactivity and resistance to diet- 
induced obesity 26. Characteristics of lung emphysema and hyperactivity were 
excluded in family W05-009 by history taking. The affected individuals had 
normal height and weight. No other gross abnormalities in the organs of the jbg 
mutants were detected and no other complaints from the affected siblings were 
reported so far. The lack of symptoms in organs with relatively high CLIC5 
expression (Figure 3) points towards redundancy for CLIC5 function there.
CLIC5 belongs to a family of chloride intracellular channel proteins, but its protein 
structure differs from other typical ion channel proteins. CLICs (CLIC1-6) show no 
sequence homology to any known channel family, but significant homology to 
glutathione S-transferases in the core region 27. Moreover, some of the CLIC 
proteins, including CLIC5, are not only integral membrane proteins, but are also 
found as soluble proteins in the cytoplasm 28. In the inner ear, CLIC5 localizes to 
stereocilia of both the cochlear and vestibular hair cells and on the surface of 
Kolliker’s organ during cochlea development in mice 10. Specifically, CLIC5 is 
predominantly present at the base of stereocilia and, to lesser extent, in the cell 
bodies of hair cells in the region surrounding the cuticular plate 10. CLIC5 was 
initially identified in placental microvilli as a component of a multimeric complex 
consisting of several known cytoskeletal proteins, including actin and ezrin 29. 
Although the function of CLIC5 is still elusive, there are several facts that support 
its role in stereocilia integrity. Firstly, radixin immunostaining is reduced in the 
hair bundle of jbg mice where it colocalizes with Clic5 10. This suggests that Clic5 
is needed for proper radixin activity, so when interacting with the ERM (erzin, 
radixin and moesin) complex, Clic5 may stabilize connections between the plasma 
membrane and the filamentous actin core 10. Secondly, Clic5 functions as an 
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adapter between the plasma membrane of podocytes and the actin cytoskeleton by 
facilitating the interaction between ezrin and podocalyxin 24, 25, 30. Thirdly, a recent 
study proposes that Clic5 functions as part of a multiprotein linker complex in 
companion with radixin, erzin and taperin 31. Protein tyrosine phosphatase 
receptor Q (Ptprq), which is mislocalized as radixin in the jbg mice, and Myosin VI, 
key regulator of the proper localization of Ptprq32, might well participate in this 
complex too. Radixin33, Ptprq32, 34 Myosin VI35 and Clic5 deficient mice10 show loss 
of stereocilia at the bundle vertex and fusion of stereocilia in postnatal stage. This 
suggests that this multiprotein complex is essential for stable membrane-cytoskel-
etal attachments at the stereocilia base. 
Conclusion
We show that a homozygous nonsense mutation in CLIC5 (p.(Cys32X)) underlies the 
progressive hearing impairment, vestibular and possibly mild renal dysfunction 
in a family of Turkish origin. CLIC5 mutations do not seem to be a common cause 
of arNSHI in the Dutch and Spanish populations. Further screening of CLIC5 in 
other populations will provide important information about the frequency of 
CLIC5 mutations and may aid to further define the phenotype associated with CLIC5 
mutations.
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Supplemental Table S1   Primer sequences and PCR conditions for genomic PCR, 
sequence analysis and QPCR.
Target Oligonucleotides Product 
size (bps)
Annealing 
Temperature 
(°C)
Primers for genomic PCR and sequence analysis of CLIC5, MYO6 and ESPN
CLIC5 Exon 1 Forward primer CCAGGACCAGCTCTGTCTC 733 56
 Reverse primer AACCTGCCTTCCTCCATTC   
CLIC5 Exon 2 Forward primer TTATTGAGCCCTTACATGCTG 484 56
 Reverse primer ACTTGCCTTTGCAGACTCTC   
CLIC5 Exon 3 Forward primer ACAGGCATGTTGGATAGCAC 653 56
 Reverse primer GTCACTGGGTTACCCTTTCC   
CLIC5 Exon 4 Forward primer GCTGGAAAGGGAAGTATTGC 306 56
 Reverse primer CTCTGGCCCAAGTATTTGAC   
CLIC5 Exon 5 Forward primer TCCAGGTATTCTGCAGTGTG 431 56
 Reverse primer AGGTTCTTGACCAACAGGTG   
CLIC5 Exon 6 Forward primer AAAGAAGACAGCACTGCCAC 427 56
 Reverse primer GCCTCAAGGCAGTGATACAG   
CLIC5 Exon 1a* Forward primer TCCAATGGACTTGTGGTTTG 885 56
 Reverse primer TGACTGATTTAGTCCCTCCG   
MYO6 Exon 1 Forward primer TCCGTAGCCGTGACGTG 532 56
 Reverse primer TCGGGCAGTGAACAGAAG   
MYO6 Exon 2 Forward primer TGGGCAGATGTGTTTGTTAG 388 56
 Reverse primer TGCTTTCCCAAATATCTACCTC   
MYO6 Exon 3 Forward primer GTATGCAACCAATTAAGCCC 262 56
 Reverse primer TAGATTGTTTCTGAACCCGC   
MYO6 Exon 4 Forward primer TAGGGTTTACATCAGCCAGG 337 56
 Reverse primer TCAAGCATGATTTTCTGTTAGAC   
MYO6 Exon 5 Forward primer TGGGTCCCTATAAAGATCAGG 471 56
 Reverse primer CCCTGTGTAAAATACTTGCTCC   
MYO6 Exon 6 Forward primer TGATTTCTTTAAGAGTAAGTGGTCC 322 58
 Reverse primer TACAGTGAGCTGTGGTGGTG   
MYO6 Exon 7 Forward primer TGATGATCTAGGTTTCAGTTTTATATG 238 56
 Reverse primer TGAGAGAAGAACATTCCAGACC   
MYO6 Exon 8 Forward primer GCATGAGCCACTGTGTCC 324 56
 Reverse primer TGCAAATACAGCACCAACTG   
MYO6 Exon 9 Forward primer AACCTCTTTGATAGACAAATGG 651 58
 Reverse primer CAGGCTCAAGCAATCCATC   
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Supplemental Table S1   Continued.
Target Oligonucleotides Product 
size (bps)
Annealing 
Temperature 
(°C)
Primers for genomic PCR and sequence analysis of CLIC5, MYO6 and ESPN
MYO6 Exon 10 Forward primer TTCATGGTTGGCACTATTTG 353 56
 Reverse primer CAACAAGAGGTATAAAGTATTACACTG   
MYO6 Exon 11 Forward primer AGTGCATTAATTGACCTGGTG 363 58
 Reverse primer TTTAAGCAAACTGCATATAAAGAGAC   
MYO6 Exon 12 Forward primer AAAAGTTACAAATAAGCCTTGCC 375 56
 Reverse primer TTTTGATCTACCAAGCTCAGG   
MYO6 Exon 13 Forward primer GTTTAGGTGCACTCTGTGGC 376 56
 Reverse primer CATATTATGAAATGTGAGTGTGGAC   
MYO6 Exon 14 Forward primer TGAGAACATTTGGGAAGTATAGAAC 351 56
 Reverse primer ATACACCATCCATCCACACC   
MYO6 Exon 15 Forward primer TTCAGAAACAGTGCAAAATTC 295 56
 Reverse primer CTTCCAGGCAGTAATACAGAAG   
MYO6 Exon 16 Forward primer TGTTGTTTCTGATCAGTCCTTG 389 56
 Reverse primer TCCATCTAAGGAAGATACTGTGC   
MYO6 Exon 17 Forward primer CTTACACCTATTTTCTTTCCTAAGAG 500 56
 Reverse primer TCACCACTAGTCAGTGTGGAC   
MYO6 Exon 18 Forward primer AAGTTCCTTTGGACAGAGCC 390 56
 Reverse primer CAAATATCAACAATGCAGGG   
MYO6 Exon 19 Forward primer CCAGGAGGTTGTTAAACTGG 267 56
 Reverse primer CAGGGTTACTATGCCTACTTGC   
MYO6 Exon 20 Forward primer CCCAGCCTTGAGTTCTTTAG 361 56
 Reverse primer AAGATGAAAATTTTATTGCACTG   
MYO6 Exon 21-22 Forward primer TCTCATAAATTGCCCGTTTC 580 56
 Reverse primer TGTTGTTAGTGACCATATAATTCAAG   
MYO6 Exon 23 Forward primer TGCCAAGGCCTATGTAATTG 354 56
 Reverse primer AGCATCACCTCTGAGACAGC   
MYO6 Exon 24 Forward primer GGTCGTCAAGATTTCATGTTTC 307 56
 Reverse primer AAAACCTGAGTATCCAAACTGC   
MYO6 Exon 25 Forward primer TTGAAAACAGAAGTGAAATACCC 375 56
 Reverse primer GTCTCAACACATTTTGTAATTTTG   
MYO6 Exon 26 Forward primer GCTGTATTTGCATATTGGAGTAG 460 56
 Reverse primer TTGTCATTAACCACTGTCAATACC   
MYO6 Exon 27 Forward primer TTCCCAATCTGTTACCTTTG 309 56
 Reverse primer TTGATCTCCTGACCTCGTG   
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Supplemental Table S1   Continued.
Target Oligonucleotides Product 
size (bps)
Annealing 
Temperature 
(°C)
Primers for genomic PCR and sequence analysis of CLIC5, MYO6 and ESPN
MYO6 Exon 28 Forward primer GGGGCAGTTATGCTTTCC 336 56
 Reverse primer TTCTGCATGGAAATGAGAGG   
MYO6 Exon 29 Forward primer CACAAATTTGCACAATCCAG 271 56
 Reverse primer AGCACCATACAAGAGCATTAAAC   
MYO6 Exon 30 Forward primer TGTGTTACGGCTAGATTTGTTG 309 56
 Reverse primer TCATGTAACAGGTTCTGGTCC   
MYO6 Exon 31 Forward primer TCCGGTTTTCAAACTTATGC 367 56
 Reverse primer GTGCATTCATGGACCAAAAG   
MYO6 Exon 32 Forward primer GCTTATCCTTATGAATAATTAGCTTAC 431 56
 Reverse primer GCCATCAAGGCTGTATTAGG   
MYO6 Exon 33 Forward primer ACTTTTCAGTCACCACCTCG 296 56
 Reverse primer TCCACTGAAAATTGTAGCAAAAC   
MYO6 Exon 34 Forward primer GGGGTATATTTTAGGATTAAAGGC 438 58
 Reverse primer TGGAAATGTGATTTAACCGC   
MYO6 Exon 35_1 Forward primer ATTGAAAGGGTCCTTGATGG 831 56
 Reverse primer TGCCTTGATCATTTTAAGTGG   
MYO6 Exon 35_2 Forward primer CCGCTGTAATTCCCAAAAC 614 56
 Reverse primer TCCAGTTAAGCCACTATGCC   
MYO6 Exon 35_3 Forward primer GCACAATGTGTGTTGCTGTC 658 56
 Reverse primer CCTAACTGAGGTAATCTTTCTAGGG   
ESPN Exon 1 Forward primer ATTCGAACCCAGTTTTGCTG 1010 58
Reverse primer CCACCCACTTCCAGGACTAC
ESPN Exon 2 Forward primer AGGAAGGGTGGAGAGATC 859 58
Reverse primer ATGTTGAGTGGGAGCCATTT
ESPN Exon 3-5 Forward primer GAGGTCAGACACAGCAGGTG 1954 58
Reverse primer AGCGTGGGTTTCCAGTTATG
ESPN Exon 3-5S# Forward primer AGGTGAGCTGCACCGACGTG NA NA
Reverse primer TGACCTCTAGCTCCCCGTTC
ESPN Exon 6 Forward primer GGAACCTGGGTCCTGCTG 552 58
Reverse primer CCTCCCCATGTTTAAGAGCA
ESPN Exon 7 Forward primer TGGTCTTCCCCCAGTAAGTG 673 58
Reverse primer TACTCTCCTCCCAGTCCAGTG
ESPN Exon 8 Forward primer GCTGCCCACTGTGAGAACC 933 58
Reverse primer GGGAGGCCCTTTCTAGCTG
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Supplemental Table S1   Continued.
Target Oligonucleotides Product 
size (bps)
Annealing 
Temperature 
(°C)
Primers for genomic PCR and sequence analysis of CLIC5, MYO6 and ESPN
ESPN Exon 9 Forward primer CCATCCAATCTTGGCTTAGG 377 58
Reverse primer ACTGGTGACAGTGCAGGTGA
ESPN Exon 10 Forward primer CACAGTGTTCTCAGGCATCG 444 58
Reverse primer GATGGGCTGTGCATCCAG
ESPN Exon 11-12 Forward primer TCCCAGCTACTTGTTCTCTGC 691 58
Reverse primer GTGGGGTTAGGTTAACTGAAGG
ESPN Exon 13 Forward primer CTCAGTAACCCACCCCTTG 741 58
Reverse primer ATCTGGGTCAGAGAGGAAGG
Primers for MYO6 mRNA analysis
MYO6 mRNA 
Ex1-9
Forward primer TTCACCCGTACAGGTAGCC 826 56
Reverse primer TTCCTCTTTGCCTTGAACAC
MYO6 mRNA 
Ex8-13
Forward primer CTTTGGAAATGCGAAGACTG 787 56
Reverse primer TCCAATAAAATAGGATGATGTTTC
MYO6 mRNA 
Ex13-19
Forward primer GCAAGCAAACAATGCTCG 738 56
Reverse primer CTTCGAAGTTTATCCAGAAGC
MYO6 mRNA 
Ex18-26
Forward primer TGAATCCAGAGATAAGTTTATACGG 851 56
Reverse primer GTTCCTGCGTCATCATAGTG
MYO6 mRNA 
Ex25-31
Forward primer TGATGGTCTGGTTAAGGTGG 750 56
Reverse primer TCACGTAGTTCTGCATATTTCC
MYO6 mRNA 
Ex30/31-35
Forward primer TTTGAGTAGAGGTCCTGCTG 754 56
Reverse primer GGGCACACACCCTACCTAAG
Primer for QPCR
CLIC5 Exon2-3 Forward primer CGGCAACTGTCCTTTCTCTC 115 60
Reverse primer GGCTAGGTTGTGCAGGTCAG
GUSB Exon2-3 Forward primer AGAGTGGTGCTGAGGATTGG 80 60
Reverse primer CCCTCATGCTCTAGCGTGTC
The reference sequences for exon numbering CLIC5, MYO6 and ESPN were NM_016929.4, NM_004999.3 
and NM_031475.2, respectively. *This is the first exon of an alternative CLIC5 transcript (NM_001114086.1) 
#These primers were only used for sequence analysis.
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Supplemental Figure 1  The homozygous mutation CLIC5 c.96T>A (p.(Cys32Ter)) in 
family W05-009 does not result in nonsense mediated mRNA decay (NMD).
Shown is the mean expression of CLIC5 in Epstein-Barr-virus (EBV)-transformed 
lymphoblastoid cells of affected individuals II.2 and II.3 (n=2) and controls (n=10) 
treated with (+CH) and without (-CH) cycloheximide. Quantifications were 
normalized against GUSB expression. Differences in expression between the 
affected individuals and 10 controls were calculated by using the delta delta Ct 
method.11 The p-value was derived from the standard score (Z-value) calculated for 
untreated samples (-CH) as compared to the normal distribution of the 10 controls. 
Since we assume a lower expression level as a result of NMD, a one-sided test was 
enough to reject the null hypothesis (p=0.376). Also, no difference was seen in 
CLIC5 expression between treated and untreated patient samples. In conclusion, 
occurrence of NMD could not be confirmed.
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Abstract
DFNB1 is the most prevalent type of hereditary hearing impairment known 
nowadays and the audiometric phenotype is very heterogeneous. There is, however, 
no consensus in literature on vestibular and imaging characteristics.
Vestibular function and imaging results of 44 DFNB1 patients were evaluated in 
this retrospective study.
All patients displayed a response during rotational velocity step testing. In 65% of 
the cases, the caloric results were within normal range bilaterally. The video head 
impulse test was normal in all patients. 
In 34.4% of the CT scans one or more temporal bone anomalies were found. The 
various anomalies found, were present in small numbers and none seemed 
convincingly linked to a specific DFNB1genotype.
The group of DFNB1 patients presented here is the largest thus far evaluated for 
their vestibular function. From this study, it can be assumed that DFNB1 is not 
associated with vestibular dysfunction or specific temporal bone anomalies.
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Introduction
DFNB1 is the most common type of autosomal recessive hearing impairment and 
is caused by mutations in GJB2 and/or a deletion of GJB6. Up to 40% of the autosomal 
recessively inherited sensorineural hearing impairments is caused by defects in 
these two genes 1. Many different pathogenic mutations in GJB2 have been identified 
to cause hearing impairment. Because of the high incidence of mutations in GJB2 
and deletions of GJB6 in different populations, it is recommended to first screen for 
DFNB1 in patients with suspected autosomal recessive hearing loss or in isolated 
cases with a congenital or prelingual hearing impairment 2, 3. 
The audiological phenotype of DFNB1 is highly variable. The onset is most often 
prelingual or congenital. In most cases, hearing impairment is stable, however, 
when it is not congenital it can also be progressive. The severity of hearing 
impairment varies between mild to profound. Audiogram configuration can vary 
from flat to downsloping, which therefore is not pathognomonic 1. Snoekcx et al. 4 
performed a large multicenter study to correlate the different GJB2 genotypes to 
the audiometric phenotype. They concluded that the degree of hearing impairment 
associated with biallelic truncating mutations was significantly more severe than 
hearing impairment associated with biallelic non-truncating mutations.
A genotype-phenotype correlation does not only comprise audiometric features, 
but also vestibular and imaging characteristics. The available information in 
literature on vestibular function is based on small numbers of patients and both 
imaging and vestibular results are not consistent 5-9 . 
Several studies have evaluated vestibular function in DFNB1 patients. Denoyelle 
et al. and Cohn et al. described a genotype- phenotype correlation study for DFNB1 
patients 5-6. Both have retrospectively evaluated vestibular function based on 
vestibular testing. Cohn et al. 5 described a normal vestibular function in 11 out of 
13 patients. The deviating results of the two other patients were assigned to 
immaturity of the vestibular system in a premature birth at 31 weeks gestation 
and to recurrent vestibulopathy related to migrainous vertigo. Denoyelle et al. 6 
reported on 10 DFNB1 patients with normal vestibular function.
Dodson et al. 10 assessed subjective vestibular function in DFNB1 patients by means 
of a survey study. Patients with DFNB1 had significantly more vestibular problems 
than other hearing impaired individuals. On the other hand, there were no 
subjective vestibular problems in DFNB1 patients studied by Kasai et al. 9. In this 
study six out of seven patients demonstrated unilateral abnormal responses during 
vestibular examination. In the study by Todt et al. 7 only two out of seven patients 
had normal vestibular responses. They, therefore, conclude that mutations in GJB2 
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are not only responsible for hearing impairment but also for vestibular dysfunction. 
The studies by Denoyelle et al. 6 and Cohn et al. 5 also evaluate temporal bone 
imaging in 19 and 23 patients, respectively. All 42 computed tomography (CT) 
scans did not display temporal bone anomalies. Temporal bone anatomy was also 
assessed by Propst et al. 8 by means of CT scans in 53 DFNB1 patients. In over 50% 
of their cases temporal bone anomalies were found. Among the most prevalent 
anomalies are a dilated endolymphatic fossa and an enlarged vestibular aqueduct. 
These anomalies can be associated with vestibular problems. 
Considering the varieties in findings in the different studies we evaluated both 
vestibular test results and imaging results in 44 DFNB1 patients from our clinic. 
This study further defines the genotype-phenotype correlation in DFNB1 patients. 
Patients and methods
Patients
Patients diagnosed with DFNB1 in our clinic in the time period 2002-2014 were 
eligible for inclusion in this retrospective study (n=65). DFNB1 patients were 
included when vestibular results or imaging results were available. Since vestibular 
function assessment and imaging are standard items of the cochlear implant 
selection procedure, 37 patients were cochlear implant users. 
The diagnosis of DFNB1 was based on two pathogenic mutations in GJB2, two 
pathogenic deletions in GJB6 or a pathogenic mutation in GJB2 in combination with 
a pathogenic deletion in GJB6. Hearing impaired offspring of parents both 
diagnosed with DFNB1 were also considered to have DFNB1. General features and 
genetic characteristics were collected by means of a chart review.
Vestibular testing
The vestibular function was evaluated in 28 patients. To confirm normal vestibular- 
oculomotor function and to exclude possible central lesions smooth pursuit, gaze, 
optokinetic, and saccadic tests were performed. 
Vestibular function was evaluated by electronystagmography. This involved rotary 
chair testing using the velocity-step test (VST) and caloric irrigation. For the VST, 
the patient was seated in a rotary chair. To obtain a horizontal position of the 
horizontal semicircular canals the head was ante-flexed at 30 degrees. To provoke 
a nystagmus, the chair is accelerated with 2 /˚s2 to 0.25 Hertz. After a plateau time 
of 60 seconds, the chair was suddenly stopped with a deceleration of 200 /˚s2, 
inducing a physiological response, i.e. a nystagmus in opposite direction. The 
maximum slow phase velocity of the nystagmus and time constant were recorded. 
This was done for both directions to calculate the possible presence of the 
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nystagmus’ directional preponderance (asymmetry). The reactivity and possible 
vestibular preponderance of individual vestibules were determined by caloric 
testing using bithermal (30 and 44°C) water irrigation of the external auditory 
canal (n=21). Analyses were performed as described previously 11.
In 10 patients, additionally a video Head Impulse Test (vHIT) has been performed 
to evaluate the individual function of the semicircular canals in the higher 
frequency domain. The patient has to focus on a dot on the wall while the examiner 
makes a short but rapid movement with the head in the plane of the canal. All 
three canals are examined individually. The eye movements were recorded by a 
camera (vHIT Ulmer, Synapsys, Marseille, France) 12. 
In 17 patients vestibular function was evaluated after cochlear implantation.
Three patients were too young to complete the VST and/ or caloric test reliably 
because of fatigue or loss of concentration. In three patients the tests was 
considered to be unreliable due to ear abnormalities (otitis media, tympanic 
membrane perforation). In four patients the results were not available for 
evaluation. In seven patients the VST was not performed according to the procedure 
described here, therefore results were considered unreliable. These patients were 
excluded from vestibular function analysis.
Temporal bone imaging
Temporal bone imaging by means of computed tomography (CT) or magnetic 
resonance imaging (MRI) has been evaluated in 41 patients. A CT scan was available 
for 33 patients but was evaluated in 32 patients. One CT scan was excluded from 
evaluation since a combined approach tympanotomy altered the anatomy. The 
temporal bones of three of these patients were also evaluated by MRI scan. In nine 
patients only an MRI scan of the temporal bone was performed. All scans were 
displayed to an experienced head-, neck- and neuroradiologist (BV) and an 
experienced otologist (RP) using IMPAX (version 6.5.3.1005 AGFA healthcare 
Mortsel, Belgium). Both ears were evaluated separately according to a structured 
list of items (size and aspect of external auditory canal, middle ear, ossicles, 
mastoid, cochlea, vestibule, semicircular canals (SCC), vascular structures, 
endolymphatic fossa/vestibular aqueduct) . Precise measurements of the cochlear 
height, width, length size of the bony island were executed with the electronic 
calipers available in IMPAX. All CT scans were systematically scored on 33 items 13. 
The MRI scans were scored on 14 items.
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Results
General characteristics
Forty-four patients were included in this study. Forty-three patients were diagnosed 
with DFNB1 based on two mutations in GJB2 and/or GJB6. An additional patient was 
included because both parents were diagnosed with DFNB1 (table 1). Twenty-two 
female and 22 male patients were evaluated. The mean age at vestibular testing 
was 14.4 years (range 0.38-68.4) and the mean age during temporal bone imaging 
was 9.6 years (range 0.21-62.3).
In 25 patients results of both VST and temporal bone imaging were available. In sixteen 
patients only imaging results were available, in three patients only vestibular results 
were present.
In general, these patients were cochlear implant candidates and had profound 
hearing loss with a congenital onset. Two patients had a moderate to severe hearing 
impairment. Temporal bone imaging abnormalities were not seen in these patients 
and vestibular testing was not performed. 
In four patients, history was not taken on vestibular complaints or motor milestone 
development issues. Five patients complained about balance problems or demonstrated 
delayed motor milestones. Two of them displayed normal results on the VST and 
one showed hyporeflexia on VST and areflexia during calorisation. Temporal bone 
imaging demonstrated an opacification of the mastoid and middle ear in two 
patients (age 0.5-1.1 years old) and another patient with delayed motor milestones 
demonstrated a superior semicircular canal dehiscence.
Vestibular tests
Eye movements were evaluated in 20 patients. In two patients oculomotor test 
responses were deviant. One patient presented with slow responses during the 
saccadic and optokinetic test. However, VST, calorics and vHIT displayed normal 
responses in this patient. Another patient demonstrated a disturbed optokinetic 
response to the right. VST revealed a vestibular hypofunction and an areflexia of 
the right vestibulum during calorics. This was tested before cochlear implantation. 
The results of the vestibular tests are displayed in figure 1. Twenty-one patients 
had normal VST responses, of which 12 also showed normal calorics results. Six 
patients demonstrated hyporeflexia during VST (aged 3.6- 42.2), four of them were 
tested after cochlear implantation. The two who were tested before implantation 
displayed unilateral areflexia during calorics (tested at 45.7 and 51.5 years). One of 
these two patients demonstrated normal vHIT results.
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Imaging results
Table 2 summarizes the results of the evaluation of temporal bone imaging. In 34,4% of 
the CT scans a temporal bone anomaly was detected (i.e. enlarged endolymphatic 
fossa, semicircular canal dehiscence, bifide malleus, hyper- or hypoplasia of the 
cochlea/ semicircular canal). Evaluation of the CT scans demonstrated a (partially) 
opacified middle ear in seven patients. The age of these patients ranged from 
0.21-1.10 years and the opacification was considered to be based on otitis media 
with effusion. 
Evaluation of the labyrinth demonstrated minor abnormalities. The measured 
cochlear height was within normal range in 28 patients (4.4 mm-5.9 mm; <4.4 mm 
is categorized as hypoplasia, >5.9 mm is defined as hyperplasia) 13. The median 
measured cochlear height was 5.3 mm. In two patients the cochlear height was 
unilaterally 4.1 and 4.3 mm (hypoplasia), respectively. Another patient displayed a 
hyperplasia of the cochlea unilaterally (6.0 mm)(Figure 2 and 3). In the remaining 
patient the cochlear height could not be assessed due to absent coronal section. 
Table 1  Overview of mutations and/ or deletions of GJB2/ GJB6 in the study population. 
Mutation 1 Mutation 2 N (%)
c.35delG (p.(G12fs)) c.35delG (p.(G12fs)) 22 (50.0)
c.35delG (p.(G12fs)) deletion GJB6 5 (11.4)
c.35delG (p.(G12fs)) c.229T>C (p.(W77R)) 3 (6.8)
c.35delG (p.(G12fs)) c.IVS1+1G>A 1 (2.3)
c.35delG (p.(G12fs)) c.71G>A (p.(W24X)) 1 (2.3)
c.35delG (p.(G12fs)) c.427C>T (p.(R143W)) 1 (2.3)
c.35delG (p.(G12fs)) c.139G>T (p.(E47X)) 1 (2.3)
c.35delG (p.(G12fs)) c.313-326del14 1 (2.3)
deletion GJB6 deletion GJB6 1 (2.3)
deletion GJB6 c.313-326del14 1 (2.3)
deletion GJB6 c.IVS1+1G>A 1 (2.3)
c.-23+1G>A c.-23+1G>A 1 (2.3)
c.235delG (p.(L79fs)) c.235delG (p.(L79fs)) 1 (2.3)
c.407dup (p.(Y136X)) c.71G>A (p.(W24X)) 1 (2.3)
c.238C>A (p.(Q80K)) c.-23+1G>A 1 (2.3)
c.283G>A (p.(V95M)) c.101T>C (p.(M34T)) 1 (2.3)
Both parents deaf due to DFNB1 1 (2.3)
Between brackets the protein change is noted.
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The CT scan of fifteen patients demonstrated opacification in different degrees of 
the horizontal semicircular canal (SCC). In 10 patients this was present bilaterally. 
The size of the bony island of the horizontal SCC is correlated to vestibular 
abnormalities. In one patient the bony island of the left labyrinth measured 5.2 
mm (>4.8 mm is defined as hyperplasia). The size in the remaining 63 ears ranged 
from 2.9 mm – 4.8 mm (normal 2.6 mm - 4.8 mm) 13 (Figure 3 and 4). The median 
size of the bony island was 3.9 mm. The superior SCC appeared dehiscent in three 
patients (unilaterally), clinically there were no indications for a SSCC dehiscence. 
In four patients an enlarged endolymphatic fossa was present, two cases showed 
this bilaterally (Figure 5). The endolymphatic fossa was not visible in seven patients 
and therefore not assessable.
Twelve MRI scans of in total 24 ears did not show any abnormalities except for one 
patient with a subarachnoidal cyst as an incidental finding.
Figure 2  Different sizes of the cochlea. A. Normal size. B. Hypoplasia. C. Hyperplasia.
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Figure 3  Scatter plot of the cochlear height and bony island size. Line indicates the 
median. The filled symbols are the deviating results, hypoplasia or hyperplasia. 
The upper and lower limit of the normal range is indicated by dashed lines.
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Figure 4  Different appearances of the horizontal semicircular canal. A. Normal 
appearance (white arrow). B. Opacification of the horizontal semicircular canal 
(white arrow). C. Enlarged bony island (white arrow).
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Correlation between vestibular and radiological findings
The more prevalent radiological findings in this study are combined with 
vestibular results in figure 6. The patient with unilateral cochlear hypoplasia had 
normal results on VST and calorics. The patient with hyperplasia of the cochlea also 
displayed normal VST results, results of calorics were not available. The patient 
with hyperplasia of the horizontal SCC presented with a normal VST and calorics 
response. 
Truncating versus non-truncating mutations
Thirty-nine patients presented with homozygous truncating mutations. Four patients 
presented with compound heterozygous truncating/ non-truncating mutations. 
VST results were available in two out of these four patients and both showed 
hyporeflexia, although caloric results were normal and both patients were tested 
after cochlear implantation. In three of these four patients temporal bone imaging 
results were present, none demonstrated temporal bone anomalies. One patient 
presented with heterozygous non-truncating mutations, temporal bone imaging 
did not display any anomalies.
Figure 5  Variations of the endolymphatic fossa. A. Normal appearance (white arrow). 
B. Enlarged endolymphatic fossa (white arrow).
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Discussion
Because of the relatively high incidence of DFNB1 the audiological phenotype has 
been extensively studied previously. The audiological phenotype is very divergent. 
Vestibular function and imaging of the temporal bones remain underexposed in 
these descriptions. In addition, the scarce reports on vestibular function and 
imaging in DFNB1 patients are not consistent with each other. This retrospective 
study presents an evaluation of vestibular function and imaging results, including 
CT as well as MRI in a relatively large number of DFNB1 patients (n= 44). Based on 
the present vestibular examinations and temporal bone imaging, our results in 
general show that neither vestibular dysfunction nor evident temporal bone 
anomalies are associated with DFNB1. 
Radiological phenotype of DFNB1
In 34,4% (11/32) of the CT scans one or more asymptomatic temporal bone anomalies 
were identified. This is a higher percentage than previously reported for DFNB1 
patients (0-11%) 5, 14-19. However, much less than the percentage reported by Propst 
et al. 8 (72%). 
The temporal bone anomalies found in the previously mentioned studies are very 
diverse. Each anomaly is only detected in a limited number of cases, except for the 
anomalies mentioned by Propst et al. (table 3). They found an enlarged endolymphatic 
fossa (28.3%), a modiolus deficiency (24.7%) and an EVA (14.2%) in a substantial 
proportion of their cases. In 10,3% of the temporal bones in which the endolymphatic 
fossa could be assessed, it was enlarged in our patients. A modiolus deficiency or 
EVA were not identified in any of our cases. The number of DFNB1 patients with 
an enlarged endolymphatic fossa did not significantly differ from age-matched 
normal hearing controls in the study of Propst et al. Given the fact that the 
enlargement is only found in a limited number of patients, where it could not be 
linked to a specific GJB2/ GJB6 genotype, we draw the conclusion that DFNB1 is not 
associated with an increased prevalence of an enlarged endolymphatic fossa. 
However, it cannot be completely ruled out that specific GJB2 mutations present 
with an increased risk for an enlarged vestibular aqueduct. 
Opacification of the horizontal semicircular canal is a remarkable detail, present 
in 15 patients. Since the scans were of optimal quality and were evaluated with 
utmost care but the opacification could not be linked to vestibular dysfunction, we 
consider this as a true finding without clinical significance rather than an artifact. 
All together, a variety of abnormalities were found in this group of patients, each 
in small numbers and none seemed consistently linked to a specific genotype.
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No vestibular abnormalities in DFNB1 patients
A vestibular response was found in all patients during the VST, additionally all 
patients had at least one excitable vestibule during calorics and, as far as data was 
available, the vHIT was normal in all patients. In two patients the vHIT was normal, 
while calorics demonstrated areflexia or hyporeflexia, respectively. This difference 
can be explained by the fact that the vHIT stimulates the vestibule in the 4-7 Hz 
frequency range, while caloric irrigation stimulates the vestibule in a much lower 
frequency range i.e. 0.003 Hz 20. There was no correlation between vestibular 
function and the underlying genotype (homozygous truncating mutations or 
compound heterozygous non-truncating/ truncating mutations). This conclusion 
is, however, based on a small number of patients. 
The vestibular function is considered to be normal in DFNB1 patients, however 
since this is a retrospective study we should take into account that the vestibular 
function was evaluated after cochlear implantation in 17 patients. On the other hand, 
this only endorses the point of normal vestibular function in DFNB1 patients.
With a mean age of 14.4 at vestibular testing and 9.6 at temporal bone imaging, 
a relatively young group of patients is presented here. Since the auditory phenotype 
of DFNB1 with a congenital onset in general is not progressive, the vestibular 
phenotype is not expected to deter later in life. However, further research should 
include older patients since vestibular dysfunction could appear later in life together 
with temporal bone imaging abnormalities. This is for example seen in patients 
with DFNA9, a dominantly inherited progressive cochleovestibular disorder. DFNA9 
patients develop focal sclerosis of the semicircular canals and cochlea later in life 21. 
Evaluation of connexin function and dysfunction in the vestibule
GJB2 and GJB6 encode connexin 26 and connexin 30, respectively. Co-localized 
connexin 26 and connexin 30 form intercellular gap junctions which, in addition 
to others, are responsible for potassium diffusion in the membranous labyrinth. 
This is necessary in maintaining cochlear ion homeostasis 22. When one of both 
genes is mutated, insufficient or less functional gap junctions will be formed. This 
will change the potassium concentration in the endolymph, which is toxic to hair 
cells 23. 
Connexin 26 and connexin 30 are expressed in the sensory and non-sensory 
epithelia of the saccule, utricle and ampullae of mice. A crucial difference in these 
structures is the presence of dark cells in the utricle and ampullae 24. These dark 
cells are also involved in potassium recirculation by other potassium regulating 
channels: NaK-ATPase, NaKCl and KCNQ1/KCNE1 25, 26 . In the absence of sufficient 
connexin 26 and connexin 30 based gap junctions, these dark cells may correct 
the ratio of potassium in the endolymph in the utricle and ampullae. Hence, a 
change in gap junction may mainly affect the function of the saccule.
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The function of the utricle and saccule can be evaluated by measuring vestibular 
evoked myogenic potentials (VEMPs). Cervical VEMPs have been tested in DFNB1 
patients in two previous studies by Todt et al. 7 and Kasai et al. 9. They performed 
VEMPs in nine patients with biallelic GJB2 mutations. Two patients did not show 
any response, three patients only demonstrated a unilateral response and four 
patients responded normal. When the genetic defect would affect saccular 
function as suggested above, it would be logically to find this deterioration 
bilaterally, regarding the symmetry of the hearing impairment. Although the 
number of patients in the studies by Todt et al. 7 and Kasai et al. 9 are relatively 
small, the results indicate no or minimal effect of the genetic defect on the saccule. 
With the VST, caloric test and the vHIT, the focus in this retrospective study is on 
the semicircular canals, and not on the utricle and saccule. To rule out or confirm 
a functional role of connexin 26 or connexin 30 in the saccule, we recommend to 
examine cervical VEMPs in future DFNB1 patients.
In connexin 30 knockout mice, the early development of hair cells in the saccule 
was not affected. The hair cells, however, degenerate similar to hair cells of the 
cochlea. When connexin 26 is overexpressed in these mice, the morphology of the 
saccular hair cells was restored. The hair cells of the utricle and ampullae were not 
affected in knockout mice 24. Insufficient quantity of gap junctions probably leads 
to saccular hair cell death. This raises the question which combination of mutations 
and how severe these mutations need to be, before the gap junction quantity is 
poor enough for saccular dysfunction. And what will the clinical consequences be, 
or will this be compensated well? 
Conclusion
In this study, a large variety of temporal bone anomalies in DFNB1 patients were 
identified. These anomalies were only found in small numbers and not linked to 
specific genotypes. Therefore, we assume that DFNB1 is not associated with specific 
temporal bone anomalies. In addition, no significant vestibular dysfunction is 
seen in DFNB1 patients, nor was there a relation between vestibular findings and 
imaging results. This retrospective study did not evaluate saccular function. 
Because of a hypothetical relationship between saccular dysfunction and DFNB1 it 
is recommended that future studies evaluate this shortcoming, in order to assess 
saccular function in DFNB1 patients. 
Since temporal bone anomalies and vestibular dysfunction (except potential saccular 
dysfunction) could not be linked to DFNB1, it is currently not recommended to 
routinely perform temporal bone imaging or vestibular testing in DFNB1 patients.
From a scientific point of view these diagnostic tools should, however, be considered 
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in order to expand the genotype-phenotype correlation or to emphasize the current 
correlation.
During the cochlear implant selection procedure or when clinical features of 
vestibular dysfunction or temporal bone anomalies (e.g. mixed hearing loss) are 
present, additional vestibular testing or temporal bone imaging should be 
considered. Before implantation of a second cochlear implant, vestibular function 
should always be re-assessed in order to rule out vestibular areflexia of the first 
implanted ear.
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Abstract
Genetic testing for hereditary hearing impairment becomes more routinely available 
as a diagnostic tool in the outpatient clinic. Little is, however, known on the 
psychological impact of a genetic diagnosis. In order to evaluate this impact, an 
exploratory study was conducted.
Prospectively, 48 individuals who underwent genetic testing for hereditary 
hearing impairment were included in this study. They were asked to fill out the 
following different questionnaires: Hospital Anxiety Depression Scale, Impact of 
Event Scale, Self Efficacy 24, Illness Cognition Questionnaire and the Inventory for 
Social Reliance. The questionnaires were filled out at three time points; before 
genetic testing, directly after counseling on the either positive or negative test 
result and six weeks thereafter.
No statistical differences were found between the groups who received a genetic 
diagnosis for their hearing impairment (positive group) and the group who did not 
(negative group).
Special attention to the psychological well being should be offered to hearing 
impaired patients who seek a genetic diagnosis for their hearing impairment. In 
addition, the psychological impact of sensorineural hearing impairment might be 
larger than the impact of a genetic diagnosis itself. Based on the current exploratory 
study, there are no psychological reasons in favor or against genetic testing for 
hereditary hearing impairment. In the future, studies should focus on the impact 
of the genetic diagnosis retrieved from whole exome sequencing and on the impact 
of a syndromic or nonsyndromic hearing impairment. 
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Introduction
Early onset hearing impairment has a hereditary cause in about 50% of cases 1. 
Nowadays, over 75 genes have been identified to be associated with hereditary 
hearing impairment 2. In addition, genetic testing for a hereditary cause of hearing 
impairment is increasingly available in out-patient clinics as routine diagnostics. 
After establishing a genetic diagnosis for hearing impairment, the individual and 
his/her relatives need proper counseling. This counseling should focus on inheritance, 
prognosis of hearing impairment, potential vestibular dysfunction, additional 
symptoms 3 and possible effects of rehabilitation 4. So far, only little is known on 
the psychological impact of a genetic diagnosis for hearing impairment 5.
More research has been performed on the impact of genetic testing in, for example, 
Huntington disease or hereditary breast and ovarian cancer. Some patients with 
these disorders demonstrated an increase in psychological distress after receiving 
a positive test result. The observed psychological distress mostly vanished within 
a short period of time 6, 7. On the other hand, patients who received negative results 
displayed a decrease in psychological distress 8.
Results of counseling on a genetic diagnosis in these more frequently studied 
diseases can probably not be transposed to hereditary hearing impairment because 
they may be fatal or may require medical intervention to avert this fatality. 
In addition, research on the impact of genetic testing for Huntington disease 
or hereditary breast and ovarian cancer also concerns pre-symptomatic testing. 
Genetic testing for hereditary hearing impairment in adults is usually performed 
when hearing impairment is already symptomatic. 
Humans naturally seek explanations to elucidate the cause of an event. Some of 
these causes are controllable (e.g. will power), and some are uncontrollable (e.g. 
genetics). Research by Gordon et al. demonstrated that patients who were counseled 
on a neutral genotype (no mutations with beneficial or adverse effects) had an 
increase in health perception and self concepts, which was designated as increased 
psychological well being. This was dedicated to a probable increase in personal 
control 9. 
Based on the study of Gordon et al., Palmer et al. hypothesized that hearing 
impaired individuals who receive a genetic diagnosis for their hearing impairment 
would display an increase in psychological well being compared to those without 
a genetic diagnosis 5. They tested this hypothesis in adults with an early onset 
hearing impairment, who were tested for mutations in GJB2/ GJB6 (DFNB1). A positive 
test result led to an increase in perceived personal control and a decrease in 
anxiety level. Patients who received a negative result, had an increase in anxiety 
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level and decrease in perceived personal control. These effects were still substantially 
present six months after diagnosis and were more outspoken and lasted longer 
than to be expected from previous research 5. Palmer et al. focused only on patients 
who were tested on mutations in GJB2/ GJB6 (DFNB1). The hearing impairment in 
these patients is mostly congenital and severe to profound. 
The present exploratory study aimed to evaluate the psychological impact of a 
genetic diagnosis on nonsyndromic hearing impairment in adult individuals in 
order to improve counseling of genetic hearing impairment.
Patients and methods
Patients
This study was approved by the local medical ethics committee. Individuals were 
requested to participate in this study when they fulfilled three criteria. First, 
subjects had to be at least 18 years of age. Second, a hereditary cause of their 
hearing impairment was suspected. Third, a single gene mutation analysis was 
applied in order to identify the cause of their hearing impairment. Individuals 
who were not mentally competent and/ or not able to read and understand Dutch 
were excluded from the study. Subjects were recruited over a 15 month period of 
time (September 2013- November 2014). The study protocol contained three time 
points of evaluation. The first time point concerned inclusion, the moment genetic 
testing was requested (T0). The second evaluation concerned the period from 
counseling on the result of the genetic test (either positive or negative) until two 
weeks after (T1). The third time point was six weeks after the questionnaires of T1 
were completed (T2). 
At the time of these three evaluation time points, individuals were asked to 
complete several questionnaires. The questionnaires of T0 were completed at the 
outpatient clinic. The questionnaires of T1 and T2 were sent and returned by mail. 
Questionnaires
Demographic data
Demographic data were collected at T0 by means of a questionnaire. This self-con-
structed questionnaire assessed educational level 10, (history of) psychological 
complaints, medication, offspring or the desire to have children, hereditary 
disease in the family and reasons for genetic testing. This questionnaire also 
assessed hearing characteristics including onset, progression and rehabilitation of 
hearing impairment. 
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Illness Cognition Questionnaire (ICQ)
The ICQ was developed to evaluate three subscales: acceptation, helplessness and 
disease benefits of a chronic disease 11. In this study the ICQ was focused on hearing 
impairment as chronic disease. The questionnaire was completed at T0. The 
questionnaire contains 18 items, six for each subscale. Each item can be scored 
according to a four points Likert scale. Scores range from six to twenty-four for 
each subscale. A higher score indicates a higher level of acceptation, helplessness 
or disease benefits. The crohnbach т ranged from 0.84-0.90 for the three subscales 11. 
Inventory for Social Reliance (ISR)
The ISR is a self report questionnaire on social support. It consists of different 
subscales 12. For this study, the subscale on perceived emotional support was used. 
This subscale contains five items, that can be scored on a four point Likert scale. 
Scores ranged from five to twenty, higher scores indicate a greater level of perceived 
emotional support 12. This questionnaire was completed at T0 only. 
Hospital Anxiety and Depression Scale (HADS)
The HADS is a self reporting scale to indicate possible presence of anxiety and 
depression 13. This questionnaire was completed at T0, T1 and T2 and contains 14 
items. Each item has four response options. The subscales for anxiety and 
depression consist of seven items each. Scores can range from zero to twenty-one 
for each subscale 13, 14. Higher scores indicate higher levels of anxiety or depression, 
respectively. Scores ≤7 are considered normal. Percentages of individuals with 
scores of ≥8 were calculated. Cronbachs т for the subscale scores ranged from 
0.67-0.93 15. 
Self Efficacy Scale (SE24)
The SE24 scale was focused on hearing impaired individuals in this study and was 
completed at T0, T1 and T2. This scale is used to evaluate the sense of control by 
means of five items. Four items can be scored on a five points Likert scale, one item 
can be scored on a four point Likert scale. Total scores range from five to twenty-four. 
A higher score reflects more sense of control. Crohnbach т ranges from 0.70-0.77 16. 
Impact of Event Scale (IES)
The IES was completed at the T1 and T2. This scale evaluated the response on an 
event (getting acquainted with the genetic diagnosis). The scale consists of 15 
items, which can be scored by a four point Likert scale. The 15 items can be divided 
into two subsets, avoidance and intrusion 17. Higher scores indicate more avoidance 
or intrusion due to the event.
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Audiometry and genetic evaluation
The data gathered with the questionnaires were complemented with audiometric 
results. Pure tone audiometry was performed according to current standards to 
determine hearing thresholds at frequencies of 0.25, 0.5, 1, 2, 4 and 8 kHz. The 
mean thresholds at 1, 2 and 4 kHz of the best hearing ear from the last available 
audiogram was noted as the pure tone average (PTA) for every individual. In all 
subjects Sanger sequencing of a specific deafness- associated gene was requested at T0. 
The selection of the gene to be tested was based on family history and audiometric 
phenotype. At T1 individuals were counseled about the positive (a mutation was 
identified) or negative (no mutation was identified) result of the genetic test. 
Statistic analyses
Individuals were divided into two groups; a group with a positive genetic test result 
and a group with a negative test result. Demographic characteristics, including 
degree of hearing impairment and the results of the ICQ and ISR were compared 
between both groups by means of Chi square test for categorical variables and 
t-test for continuous variables. Continuous variables are presented by the median 
combined with the interquartile range (IQR). Linear mixed models for repeated 
measures were used for studying the differences between groups for each of the 
outcomes of the HADS subscales, SE24 and the IES subscales. The dependent variable 
was the genetic test result.
The independent fixed variables were point of measurement (two levels: two and six 
weeks since baseline), group (Negative, Positive) and the baseline value. Individuals 
were treated as a random variable. Baseline-adjusted mean difference between 
groups at each measurement point with 95% confident intervals are presented. 
The statistical analysis was carried out by using IBM SPSS Statistics 20 (Chicago, IL) 
and SAS 9.0 for Windows (SAS Institute inc., Cary, NC)..
Results
Fifty-four individuals were eligible to be enrolled in this study. Four subjects did 
not complete the questionnaires at the first time point (T0). Two subjects were 
analyzed by means of next generation sequencing instead of single gene mutation 
analyses and were therefore excluded. Thus, 48 individuals were included in this 
study. In 11 of the 48 individuals (23%), a genetic cause of their hearing impairment was 
identified. Eight individuals were diagnosed with autosomal dominant inherited 
deafness (DFNA) based on mutations in COCH (DFNA9), two with DFNB8/10 (autosomal 
recessive inherited deafness (DFNB) based on mutations in TMPRSS3) and one with 
DFNA8/12 (TECTA).
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Table 1  Demographics and baseline characteristics.
Positive (n=11) Negative (n=37)
T0
T1
T2
11/11 (100%)
8/11 (73%)
6 (55%)
37/37 (100%)
26 (70%)
20 (54%)
Age 54 (52-66) 48 (36-58)
Sex: 
-  Female
- Male
7/11 (64%)
4/11 (36%)
23/37 (62%)
14/37 (38%)
Education:
- ISCED 7
- ISCED 6
- ISCED 5
- ISCED 4
- ISCED 3
- ISCED 2
- ISCED 1
0/11 (0%)
0/11 (0%)
2/11 (18%)
2/11 (18%)
0/11 (0%)
6/11 (55%)
1/11 (9%)
9/37 (24%)
13 (35%)
0/37 (0%)
6 (16%)
3 (8%)
6 (16%)
0 (0%)
PTA 
(average 1, 2 and 4 kHz of the best hearing ear)
73 (47-93) 48 (32-71)
Progression:
- Yes
- No
11/11 (100%)
0/11 (0%)
31/37 (84%)
6/37 (16%)
Rehabilitation:
- None
- Hearing aid
- Cochlear implant
- Hearing aid and cochlear implant
- SOLO
 
2/11 (18%)
7/11 (64%)
0/11 (0%)
2/11 (18%)
0/11 (0%)
14/37 (38%)
21/37 (57%)
1/37 (3%)
0/37 (0%)
1/37 (3%)
History of psychiatric diseases:
- Yes
- No
0/11 (0%)
11/11 (100%)
7/37 (19%)
30/37 (81%)
Children/ childrens wish:
- Yes
- No
- Do not know
9/11 (82%)
1/11 (9%)
1/11 (9%)
28/37 (76%)
6/37 (16%)
3/37 (8%)
Other hereditary diseases in the family
- Yes
- No
- No answer
2/11 (18%)
8/11 (73%)
1/11 (9%)
9/37 (24%)
28/37 (76%) 
0/37 (0%)
Why do you pursue a genetic diagnosis?
- Treatment
- Prognosis
- Inheritance patterns
5/11 (45%)
6/11 (55%)
8/11 (73%)
21/37 (57%)
33/37 (89%)
26/37 (70%)
ICQ (range 6-24)
- Acceptation
- Helplessness
- Disease benefits
13 (7-14)
18 (13-21)
8 (7-11)
11 (8.5-14)
17 (12-18.5)
9 (7-12.5)
ISR (range 5-20) 20 (19-20) 18 (14.5-20)
ISCED (International Standard Classification of Education). Numbers between brackets are percentages or 
the median is presented with the upper and lower quartile between brackets. 
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Baseline characteristics
All 48 subjects completed the questionnaires at T0. At T1, 34 individuals filled out 
the questionnaires. Eight of these received a positive result on genetic testing. 
Twenty-six individuals completed the questionnaires at T2, six of them had a 
positive genetic test result. As a consequence, 22 subjects were lost to follow up. 
Overall, the participants pursued a genetic diagnosis in order to be informed 
about treatment in 54% (26/48), about prognosis in 81% (39/48) and about 
inheritance patterns in 71% (34/48). Baseline characteristics were comparable for 
the positive and negative genetic test result group and are shown in Table 1. The 
only significant difference was observed for educational level. Individuals who 
received a negative result for genetic testing had a higher level of education than 
those with a positive result (p= 0.03).
Illness cognition and social reliance
Individuals of the positive and negative test result group were also comparable for 
each subscale of the ICQ. The mean score of all included subjects for helplessness 
was 11.2 and for disease benefits 9.7 (scoring range 6-24). This indicates that the 
hearing impaired individuals in this study experience helplessness toward their 
hearing impairment and do not experience disease benefits. The mean score for 
acceptance was 16.6 (scoring range 6-24). This indicates that the acceptance of 
hearing impairment is of an average level (figure 1A). Both groups also experienced 
similar levels of social support with a mean score for all subjects of 18.6. The scores 
Figure 1  Mean scores for the Illness Cognition Questionnaire (A) and the Inventory 
Social Reliance (B). The minus indicates the negative group, the plus indicates the 
positive group. The dashed lines indicate the possible scoring range.
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of the ISR range from 5-20, which indicates that the individuals in this study 
experience a great amount of perceived emotional support (figure 1B). 
Hospital Anxiety Depression Scale (HADS)
The results of the HADS are shown for both the positive and negative test result 
group in table 2. Evaluation of the anxiety subscale shows some differences in both 
groups. The positive result group scores higher at T1, at T2 the scores have increased 
even more. Scores of the negative group at T2 have decreased and as a result the 
difference between both groups has increased at T2. This difference at T2 shows a 
trend towards significance (p=0.05; figure 2).
Between the negative and positive result group no significant differences were 
found at both T1 and T2 for the depression subscale.
In total, 14.6% of the cases scored 8 or higher on the anxiety subscale; 9.1% (1/11) of 
the positive group, 16.2% (6/37) of the negative group and 12.5% scored 8 or higher 
on the depression subscale (9.1% (1/11) of the positive group, 13.5 (5/37) of the 
negative group). When looked at the severely to profoundly hearing impaired 
individuals (PTA of ≥70 decibel hearing level) 13.3% (2/15) scored ≥ 8 on the anxiety 
subscale and 20% (3/15) scored ≥ 8 on the depression subscale.
Self Efficacy 24 scale
The Self Efficacy 24 Scale evaluates sense of control. No statistic significant 
difference was found between the scores for this sense of control of the positive 
and negative result group at T1 and T2. 
Figure 2  Anxiety level. Mean scores of the anxiety subscale of the HADS 
questionnaire at diagnosis and six weeks after in the positive and negative test 
result group. Dashed lines demonstrated the 95% CI’s. Dots and bars are means and 
standard deviation.
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Impact of Event Scale
Overall, scores of IES were low. This means that either a positive or negative genetic 
test result does not lead to much avoidance or intrusion. The differences at T1 and 
T2 for both subscales were not statistically significant between the positive and 
negative result group. 
Discussion
Currently, efficacy of genetic testing for hearing impairment is much higher than 
10 years ago. Little is, however, known on the impact of such a diagnosis on 
psychological well being of hearing impaired individuals. The psychological 
impact of receiving a positive or negative genetic test result was evaluated in 48 
individuals in this exploratory study. These individuals pursued a genetic diagnosis 
in order to be informed about treatment in 54%, about prognosis in 81% and about 
inheritance patterns in 71%. Receiving a positive result on genetic testing was not 
associated with an increase in psychological distress in the short term. Only a 
trend towards a significantly higher anxiety level in the positive genetic test result 
group was found. 
Comparison to other studies on the impact of a genetic diagnosis
The study by Palmer et al. presented opposite findings compared to the current 
study. Patients who received a negative genetic test result had significantly higher 
anxiety levels after six months when compared to patients who received a positive 
test result (n= 183) 5. The effect demonstrated by Palmer et al. is also the opposite of 
other studies and remains present for a longer period of time 5, 7. A systematic review 
by Vansenne et al. demonstrated that a positive genetic test result might first lead 
to an increase in psychological distress levels that, however, vanishes over time 7. 
In the present study, we only evaluated short term effects of genetic testing. 
The result of the current study is similar to the outcome of the study by Reichelt 
et al. 18. This study investigated females who were presymptomatically tested on 
mutations in BRCA1, involved in increased susceptibility for ovarian and breast cancer. 
Receiving a positive genetic test result of a BRCA1 mutation was not associated with 
an increase in psychological distress. Reichelt et al. therefore stated that receiving 
a genetic diagnosis might be less distressing than getting the diagnosis of cancer 
itself. Considering the low scores on the impact of event scale in the current study, 
a similar consideration might be applicable to hereditary hearing impaired 
individuals. It could be hypothesized that receiving the diagnosis and dealing 
with sensorineural hearing impairment might increase levels of distress far more 
than receiving the genetic diagnosis that might explain the hearing impairment. 
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Attention to psychological distress
In the current study, many individuals added personal information to the 
questionnaire, stating their appreciation for the attention to their psychological 
well being as a hearing impaired individual. Kvam et al. demonstrated that anxiety 
and depression occur significantly more in the hearing impaired population 
compared to the normal hearing population 19. Carlsson et al. demonstrated that 
31.2% and 22.5% of the severely to profoundly hearing impaired patients score 
above the cutoff point of 8 on the HADS for anxiety and depression, respectively. 
The Swedish reference population scored in 12% and 9% of the cases above the 
cutoff point of 8 for anxiety and depression, respectively 20. In comparison, the 
present group of individuals has scores of ≥ 8 in 13.3% and 20% of the cases for 
anxiety and depression, respectively for the severe to profound hearing impaired 
individual. The percentage for depression is comparable to the one reported by 
Carlsson et al. 
This indicates that counselors on genetic testing for hereditary hearing impairment 
need to be aware of a possible increased level of psychological distress in individuals 
seeking a genetic diagnosis for their hearing impairment. In order to screen for 
psychological distress, a questionnaire focusing on these problems may be useful. 
As there were no significant differences in psychological distress between the 
positive and negative genetic test result group over time, this screening can take 
place at the first visit to the outpatient clinic. In 2013, Esplen et al. described the 
Genetic Psychological Risk Inventory (GPRI) that aims to identify subjects at risk 
for psychological distress after genetic testing for adult onset hereditary diseases 
21. This inventory is a useful screening tool to implement in the first visit. 
Dominant versus recessive inheritance patterns
A possible explanation for the lack of difference in psychological impact between 
a positive and a negative diagnosis might be the large number of individuals with 
an autosomal dominantly inherited type of hearing impairment within this study. 
It can be assumed that patients with a dominantly inherited hearing impairment 
know a lot about the phenotype of their hearing impairment, based on the 
experiences of their relatives. They also might expect the genetic diagnosis more 
than subjects with a recessive type of inheritance. This study only included two 
subjects with autosomal recessive hearing impairment. Only one of them completed 
the questionnaires at T1 and T2. Therefore, the conclusion on the impact of a 
genetic diagnosis in DFNB patients remains more unclear. 
Study limitations and further recommendations
One of the limitations of this study is the small number of subjects. This small 
number is due to the fact that this study was carried out at the time that testing a 
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panel of hearing impairment genes by whole exome sequencing (WES) was being 
implemented in our clinic. The implementation of targeted exome sequencing as 
a routine diagnostics in our out-patient clinic has completely changed our protocol 
and single gene analysis is currently only performed in selected cases with a very 
directive phenotype such as is seen in DFNA9 and GJB2 is tested due to the large 
prevalence of DFNB1. In all other cases, the deafness gene panel test by WES is the 
preferred first choice of diagnostics. Therefore, the number of individuals who 
were suitable for single gene genetic testing decreased. 
The gene panel test entails other factors that might influence the psychological 
status of a hearing impaired individual, such as finding a mutation in a gene 
associated with syndromic hearing impairment. This study needs to be repeated 
for individuals tested by whole exome sequencing in order to state something on 
the psychological distress in individuals who undergo whole exome sequencing to 
find the cause of their hearing impairment. When this study is repeated it should 
be considered to include hearing impaired subjects who do not request genetic 
testing in order to exclude a possible selection bias. In this study only subjects 
eligible for genetic testing were included which could lead to a selection bias. 
In addition to the small number of individuals that could be included, quite a 
number of individuals were lost to follow up. A possible explanation could be the 
small window of time in which individuals were allowed to complete the 
questionnaires of T1. 
This study only focused on non-syndromic hearing impairment. In several 
syndromic types of hearing impairment, the additional symptoms occur at a later 
age 22. The knowledge that these additional symptoms can eventually occur might 
cause more psychological distress. Therefore, the results of this present study 
might not be applicable to individuals who are genetically tested for syndromic 
hearing impairment. 
Conclusion
This pilot study evaluated the psychological impact of a genetic diagnosis of hereditary 
hearing impairment in 48 individuals. There was no difference in psychological 
impact between a positive or negative genetic test result and the test results did 
not significantly influence psychological well being of the participants in a positive 
or negative way. 
This study also demonstrated that increased levels of depression can be observed 
in severe to profound hearing impaired individuals that visit the out-patient clinic 
for a genetic diagnosis. 
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Further research is needed to evaluate the psychological impact of a genetic 
diagnosis of hereditary hearing impairment and of the impact of hearing 
impairment itself. Testing of a panel with known deafness- associated genes has 
led to an increased percentage of positive genetic diagnosis in our clinic. The 
present study, therefore needs to be repeated in individuals who are tested by the 
hereditary hearing impairment gene panel test. 
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The aim of this thesis was to describe new genotype-phenotype correlations for 
autosomal recessively inherited hearing impairment in order to improve counseling 
and to gain more knowledge on the effect of different (mutated) genes on cochlear 
performance.
Clinical characteristics of known genotype-phenotype correlations were first 
summarized in a general review on autosomal recessively inherited hearing 
impairment in chapter 1.2. The first described genotype-phenotype correlation in 
this thesis are those of DFNB18B and DFNB84B. In chapter 2.1, phenotypes of 
patients with mutations in OTOG and OTOGL were compared. Previous studies 
concluded that OTOG and OTOGL are comparable in terms of expression and that 
otogelin and otogelin-like have structural similarities. The present study 
demonstrated that phenotypes resulting from mutations in these two genes are 
also similar. The second genotype-phenotype correlation described in chapter 2.2, 
focused on mutations in USH1G. Mutations in USH1G were prior to this study only 
linked to syndromic hearing impairment, i.e. Usher syndrome type 1, or atypical 
Usher syndrome. The patients in this study, however, presented with moderate 
hearing loss, and in addition, normal vestibular and ophthalmologic function was 
found. Therefore, this is the first description of nonsyndromic hearing impairment 
based on mutations in USH1G. In chapter 2.3, the third genotype-phenotype 
correlation was the description of a phenotype resulting from recessive mutations in a 
novel deafness gene: CLIC5. Besides hearing impairment and vestibular dysfunction, 
also early indications of a possible mild renal dysfunction were found.
In the third chapter of this thesis, the genotype-phenotype correlation of DFNB1, 
the most common autosomal recessively inherited type of hearing loss, was 
expanded by further examining temporal bone imaging and assessing vestibular 
function. It was concluded that DFNB1 might not be associated with specific 
temporal bone anomalies or with vestibular dysfunction. In chapter 4, we focused 
on the psychological impact of receiving genetic results concerning hearing 
impairment. From this study it was concluded that receiving a genetic diagnosis 
on hearing impairment does not affect psychological distress levels. Therefore, 
genetic evaluation of hearing impairment can be offered to each hearing impaired 
patient. Physicians in general should also be conscious of the enhanced 
susceptibility to psychological stress in severe to profound hearing impaired 
patients. 
The results of these studies contribute to counseling of patients with hereditary 
hearing impairment and their families. These studies are also essential for future 
studies on therapy for hereditary hearing impairment, because they provide 
insight in the natural progression of the disease. 
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From animal models to clinical consequences
Mouse models
When a novel human deafness gene is identified, knowledge on the function of the 
encoded protein in the cochlea is often obtained from animal models. Different 
animal models are used to study hereditary hearing impairment e.g.: mice, guinea 
pigs and zebrafish. Most of the knowledge on hereditary hearing impairment is, 
however, based on studies in mouse models. A candidate human deafness gene can 
be studied in animal models by performing gene targeted mutagenesis to create a 
knock-out mouse model. Not only the expression of the mutated gene can be 
studied in vivo in an animal model, but also the functional consequences can be 
studied for example by testing auditory brainstem responses 1. 
Since otogelin was found to be part of the tectorial membrane in mice 2, we 
hypothesized a conductive cochlear hearing loss in patients with hearing loss 
resulting from mutations in OTOG. However, psychophysical testing did not 
confirm this hypothesis (chapter 2.1). On the other hand, Clic5 knockout mice 
displayed, besides hearing loss, also dysfunction of various other organs. Therefore, 
the DFNB102 patients were screened for other, subclinical organ dysfunctions 
and, the first signs of nephropathy were discovered. Without the clues from the 
mouse model, this would have remained unnoticed until the first symptoms 
would appear. Now these patients can be followed up and early interventions are 
possible when necessary (chapter 2.3).
In chapter 3, the results of vestibular testing in DFNB1 patients are correlated to 
histological observations in connexin 26 (GJB2) and connexin 30 (GJB6) knock-out 
mice. From connexin 30 knock-out mice it can possibly be concluded that 
insufficient numbers of gap junctions may lead to saccular hair cell death 3. The 
human sacculus can be evaluated in vivo by means of measuring cervical vestibular 
evoked myogenic potentials (cVEMP). These cVEMPs could not be evaluated due to 
the retrospective character of the study in chapter 3. However, a recent study 
demonstrated signs of saccular dysfunction in DFNB1 patients 4.
In conclusion, it can be stated that mouse models are very valuable to study the 
function of proteins in the cochlea and other organs, when these proteins are 
encoded by newly identified human deafness- associated genes. The translation 
to humans, however, should be made very carefully and supported by clinical 
audiometric findings. 
Phenotype evaluation and number of affected patients
When a phenotype description is based on a large group of patients, it is considered 
to be more precise than when it is substantiated by a small number of cases. This 
makes research on autosomal recessively inherited hearing impairment in the 
Discussion and conclusion | 179
Western world with small families and low numbers of affected individuals 
difficult. In order to make phenotype descriptions of autosomal recessive hearing 
loss more accurate and to uncover possible variability, larger numbers of patients 
are needed. 
Variability of phenotypic effect of mutations
The phenotypic effect of different mutations in a gene can be highly variable. 
This is, for example, clearly demonstrated in DFNB1. Snoeckx et al. performed a 
multicenter study on DFNB1 patients and showed that phenotypes of biallelic 
truncating mutations are more severe than those of biallelic non-truncating 
mutations 5. Studies describing novel deafness- associated genes often include 
different families with different mutations in the same deafness gene. The numbers of 
patients with autosomal recessive hearing loss based on a specific gene are usually 
small. Therefore, it is difficult to establish robust genotype-phenotype correlations. 
The variation in phenotypes caused by mutations in the same gene is demonstrated 
in chapter 2.2. In this chapter, the examined family with causative mutations in 
USH1G was compared to a family studied earlier by Weil et al. 6. Both families, with 
similar genotypes, present with completely different phenotypes: syndromic as well 
as nonsyndromic. 
Modifier genes
Differences in phenotypes can even exist between patients with the same genotype. 
Weegerink et al. described, for example, that the age of onset within DFNB8/10 
families could differ by more than ten years 7. This heterogeneity can possibly be 
explained by effects induced by, amongst others, modifier genes. When it comes to 
phenotypic expression of a mutation, the modifier gene can enhance the mutant 
phenotype, or suppress it. Modifier genes may therefore lead to more severe or 
milder hearing impairment, respectively 8. Research into modifier genes and associated 
mutations will provide more insight in the biological pathways influenced by the 
primary mutated gene in the inner ear. In order to identify these modifier genes, 
large numbers of patients with comparable genotypes need to be studied. When 
there is a large variability in phenotype, the whole exome sequencing (WES) data 
of the worst and best hearing individuals can be compared. Since WES is emerging 
as a diagnostic tool, it will facilitate identification of modifier genes.
The first dominant modifier gene is located at DFNM1. In a Pakistani family with 
eight hearing impaired family members affected by DFNB26, seven non-affected 
family members appeared to display the same haplotype as the affected subjects. 
During linkage analysis the DFNM1 locus was defined 9. However, the identity of 
the DFNM1 modifier is still elusive. Autosomal recessively inherited modifier 
genes have not been identified thus far. 
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Environmental factors
Hearing impairment can also be influenced by environmental factors. The most 
important environmental factor in hearing is noise exposure. Daily exposure to 85 
dB SPL (sound pressure level) or more may lead to noise induced hearing impairment 
10. Genetic factors can predispose to hearing impairment caused by noise exposure. 
This is demonstrated in several mouse models 11. Mutations in TRPV4 may enhance 
susceptibility to noise induced hearing impairment . This might explain the large 
variability in hearing thresholds within a family known with hearing impairment 
due to mutations in TRPV4 12. 
Exposure to different types of chemicals may also lead to hearing impairment. No 
consensus has been reached yet on the influence of tobacco and alcohol on hearing. 
Another familiar environmental factor is ototoxic medication; loop diuretics, 
chemotherapy and aminoglycoside antibiotics are known to cause hearing 
impairment 11. The latter is also associated with genetic predisposition. Some 
mitochondrial mutations are, for example, known to enhance the susceptibility to 
hearing impairment caused by the use of aminoglycoside antibiotics. Mutations in 
MT-RNR1 are known to cause this predisposition 13. Therefore, testing for known 
mutations associated with susceptibility to aminoglycosides should be performed. 
Clinicians should be aware of this susceptibility before starting treatment with 
aminoglycoside antibiotics. For example when the mother of the patient is hearing 
impaired after antibiotic use, since mitochondrial mutations inherit maternally. 
Improving diagnostics in hereditary  
hearing impairment
Genetics
Due to the heterogeneous nature of hereditary hearing loss, it is difficult to select 
the right candidate gene for diagnostics based on clinical features. The introduction 
of WES has changed this process since all exons are screened for mutations and 
candidate gene selection is no longer necessary. Phenotype driven testing is in the 
Netherlands often replaced by analyzing only known deafness- associated genes 
from the WES data (targeted exome sequencing). When the mutated gene cannot 
be found by this analysis, targeted exome sequencing can be followed by opening 
the exome. Up to 60% of cases of hereditary hearing impairment are currently 
solved by WES 14. It can, therefore, be expected that phenotype driven genetic 
testing will become less valuable than previously and will only be applied to 
clearly distinguishable phenotypes, such as amongst others DFNA9 (COCH). Due to 
its high prevalence, DFNB1 (GJB2/ GJB6) should always be tested in non syndromic 
recessive hearing impairment or isolated cases 15.
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Novel exome and whole genome sequencing technologies are still evolving, the 
techniques become faster and cheaper. One of these new techniques is, for example, 
nanopore sequencing. With this method, individual DNA strands pass through 
tiny protein pores. While these strands pass, the changes in electrical current are 
measured 16, 17. Up to 512 DNA molecules can be read simultaneously. This is a 
single molecule method that does not require fluorescent labeling. This will 
improve the speed of sequencing and will reduce costs 18. These new techniques 
produce data faster and in larger quantities than ever before. 
These new techniques also have their disadvantages. Since the amount of data 
keeps increasing, data storage needs to improve in order to handle the large 
amounts of sensitive data. This type of data is interesting for different people and 
therefore should be carefully managed in order to prevent genetic discrimination 19. 
Data interpretation is another issue. Variants of unknown significance and 
secondary findings should be handled with care. In addition, the patient and its 
counselor need to be aware of what the patients wants and must know 20-22. For 
example, in case of incidental findings on predisposing mutations associated with 
hereditary breast cancer or spinal muscular atrophy.
Imaging in hereditary hearing impairment
When the genetic defect has been determined, the next step is to evaluate whether 
there is an effect on the inner ear structures. The resolution of magnetic resonance 
imaging and computed tomography scans is improving, but up until now it is still 
not possible to reveal pathogenic pathways in the cochlea on a micro scale.
Currently, the only way to visualize the microanatomy of the cochlea is by 
histopathology. Optical coherence tomography is an imaging technique that 
allows evaluation of the microanatomy of the cochlea in vivo. In ophthalmology 
this technique is already extensively used and depicts, amongst others, structural 
and functional characteristics of the complete eyeball 23 (chapter 2.2). Therefore, 
this is also an interesting research topic in the inner ear 24, 25. Optical coherence 
tomography can determine structures with a resolution between 2 and 20 +m. The 
principle of this technique is analogous to the principle of ultrasound. Ultrasound 
is, however, based on reflection of acoustic stimuli from biological tissue layers, 
while optical coherence tomography is based on the reflection of light. A disadvantage 
thus far is that direct sight on the cochlea was necessary in mouse models to 
retrieve good images of the microstructures 26. 
Imaging of the cochlea on a micro scale in vivo would reveal insight into the 
effect of genetic defects on structural dysfunction. For example, in mice defective 
for otogelin, detachment of the otoconial membrane in the utricle and saccule 
is seen. Since DFNB18B (OTOG) patients demonstrated vestibular hyporeflexia it 
can be expected that the otoconial membrane in humans is also defective. 
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With in vivo imaging of the cochlea this hypothesis could be directly confirmed 
or rejected. 
Improving audiometric evaluation
Patients not only want to be informed on the cause of their hearing loss, but 
usually also prefer to know how their hearing will function in the future. For this 
purpose, expanding knowledge on psychophysical results is necessary. In 
Nijmegen, several families with hereditary hearing impairment have been 
evaluated by means of the Nijmegen psychophysical test battery. Unfortunately, no 
indisputable conclusion could be drawn from the studies on sensory types of 
hearing impairment since the numbers of tested patients were small and the 
results demonstrated variability between patients from the same families 27-31. On 
the other hand, the Nijmegen psychophysical test battery did successfully indicate 
the cochlear conductive type of hearing impairment in DFNA8/12 (TECTA) and 
DFNA13 (COL11A2) patients 32, 33. 
The test battery proposed by the HEARCOM project could be a solution for the 
small number of patients. One of the goals of the HEARCOM project was to create 
an auditory profile for each patient. In order to do so, a test battery was composed 
which could be used in several European countries. This test battery contains the 
Acalos test to determine loudness perception and the combined F and T-test for 
frequency resolution and temporal acuity. To evaluate speech reception the SRT in 
quiet, stationary and fluctuating noise and the MATRIX-OLSA test are used 34. 
When the same tests are used internationally, larger numbers of patients can be 
evaluated and compared. Hopefully, these kind of studies lead to more knowledge 
on the auditory phenotype. 
Ultimate goal: normal hearing 
Normal hearing is the ultimate wish of every patient with hereditary hearing loss. 
This wish can currently not be fulfilled and therefore the main focus lies on 
rehabilitation by (implantable) hearing devices. Another treatment option that is 
explored is based on preservation and restoration of dysfunctional parts of the 
cochlea.
Rehabilitation 
Hearing aids
The first choice of rehabilitation in patients with a mild to moderate sensorineural 
hearing loss is a hearing aid. Remarkably, research on hearing aids in hereditary 
hearing-impaired patients is rather scarce. Research on outcomes of different 
hearing aid settings in different types of hearing impairment can enhance fitting 
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of hearing aids in hereditary hearing impaired patients. For example, patients 
with a cochlear conductive hearing impairment can be predicted to benefit more 
from a linear setting of their hearing aids than patients with a sensory type of 
hearing impairment. A cochlear conductive hearing loss, such as DFNA13 (COL11A2) 
and DFNA8/12 (TECTA), is associated with a shifted curve during loudness scaling 32, 33. 
Patients with sensorineural hearing loss present with a steeper than normal curve, 
which is distinctive for recruitment. To overcome recruitment, hearing aids are 
set with a compressed setting 35. Since DFNA13 (COL11A2) and DFNA8/12 (TECTA) 
patients present with sensorineural hearing loss during standard audiometric 
evaluation, their hearing aids are set to a compressed setting. While patients 
without recruitment (and a (cochlear) conductive hearing loss) might benefit more 
from a linear setting. More research is therefore needed on the translation of 
cochlear dysfunction and audiometric profiles into hearing aid adjustments. 
Cochlear implantation
A number of correlation studies on performance after cochlear implantation in 
patients with hereditary hearing impairment have been published so far. For 
example, Vermeire et al. evaluated speech perception after cochlear implantation 
in DFNA9 patients. When compared to other patients with adult onset sensorineural 
hearing loss, DFNA9 patients performed equally or even better after cochlear 
implantation. Since DFNA9 patients demonstrate severe auditory neuronal 
damage, these results were not expected 36.
Performance after cochlear implantation is influenced by multiple factors. The most 
important factors are age at implantation, inner ear malformations and duration of 
hearing impairment before implantation 37-39. Therefore, drawing conclusions on the 
effect of the type of hereditary hearing impairment on postoperative performance 
is rather difficult. This is particularly difficult because the numbers of patients in 
these studies are still relatively low. In the mean time, cochlear implantation 
keeps improving considering every aspect. One of these aspects is electro-acoustic 
stimulation (EAS). EAS combines acoustic and electric stimulation in the same ear 
and yields better performance than electric stimulation only. EAS also improves 
results of speech perception, hearing in noise and music appreciation 40.
In order to preserve residual hearing after cochlear implantation different aspects 
of the procedure have been studied. Different characteristics of hearing 
impairment influence preservation of residual hearing after implantation. In 
congenital hearing loss, more residual hearing is retained after implantation than 
in acquired or idiopathic hearing loss. Progressive hearing impairment is less 
likely to retain residual hearing after implantation 41. Therefore, accurate geno-
type-phenotype correlations are important in counseling of cochlear implant 
candidates on the expectations of a cochlear implant (CI). 
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A shallow insertion depth would reduce trauma to the cochlea, and therefore give 
better results concerning residual hearing 40. In progressive types of hearing 
impairment this should be a point of interest since the possibility of acoustic 
stimulation will diminish over time. In such cases, a deeper insertion depth, with 
a longer, atraumatic electrode should be considered. In this respect, accurate gen-
otype-phenotype correlations are also important. Initially, EAS seems a good 
option in DFNB8/10 patients, since hearing thresholds of the lower frequencies 
remain well at first. However, at a later stage hearing loss progresses7 and complete 
electric stimulation is necessary. 
Insertion of the electrode can provoke an inflammatory response, which can 
further damage the cochlea. Administration of topical or systemic steroids periop-
eratively, reduces the inflammatory intracochlear response and leads to better 
preservation of residual hearing 41, 42. 
Besides preservation of residual hearing, improving the coating of the electrode is 
also an interesting field of research, since it can be used as a drug delivery system. 
Maintenance or stimulating of the outgrowth of spiral ganglion cell neurites by 
neurotrophic factors is of special interest 43, 44. This could also be interesting in 
hereditary hearing impairment types that involve the spiral ganglion, such as 
DFNB8/10 45. 
Increasing knowledge on proteins encoded by deafness- associated genes and their 
function, or dysfunction in hearing impaired individuals, might provide insights 
in new factors to investigate for their positive effect when applied via the coating 
of electrodes. 
Intracochlear therapy 
Hearing with hearing aids is not a perfect solution. Restoration of normal hearing 
without having to use a hearing aid is the ultimate goal. The first steps are being 
made towards this prospect. Different therapies are currently explored like gene 
therapy, stem cell therapy and regeneration of cochlear structures. 
Gene therapy
With genetic therapy a disease is treated by genetic molecules. Specific DNA or 
RNA is administered by a vector into the target cells in order to compensate for 
loss-of-function mutations, interfere with gain-of-function mutations or suppress 
a dominant negative mutation. Gene therapy has already been performed in mice 
with hereditary hearing impairment. Mice that do not express vesicular glutamate 
transporter 3 (Vglut3) are congenitally deaf. Normal synaptic transmission cannot 
be carried out without a glutamate transporter. Vglut3 was introduced in the 
inner hair cells of Vglut3 knockout mice by means of an adeno-associated viral 
vector encoding the wild type Vglut3. As a result, auditory brain stem responses 
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normalized and this effect remained for at least some weeks. Another interesting 
result is that the delivery technique also influenced the results since a cochleostomy 
was found to be more traumatic than delivery through the round window 
membrane 46. 
Splice site mutations can also be corrected by means of genetic therapy. In mice 
with splice site mutations in Ush1c hearing impairment and vestibular dysfunction 
occur. Antisense oligonucleotides can be used to correct defective splicing. In 
Ush1c.216A knock–in mice, antisense oligonucleotides were administered intra-
peritoneally. When this administration took place early in the development of the 
inner ear, hearing and vestibular function could be retained 47. 
In humans, SLC17A8 codes for VGLUT3 48 and mutations in USH1C can cause Usher 
syndrome and nonsyndromic hearing loss 49, 50. However, before these therapies are 
applicable in humans, some difficulties have to be overcome. For the strategies 
mentioned above the different routes of delivery are outlined in table 1. Many factors 
such as safety, immunogenicity, expression regulation and long term efficacy need 
to be addressed before genetic therapies can be broadly applied in humans 51. 
Autosomal recessively inherited hearing impairment often has a congenital onset. 
This congenital onset occurs due to partial failure of development of the cochlea. 
Development of the human ear is completed in utero and this means that genetic 
therapy should also be applicable in a later stage, since treatment in utero is fairly 
impractical 54.
Other organs, such as the eye, are more suited for gene therapy research. In 
ophthalmology, gene augmentation therapy has been studied extensively in retinal 
degeneration disorders and positive results in humans have been published 
already 55-57. A phase 3 clinical trial is currently initiated 58. This expertise on 
genetic therapies in retinal degeneration disorders may well provide new insights 
applicable to disorders of the cochlea. 
Stem cell therapy
Another future treatment option could be stem cell therapy. Stem cells are 
introduced into the cochlea with the aim that these cells differentiate into cells 
specific to the inner ear (e.g. hair cells, auditory neurons) once they are in the right 
environment 59. Differentiation into hair cells encounters still some difficulties. A 
large amount of the stem cells transplanted into the cochlea do not integrate into 
the organ of Corti and therefore, do not develop into hair cells 60.
However, some promising results have been achieved with human fetal auditory 
stem cells (hFASCs). These specific stem cells could differentiate into auditory 
neurons in vitro. Eventually, these stem cells were transplanted into the cochlea of 
gerbils with an auditory neuropathy. This improved the auditory function 
substantially 61.
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Regeneration therapy
Humans do not have the capacity to regenerate hair cells, however, regeneration of 
hair cells is seen in, amongst others, avian and zebrafish’ inner ear. Atoh1 has been 
demonstrated to be regulating the behavior of progenitor cells 62. In human, ATOH1 is a 
gene of great interest for regeneration therapy since it codes for a transcription factor 
necessary for hair cell development. Different studies have already demonstrated that 
delivery of Atoh1 in mice by an adeno-associated virus can restore auditory and 
vestibular hair cells and therefore, can restore loss of function 54. Some remaining 
cells need, however, to be present in order to restore hair cells. This is not possible 
from undifferentiated epithelium 63. 
The difficulties of genetic therapy mentioned above also apply to this type of 
regeneration therapy.
Future directions
In different paragraphs of this discussion it is indicated that larger numbers of 
patients are needed to determine genotype-phenotype correlations more accurately 
and to evaluate and identify possible influences of environmental factors and 
modifiers genes. In addition, larger numbers of patients with hereditary hearing 
impairment need to be evaluated by psychophysical testing in order to be able to 
draw conclusions on the type of hearing loss. Also, more patients are to be evaluated 
to establish a correlation between performance with a CI or hearing aids and genetic 
types.
Since the numbers of patients with defects in a specific gene for autosomal 
recessive nonsyndromic hearing impairment are small for most of the deafness- 
associated genes, international collaborative studies with standardized evaluation 
protocols are necessary to establish correlations between genetic defects, the 
deafness phenotypes and efficacy of rehabilitations methods. Only then, counseling on 
hereditary hearing impairment can be improved and therapeutic strategies evaluated 
to reach optimal results for individuals with hereditary hearing impairment in 
the future. 
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Summary
This thesis starts with a general introduction on hereditary hearing impairment. 
Different topics are discussed, from the basics of sound and anatomy and physiology 
of the human ear to characteristics of hearing impairment and genetic testing. 
A review that summarizes all currently known genes involved in autosomal recessively 
inherited types of hearing impairment is found in chapter 1.2. The review concludes 
that genotype-phenotype descriptions in deafness gene identification studies often 
lack precise information on audiovestibular characteristics.
Chapter 2 describes several novel genotype-phenotype correlations. In chapter 2.1 
the phenotypes of two novel human deafness- associated genes are described, OTOG 
and OTOGL. Seven hearing impaired patients of two families demonstrated mutations 
in OTOGL. In two other families six hearing impaired patients showed mutations in 
OTOG. A similar type of hearing impairment is found in patients with mutations 
in either one of the genes. In general, patients present with a mild to moderate 
hearing impairment and with a flat to downsloping audiogram configuration. 
Speech recognition scores remain fairly well (>90%). In one of the four families 
progression was seen after the second decade. 
In order to further characterize the hearing impairment, extensive audiometric 
tests were performed. The curves of loudness scaling at two kHz run steeper than 
normal hearing individuals and speech recognition scores in noise are worse than 
normal hearing individuals. These results indicate a sensorineural type of hearing 
impairment, instead of a intracochlear conductive hearing impairment. The latter 
could be expected, based on the involvement of otogelin and otogelin-like in the 
tectorial membrane. Previous studies on TECTA and COL11A2, which are expressed 
in the tectorial membrane, displayed an intracochlear conductive type of hearing 
impairment. In two families the vestibular function was assessed which 
demonstrated a hyporeflexia. Therefore, it is concluded from this chapter that 
both novel deafness genes give rise to a similar phenotype when mutated.
In chapter 2.2, a novel non-syndromic hearing impairment is linked to mutations 
(c.310A>G, p.(Met104Val) and c.780insGCAC, p.(Tyr261Alafs*96)) in USH1G. Thus far, 
only Usher syndrome type I and atypical Usher syndrome were linked to mutations 
in USH1G. Usher syndrome type I is characterized by congenital, stable, severe to 
profound hearing loss, vestibular areflexia, and retinitis pigmentosa that has an 
onset before puberty. The phenotype described in this chapter displays an early 
onset hearing impairment with a downsloping audiogram configuration. The 
hearing impairment only progresses slightly. Extensive examination of the eyes 
and vestibulum did not display any abnormalities.
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This non-syndromic character of this hearing impairment is assigned to the 
non-truncating mutation (c.310G>A). Modeling of this mutation predicted only a 
surface change and not a structural change of the SANS protein. 
In chapter 2.3, the genotype-phenotype correlation of two siblings from a 
consanguineous Turkish family is described. Both patients presented with early 
childhood onset of hearing impairment. Hearing impairment progressed quickly 
from mild to severe to profound before the second decade. Initially, motor 
milestones were normal, however, also vestibular function deteriorated to vestibular 
areflexia over time. Additionally, in one of the patients mild renal dysfunction is 
noted. 
This phenotype is linked to a homozygous nonsense mutation c.96T>A (p.(Cys32X)) 
in CLIC5. In this chapter it is demonstrated that CLIC5 is expressed in many human 
tissues. However, besides the mild renal dysfunction no additional symptoms have 
been found.
Mutation analysis for CLIC5 was applied to 213 patients with autosomal recessive 
non-syndromic hearing impairment from mostly Dutch and Spanish origin. No 
additional pathogenic variants were revealed. CLIC5 is therefore a novel deafness- 
associated gene, however, mutations in this gene are not a common cause of 
autosomal recessive hearing loss in the Dutch and Spanish populations.
Chapter 3 is aimed to expand the phenotype description of the most prevalent 
type of hereditary hearing impairment, DFNB1. The audiometric phenotype is 
very heterogeneous and extensively described in literature. Less is known on 
temporal bone anomalies and vestibular function and in literature there is no 
consensus on these topics. In this chapter, 44 DFNB1 patients were evaluated for 
their vestibular function and/ or temporal bone imaging results. Five patients 
complained of balance problems or displayed delayed motor milestones. However, 
all patients demonstrated a response during velocity step testing. The calorisation 
test results were within normal range bilaterally in 65% of cases and the video 
head impulse test was normal in all tested patients. Therefore, vestibular 
dysfunction is not correlated to DFNB1. In this retrospective study, saccular 
function was not evaluated by cVEMPs and it is therefore recommended to evaluate 
this in future studies. 
In 34.4% of the computed tomography scans one or more temporal bone anomalies 
were identified. A variety of anomalies was found and all presented in small 
numbers, therefore, none seemed convincingly connected to a specific DFNB1 
genotype.
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In chapter 4 the focus is not on hearing impairment itself, but on the impact of a 
genetic diagnosis of hereditary hearing impairment. 
Forty-eight patients were asked to fill out the Hospital Anxiety Depression Scale, 
Impact of Event Scale, Self Efficacy 24, Illness Cognition Questionnaire and the 
Inventory for Social Reliance. General characteristics were collected by means of a 
self constructed questionnaire and reviewing patient files.
The questionnaires were completed at three time points: before genetic testing, 
directly after counseling on the results and six weeks thereafter.
There were no differences between patients who received a genetic explanation for 
their hearing impairment (positive result) and the patients who did not (negative 
result). This study also confirmed that hearing impaired individuals may present 
with an increased level of psychological distress. It is, therefore, recommended to 
pay special attention to the psychological well being of hearing impaired 
individuals, who present at an outpatient clinic to have the cause of their hearing 
impairment identified. A positive genetic test result, however, does not affect their 
psychological well being. No reasons in favor or against genetic testing on 
hereditary hearing impairment were found in this chapter.
By means of this thesis a contribution is made to the knowledge of autosomal 
recessive hearing impairment. This is, however, only a small part of the research 
on hereditary hearing impairment. Expansion of the possibilities to find novel 
genes or mutations, to examine the cochlea or to treat hereditary diseases will 
eventually lead to the ultimate goal: 
normal hearing.

6.2
Nederlandse samenvatting
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Samenvatting
Dit proefschrift begint met een algemene introductie over erfelijke slechthorend-
heid. Deze introductie beschrijft onder andere de basiskarakteristieken van geluid, 
de anatomie en fysiologie van het menselijk oor, de kenmerken van gehoorverlies 
en tot slot genetische diagnostiek.
Hoofdstuk 1.2 bevat een overzicht van alle genen die op dit moment geïdentificeerd 
zijn voor autosomaal recessief gehoorverlies. Een van de conclusies van dit overzicht is 
dat artikelen die een nieuw doofheidsgen beschrijven vaak een grondige genotype- 
fenotype beschrijving missen over de audiovestibulaire karakteristieken. Dit belemmert 
adequate counseling van patiënten met een zelfde vorm van erfelijk gehoorverlies. 
Hoofdstuk 2 bevat enkele genotype-fenotype correlaties van nieuwe doofheids-
genen. Hoofdstuk 2.1 beschrijft de fenotypes van twee nieuwe doofheidsgenen, 
OTOG en OTOGL. Zeven slechthorende patiënten uit twee families dragen mutaties 
in OTOGL. In twee andere families zijn er zes patiënten met gehoorverlies en 
mutaties in OTOG geïdentificeerd. Gehoorverlies met dezelfde karakteristieken 
werd in alle vier de families gevonden. Mild tot matig van ernst en met een vlak tot 
aflopende audiogramconfiguratie. Het spraakverstaan bleef redelijk goed (>90%). 
In een van de vier families werd progressie gezien na het twintigste levensjaar. Om het 
gehoorverlies nog verder te karakteriseren zijn psychofysica-testen uitgevoerd. 
De luidheidsschaling bij 2 kHz resulteerde in curven die steiler verlopen dan bij 
normaal horenden en daarnaast werden er ook slechtere spraakverstaan in ruis 
scores gevonden in vergelijking met normaal horende individuen. Deze resultaten 
wijzen op een sensorineuraal gehoorverlies, in plaats van een intracochleair 
conductief verlies. Dit laatste werd verwacht gezien de lokalisatie van otogelin en 
otogelin-like in de tectoriaal membraan. Eerdere studies hebben laten zien dat 
genen die tot uiting komen in de tectoriaal membraan juist een intracochleair 
conductief verlies veroorzaken. De vestibulaire functie werd in twee families 
onderzocht en dit liet een hyporeflexie van het vestibulaire orgaan zien. De 
conclusie van het onderzoek uit dit hoofdstuk is dat mutaties in beide nieuwe 
doofheidsgenen eenzelfde fenotype veroorzaken.
Hoofdstuk 2.2 beschrijft een niet syndromaal gehoorverlies dat veroorzaakt wordt 
door mutaties (c.310A>G, p.(Met104Val) en c.780insGCAC, p.(Tyr261Alafs*96)) in 
USH1G. Tot dusver zijn alleen Usher syndroom type I en het atypische Usher 
syndroom geassocieerd met mutaties in USH1G. Usher syndroom type I wordt 
gekenmerkt door een congenitaal, stabiel, ernstig tot zeer ernstig gehoorverlies, 
vestibulaire areflexie en retinitis pigmentosa die begint voor de puberteit. Het in 
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dit hoofdstuk beschreven fenotype laat een gehoorverlies zien dat vroeg in het 
leven tot uiting komt en een aflopende audiogramconfiguratie heeft. Het 
gehoorverlies is maar matig progressief. Uitgebreid onderzoek van de oculaire en 
vestibulaire functie lieten geen afwijkingen zien. Het niet-syndromale karakter 
van dit gehoorverlies wordt toegeschreven aan een niet-truncerende aminozuur-
substitutie (c.310G>A). Een bio-informatisch model van deze mutatie voorspelde 
namelijk een oppervlakte verandering en geen structurele verandering van het 
SANS eiwit waarvoor USH1G codeert. 
Hoofdstuk 2.3 beschrijft een genotype-fenotype correlatie van een broer en zus uit 
een consanguine Turkse familie. Beide patiënten lieten een gehoorverlies zien dat 
vroeg in de kindertijd begint. Het gehoorverlies verslechterde van mild naar 
ernstig tot zeer ernstig voor het tiende levensjaar. De initiële motorische 
ontwikkeling was normaal, maar de vestibulaire functie verslechterde in de loop 
der tijd tot vestibulaire areflexie. Aanvullend werd er in één van de patiënten een 
milde nierfunctiestoornis gevonden. Dit fenotype wordt veroorzaakt door een 
homozygote nonsense mutatie c.96T>A (p.(Cys32X)) in CLIC5. In dit hoofdstuk wordt 
ook aangetoond dat CLIC5 in verschillende menselijke weefsels tot expressie komt. 
Naast de milde nierfunctie stoornis werden er geen andere afwijkingen gevonden. 
In 213 patiënten van voornamelijk Nederlandse en Spaanse afkomst met een 
verdenking op een autosomaal recessief overervend niet-syndromaal gehoorverlies 
werd mutatieanalyse voor CLIC5 uitgevoerd. Hierbij werden geen nieuwe pathogene 
varianten gevonden. De conclusie in dit hoofdstuk is dan ook dat CLIC5 een nieuw 
doofheidsgen is, maar dat mutaties in dit gen geen frequente oorzaak zijn voor 
slechthorendheid in de Nederlandse of Spaanse populatie.
Hoofdstuk 3 is een onderzoek met doel het fenotype van DFNB1, de meest 
voorkomende vorm van erfelijke slechthorendheid, uit te breiden. Het audiologische 
fenotype is zeer heterogeen en eerder uitgebreid onderzocht en beschreven. Over 
bijpassende anomalieën van het os temporale of de vestibulaire functie is minder 
bekend en in de literatuur is er over deze onderwerpen voor DFNB1 dan ook geen 
consensus. In dit hoofdstuk werden de vestibulaire functie en/of de resultaten van 
beeldvorming van het rotsbeen bij een grote groep van 44 DFNB1 patiënten 
retrospectief geëvalueerd. Vijf patiënten rapporteerden evenwichtsproblemen of 
lieten een afwijkende motorische ontwikkeling zien. Tijdens het draaistoelonder-
zoek lieten alle onderzochte patiënten echter een respons zien. Van de patienten 
had 65% een respons binnen de normaalwaarden bij calorisatie van beide oren en 
de ‘video head impulse’ test was normaal in alle geteste patiënten. Vestibulaire 
disfunctie is dan ook niet gecorreleerd aan het DFNB1 fenotype. Aanbevolen wordt 
om de sacculaire en utriculaire functie van het vestibulum nader te onderzoeken 
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omdat dit in deze studie niet is onderzocht en er in de literatuur aanwijzingen zijn 
dat het connexine 26 eiwit hier mogelijk wel een belangrijke rol speelt. In 34,4% 
van de CT scans werden één of meer afwijkingen gezien van het rotsbeen. Deze 
anomalieën waren zeer variabel en kwamen elk maar in kleine aantallen patiënten 
voor. Geen enkele anomalie kan dan ook overtuigend gecorreleerd worden aan het 
DFNB1 genotype.
In hoofdstuk 4 ligt de focus niet op het gehoorverlies, maar op de impact van een 
genetische diagnose van erfelijk gehoorverlies. Achtenveertig patiënten werden 
gevraagd om de volgende vragenlijsten: ‘Hospital Anxiety Depression Scale’, ‘Impact of 
Event Scale’, ‘Self Efficacy 24’, ‘Illness Cognition Questionnaire’ en de ‘Inventory 
for Social Reliance’ in te vullen. Algemene kenmerken werden verzameld door een 
samengestelde vragenlijst en statusonderzoek te gebruiken. De vragenlijsten 
dienden op drie momenten te worden ingevuld: ten tijde van de aanvraag van 
genetisch onderzoek, direct na de uitslag van het genetisch onderzoek en zes 
weken nadien. Tussen de patiënten die een genetische verklaring kregen voor hun 
gehoorverlies (positief resultaat) en de patiënten die dat niet kregen (negatief 
resultaat) werden geen significante verschillen gevonden. Dit onderzoek bevestigt 
ook dat een aantal slechthorenden die vragen over de oorzaak van hun slecht-
horendheid hebben, zich kunnen presenteren met een hoge mate van psychologische 
stress. Daarom wordt geadviseerd om extra aandacht te besteden aan het 
psychologisch welzijn van slechthorenden die zich met vragen naar de oorzaak 
van hun gehoorverlies presenteren. Genetische diagnostiek naar de oorzaak van 
de slechthorendheid heeft echter geen positief noch negatief effect op dit welzijn. 
Derhalve zijn er geen redenen om genetische diagnostiek naar erfelijke slecht-
horendheid wel of niet te verrichten.
Dit proefschrift draagt bij aan de toename van kennis over autosomaal recessief 
overervend gehoorverlies. Dit is hier echter maar een klein onderdeel van en 
uitgebreider onderzoek is dan ook essentieel om patiënten die de oorzaak van hun 
slechthorendheid willen weten beter voor te kunnen lichten. De toekomstige 
ontwikkeling van nieuwe technieken om makkelijker genen of mutaties te 
identificeren, de cochlea in meer detail te kunnen onderzoeken en mogelijkheden 
om erfelijke slechthorendheid te kunnen behandelen, zullen leiden tot het 
uiteindelijke doel:
een normaal gehoor
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Het dankwoord, veelal het meest gelezen hoofdstuk van een proefschrift. Ook ik 
heb hier uitermate mijn best op gedaan, want zonder de hulp van velen had dit 
boekje er nu niet gelegen.
Allereerst hartelijk dank aan alle patiënten en familieleden die hebben meegewerkt 
aan dit onderzoek. Dank dat ik jullie medische gegevens mocht gebruiken en dat 
jullie de tijd hebben genomen om al die vragenlijsten in te vullen. 
Mijn co-promotor, Dr. Pennings, beste Ronald, de beste co-promotor die ik me kon 
wensen. Jouw tomeloze enthousiasme heeft ervoor gezorgd dat dit proefschrift er 
nu ligt. Avonden, weekenden, vakanties, je was altijd bereikbaar. En als ik het even 
niet meer zag zitten wist jij mij altijd weer te motiveren om door te gaan. Dank 
voor alle tijd, betrokkenheid en energie.
Geachte professor Kremer, beste Hannie. Dank voor de introductie in de moleculaire 
genetica en de mogelijkheid om ervaring op te doen in het laboratorium. Jouw 
kritische blik heeft dit proefschrift naar een hoger niveau getild.
Beste leden van de manuscript commissie; professor Cremers, professor van Dijk en 
doctor Topsakal. Hartelijk dank voor het lezen en beoordelen van mijn proefschrift.
Geachte professor Snik, beste Ad, hartelijk dank voor het meedenken op het vlak 
van de psychophysica. Heel fijn hoe jij dit inzichtelijk wist te maken. 
Beste Joop Leijendeckers, altijd bereid om mee te denken, altijd bereid om nog een 
meting te verrichten. Dank voor de goede samenwerking.  
Beste medewerkers van het audiologisch centrum, dank voor alle metingen die 
jullie voor dit proefschrift verricht hebben. 
Beste Patrick Huygen, dank voor de hulp bij de statistiek en je geduld om dit (soms 
meerdere malen) uit te leggen.  
Beste leden van de otogenetica werkgroep, veel over de otogenetica heb ik van 
jullie mogen leren. Daarnaast waren jullie altijd bereid om mee te denken, dank 
daarvoor!
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Medewerkers van de afdeling vestibulogie, dank voor al jullie metingen. Andy, 
hartelijk dank voor al de uitleg en inzet. Jouw begeleiding was onmisbaar, vooral 
voor hoofdstuk 3. 
Een half jaar lang heb ik op het laboratorium gepoogd om de oorzaak achter de 
slechthorendheid in verschillende families te achterhalen. Zo’n dokter op het lab 
was soms wel even wennen, maar uiteindelijk heb ik hier veel geleerd. Dank aan 
alle medewerkers voor de behulpzaamheid. In het bijzonder dank aan Jaap: jouw 
geduld en manier van uitleggen zijn bewonderenswaardig. Dank dat je me dat half 
jaar wilde begeleiden. Beste Margit, ook jij hartelijk dank voor de begeleiding. 
Beste Erwin, jouw enthousiasme is eindeloos. Door met jou te discussiëren over het 
onderzoek werd mijn motivatie voor dit proefschrift altijd weer aangewakkerd. 
Dank daarvoor! Beste Lisette, helaas hebben we ons PTPRQ project niet samen 
kunnen afronden, maar gezellig was het altijd zeker. Heel fijn om gewoon even 
gezellig te kunnen kletsen, dank daarvoor!
Beste Ramon, dank voor de samenwerking. Heel leuk om tijdens dit promotietraject 
ook een klein uitstapje naar de oogheelkunde te maken.
Beste staf van de afdeling keel-, neus- en oorheelkunde van het Radboud UMC, 
dank voor het in mij gestelde vertrouwen en de kans om mijn opleiding bij jullie 
te volgen en te combineren met dit promotietraject. 
Beste dames van het stafsecretariaat, dank voor jullie hulp bij al mijn logistieke 
vragen. In het speciaal dank ik Loes Temmink, jij wist altijd de moeilijkste agenda 
puzzel op te lossen maar was ook altijd in om even gezellig te kletsen.
Beste (oud) arts-assistenten, researchers en PA: Godelieve, Stijn, Hans, Anne- 
Martine, Veronique, Rabia, Arthur, Maarten, Richard, Hubert, Lisette, Erik, 
Annemarie, Caroline, Henrieke, Jasmijn, Ingrid, Eline, Ruud, Rik, Saskia, Thijs, 
Josephine, Charlotte, Corinne, Chrisje, Luuk, Bas, Mieke, Machteld, Mayke, Ivo en 
David. Voordat ik ging solliciteren was ik nog nooit in Nijmegen geweest, maar 
onze groep maakte dat ik me hier snel helemaal thuis voelde. Dank voor alle 
gezelligheid binnen en buiten het Radboud!
Union Dames 4, wat ben ik blij dat ik met jullie mag hockeyen. Twee keer per week 
de gelegenheid om alles eruit te lopen en te slaan. Vanaf nu ga ik ook weer voor een 
basisplek in de derde helft!
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Lieve clubgenoten, al 10 jaar samen door dik en dun. Dank voor de nodige afleiding 
die jullie hebben gegeven afgelopen jaren. 
Lieve Teun en Joris, mijn grote kleine broertjes. Dank voor de nodige afleiding 
tijdens dit proefschrift in de vorm van gekke foto’s over de app of een borrel 
drinken op Schiermonnikoog, de volgende keer laat ik mijn laptop thuis!
Lieve Ingrid, jouw ambitie en doorzettingsvermogen hebben afgelopen jaren zeker 
geïnspireerd. Maar daarnaast breng je vooral veel gezelligheid en afleiding in 
fietsen, eten, lachen! Fijn dat je als medegroninger/ LvBer naast me wilt staan.
Lieve Charlotte, grote zus, rond dezelfde tijd zijn we begonnen aan een ‘vervolg’ 
van onze opleiding. Jij hebt het inmiddels afgerond. Nu ik nog! Wat fijn dat je me 
daarbij wilt ondersteunen als paranimf. En Jeroen, fijn om te weten dat jij daar 
met jouw rust achter staat.
Lieve Han en Sieka, dank voor jullie interesse en support. Ik ben blij dat we jullie 
nu zo dicht in de buurt hebben.
Lieve Loes, heel fijn hoe jij altijd luistert en zo nodig relativeert. Onze dagjes uit 
waren altijd een hele fijne afleiding. Beste Sjoerd, dat jij probeerde om mij op twee 
jarige leeftijd desoxyribonucleinezuur te laten zeggen zou wel eens de basis voor 
dit proefschrift kunnen zijn geweest. Met z’n drieën hebben we heel wat uren mijn 
opleiding en onderzoek doorgenomen, dank dat jullie er zijn!
Lieve papa en mama, van jullie mocht ik altijd worden wat ik maar wilde. Jullie 
hebben me de basis gegeven om uiteindelijk te promoveren en de opleiding tot 
KNO-arts te volgen en me daarbij zo goed mogelijk ondersteund. En als de energie 
dan echt op was, was het goed bijkomen in het Hoge Noorden. Dank dat jullie er 
voor me zijn.
Liefste Ernst, jij bent altijd onvoorwaardelijk in mij blijven geloven, ook al had ik 
het al lang opgegeven. Zonder jouw liefde en steun was het me nooit gelukt. Hoe 
vaak hebben we niet gezegd: als het straks af is.. En die straks is nu. Ik kijk uit naar 
de toekomst met jou!
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Anne Oonk werd op 3 mei 1987 geboren te Haarlem. Zij groeide op in Hoofddorp 
met haar ouders, zus en twee broertjes. In 2000 verhuisden zij naar Dokkum, 
alwaar Anne in 2005 haar eindexamen behaalde aan het VWO van het Dockinga 
College. Hierna startte zij met haar studie Geneeskunde aan de Rijksuniversiteit 
Groningen. Naast haar studie was zij onder andere actief bij de lustrumcommissie 
van M.F.V. Panacea, de public relations committee van het International Student 
Congress of (Bio)Medical Sciences (ISCOMS) en op het hockeyveld van GCHC. In 
2008 volgde zij een klinische stage op de kinderafdeling van het El Mansoura 
University Hospital in El Mansoura, Egypte. Tijdens het reguliere KNO coschap in 
het Deventer Ziekenhuis werd de interesse voor de Keel-, Neus- en Oorheelkunde 
gewekt. De reguliere coschappen werden afgesloten met een coschap sociale 
geneeskunde in het Ngwelezana Hospital in Empageni, Zuid Afrika. In 2011 startte 
zij met haar onderzoek naar triple negatieve borstkanker tumoren in het Deventer 
Ziekenhuis in samenwerking met het Antoni van Leeuwenhoek in Amsterdam. 
Hierop volgde een keuze coschap KNO in het UMC in Utrecht en in het Deventer 
Ziekenhuis. Eind 2011 behaalde zij haar artsenexamen en startte zij als arts- 
onderzoeker aan het Radboud UMC onder begeleiding van Dr. R.J.E. Pennings en 
Prof. Dr. H. Kremer. Dit onderzoekstraject resulteerde uiteindelijk in dit proefschrift.
Sinds 2013 is zij in opleiding tot KNO-arts in het Radboud UMC onder Prof. Dr. 
H.A.M. Marres en opleider Dr. F.J.A. van den Hoogen.
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EVA:   enlarged vestibular aqueduct
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yr:   year
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